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Background: There is uncertainty about the chemotherapy sensitivity of some oestrogen receptor
(ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancers. Multiparameter
assays that measure the expression of several tumour genes simultaneously have been developed to
guide the use of adjuvant chemotherapy for this breast cancer subtype. The assays provide prognostic
information and have been claimed to predict chemotherapy sensitivity. There is a dearth of prospective
validation studies. The Optimal Personalised Treatment of early breast cancer usIng Multiparameter
Analysis preliminary study (OPTIMA prelim) is the feasibility phase of a randomised controlled trial (RCT)
designed to validate the use of multiparameter assay directed chemotherapy decisions in the NHS.
Objectives: OPTIMA prelim was designed to establish the acceptability to patients and clinicians of
randomisation to test-driven treatment assignment compared with usual care and to select an assay for
study in the main RCT.
Design: Partially blinded RCT with adaptive design.
Setting: Thirty-five UK hospitals.
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Participants: Patients aged ≥ 40 years with surgically treated ER-positive HER2-negative primary breast
cancer and with 1–9 involved axillary nodes, or, if node negative, a tumour at least 30 mm in diameter.
Interventions: Randomisation between two treatment options. Option 1 was standard care consisting of
chemotherapy followed by endocrine therapy. In option 2, an Oncotype DX® test (Genomic Health Inc.,
Redwood City, CA, USA) performed on the resected tumour was used to assign patients either to standard
care [if ‘recurrence score’ (RS) was > 25] or to endocrine therapy alone (if RS was ≤ 25). Patients allocated
chemotherapy were blind to their randomisation.
Main outcome measures: The pre-specified success criteria were recruitment of 300 patients in no
longer than 2 years and, for the final 150 patients, (1) an acceptance rate of at least 40%; (2) recruitment
taking no longer than 6 months; and (3) chemotherapy starting within 6 weeks of consent in at least 85%
of patients.
Results: Between September 2012 and 3 June 2014, 350 patients consented to join OPTIMA prelim
and 313 were randomised; the final 150 patients were recruited in 6 months, of whom 92% assigned
chemotherapy started treatment within 6 weeks. The acceptance rate for the 750 patients invited to
participate was 47%. Twelve out of the 325 patients with data (3.7%, 95% confidence interval 1.7% to
5.8%) were deemed ineligible on central review of receptor status. Interviews with researchers and
recordings of potential participant consultations made as part of the integral qualitative recruitment study
provided insights into recruitment barriers and led to interventions designed to improve recruitment.
Patient information was changed as the result of feedback from three patient focus groups. Additional
multiparameter analysis was performed on 302 tumour samples. Although Oncotype DX, MammaPrint®/
BluePrint® (Agendia Inc., Irvine, CA, USA), Prosigna® (NanoString Technologies Inc., Seattle, WA, USA),
IHC4, IHC4 automated quantitative immunofluorescence (AQUA®) [NexCourse BreastTM (Genoptix Inc.
Carlsbad, CA, USA)] and MammaTyper® (BioNTech Diagnostics GmbH, Mainz, Germany) categorised
comparable numbers of tumours into low- or high-risk groups and/or equivalent molecular subtypes, there
was only moderate agreement between tests at an individual tumour level (kappa ranges 0.33–0.60 and
0.39–0.55 for tests providing risks and subtypes, respectively). Health economics modelling showed the
value of information to the NHS from further research into multiparameter testing is high irrespective of
the test evaluated. Prosigna is currently the highest priority for further study.
Conclusions: OPTIMA prelim has achieved its aims of demonstrating that a large UK clinical trial of
multiparameter assay-based selection of chemotherapy in hormone-sensitive early breast cancer is
feasible. The economic analysis shows that a trial would be economically worthwhile for the NHS.
Based on the outcome of the OPTIMA prelim, a large-scale RCT to evaluate the clinical effectiveness and
cost-effectiveness of multiparameter assay-directed chemotherapy decisions in hormone-sensitive
HER2-negative early breast would be appropriate to take place in the NHS.
Trial registration: Current Controlled Trials ISRCTN42400492.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 20, No. 10.
See the NIHR Journals Library website for further project information. The Government of Ontario funded
research at the Ontario Institute for Cancer Research. Robert C Stein received additional support from
the NIHR University College London Hospitals Biomedical Research Centre.
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Plain English summary
What was the problem?
Breast cancer is the most common cancer in the UK. After surgery, doctors often advise chemotherapy.
We know that this is life-saving for some patients. However, we also know that many patients would do
just as well without it. The problem is that doctors cannot pick out who actually needs chemotherapy,
so they play safe. They use quite simple methods, for example measuring the size of the cancer, to decide.
Therefore, many patients have to undergo chemotherapy to benefit the few who need it. Recently,
scientists have developed new laboratory tests to look at breast cancers. They claim that these tests can
find out which patients need chemotherapy.
What did we do?
We ran a pilot study using one of these tests. Our study was called Optimal Personalised Treatment of
early breast cancer usIng Multiparameter Analysis (OPTIMA) prelim, in which 313 women took part. Half of
the women had chemotherapy as usual. The other half had a test [called Oncotype DX® (Genomic Health
Inc., Redwood City, CA, USA)] to decide whether or not they should have chemotherapy.
What did we find?
We showed that patients and their doctors are willing to trust the test. The test can be used in NHS clinics
without delaying treatment. We also compared several different tests against each other. We worked out
which test we should use in a larger study.
What does this mean?
We can now run a much larger study with 4500 patients taking part. This will let us answer one of
the most important questions in breast cancer: can we safely reduce the number of people who
have chemotherapy?
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Scientific summary
Background
Breast cancer is the most common cancer in the UK and the second most frequent cause of cancer death
in women. The treatment of primary breast cancer, which is undertaken with curative intent, includes local
and systemic therapies. Decisions on adjuvant chemotherapy are informed by an individual’s risk of
developing future metastatic disease, which is a function of tumour stage and biology.
A molecular classification first proposed in 2000 that divides breast cancer into four main intrinsic subtypes
has transformed thinking about the disease. Subsequently, several gene expression signatures or
multiparameter assays that predict risk of recurrence and death, or which classify breast cancer into
subtypes, have been developed to guide the use of adjuvant chemotherapy. The best known, Oncotype DX®
(Genomic Health Inc., Redwood City, CA, USA), provides a numerical ‘recurrence score’ (RS), which predicts
residual risk for patients with oestrogen receptor (ER)-positive human epidermal growth factor receptor 2
(HER2)-negative breast cancer following endocrine treatment.
The Oxford Overview, a meta-analysis of randomised controlled trials (RCTs) in early breast cancer,
suggests that the relative benefit of chemotherapy is independent of tumour biology. However, other
evidence suggests that a subset of ER-positive HER2-negative breast cancer is insensitive to chemotherapy,
although it is not possible to identify individual patients reliably by conventional clinical criteria. Studies in
which Oncotype DX was performed on retrieved tumour blocks from participants in two historical
chemotherapy trials showed that the relative benefit of chemotherapy varied according to the RS.
This indicates that Oncotype DX can identify patients who are unlikely to benefit from chemotherapy,
irrespective of risk from other clinical factors. Evidence from other multiparameter assays supports
this conclusion.
The Optimal Personalised Treatment of early breast cancer usIng Multiparameter Analysis (OPTIMA) trial
seeks to advance personalised treatment by establishing an appropriate and effective method of
multiparameter analysis to identify which women with ER-positive HER2-negative early breast cancer are
likely to benefit from chemotherapy, and those who are not. The study population would ordinarily be
offered chemotherapy by either virtue of axillary lymph node involvement or tumour size. The OPTIMA trial
is an adaptive trial that allows more than one technology to be evaluated. This report describes the
feasibility phase, OPTIMA prelim.
Objectives
OPTIMA prelim had three objectives:
1. to establish acceptability to patients and clinicians of randomisation to test-driven treatment assignment
compared with usual care
2. to establish efficient and timely sample collection and analysis essential to the delivery of
multiparameter test-driven treatment
3. to evaluate the performance and health economics of alternative multiparameter tests to determine
which technology(s) should be evaluated in the main OPTIMA trial.
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The criteria for meeting these objectives, prespecified in the protocol, were:
l recruitment of 300 patients in 2 years from the first centre opening to recruitment, and, for the final
150 patients, (1) patient acceptance rate of at least 40%; (2) recruitment taking no longer than
6 months; and (3) chemotherapy starting within 6 weeks of signing the OPTIMA prelim consent form
for ≥ 85% of chemotherapy-assigned patients
l identification of multiparameter test technology suitable for validation in the main trial.
Methods
Women aged ≥ 40 years with ER-positive HER2-negative early breast cancer and with 1–9 involved axillary
nodes or, if node negative, a tumour of ≥ 30mm in diameter were randomised to one of two treatment
options. Option 1 (control arm) was standard treatment consisting of chemotherapy followed by endocrine
therapy. In option 2 (experimental arm), an Oncotype DX test was performed on the resected tumour;
patients with a RS of > 25 were assigned chemotherapy followed by endocrine therapy, and those with a
RS of ≤ 25 were assigned to endocrine therapy alone. Chemotherapy was selected from regimens
commonly used in the NHS. Referring centres were asked to specify intended chemotherapy at patient
registration. The study was partially blinded so that neither patients nor referring centres were aware of
whether chemotherapy was assigned through treatment option 1 or option 2.
Confirmatory retesting of ER and HER2 status was performed in the central laboratory on all consenting
patients. Patients were randomised once eligibility was confirmed.
The OPTIMA trial is investigating ‘less treatment than usual care’; thus, recruitment was likely to be
difficult. The cancer advocacy group Independent Cancer Patients’ Voice (ICPV) was consulted about study
design and a representative was included in the Trial Management Group (TMG). ICPV facilitated three
patient focus groups to explore attitudes towards the study.
The OPTIMA prelim study included an integrated qualitative recruitment study (QRS), designed to explore
the recruitment process and provide evidence for improvements. The QRS was conducted in three phases.
Phase 1 sought to identify and understand recruitment difficulties. Interviews were conducted with
members of the TMG and research staff at participating centres. Audio-recordings were made of
consultations when the OPTIMA prelim was explained to patients and transcribed for analysis, maintaining
patient confidentiality. Phase 2 involved sharing phase 1 findings with the TMG and working
collaboratively to design and deliver interventions to optimise recruitment and informed consent. Phase 3
evaluated the impact of the QRS, mapping QRS interventions and recruitment figures, and assessing
changes in recruiter practice.
To evaluate candidate tests for use in the main study, additional multiparameter assays were performed on
stored tumour blocks, irrespective of patient randomisation. Assays provided either a numerical risk score
and predefined risk categorisation or assignment to a molecularly defined intrinsic subtype, or both.
Results were analysed to determine how the assays assigned tumours into risk groups and/or subtypes,
and how these assignments differed between assays. The kappa coefficient and associated
95% confidence interval (CI) were used to assess agreement between tests. The predicted benefits of
endocrine therapy with or without chemotherapy individualised to patients were estimated using the two
predictive nomograms, ‘Adjuvant! Online’ version 8.0 (Adjuvant! Inc., San Antonio, TX, USA) and
‘PREDICT’ version 3, and two additional models developed specifically for this analysis. The additional
models assumed the relative benefit of chemotherapy is either constant for all patients, independent of
multiparameter assay result, or that it varies according to the RS.
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An economic model comprising a time-dependent discrete-state transition model (modified Markov model)
was developed for the analysis. This was used to estimate mean differences in clinical effects, including
life-years and quality-adjusted life-years (QALYs), and costs for a hypothetical cohort of women with
ER-positive, HER2-negative, lymph node-positive breast cancer using either Adjuvant! Online or the
constant and variable benefit models. The cost-effectiveness analysis was conducted in accordance with
the specifications of the National Institute for Health and Care Excellence reference case.
To characterise overall uncertainty in the output measures, a probabilistic sensitivity analysis was conducted
using Monte Carlo simulation. Value-of-information analysis was performed to set priorities for further
research into cost-effectiveness of multiparameter assays in the NHS.
Results
Recruitment
OPTIMA prelim opened to recruitment in September 2012. The database was locked on 3 June 2014, with
350 participants registered and 313 randomised into the study. The last 150 patients were recruited within
6 months at a rate of 28 per month. The average recruitment rate was 0.8 patients per open centre per
month in the final 6 months of recruitment (0.7 over the entire recruitment period).
A total of 968 patients were listed in the screening logs, 795 of whom were deemed eligible. Of the
750 patients invited to participate in the OPTIMA trial, 350 consented to join the study. This equates to an
overall 47% acceptance rate. The median time between patients giving consent and allocation of treatment
was 20 days (interquartile range 16–23 days). The proportion of chemotherapy-assigned patients starting
treatment within 6 weeks was 91% over the whole recruitment period and 92% within the last 6 months.
All three prespecified feasibility criteria were therefore met.
A total of 35 hospitals participated in the study. Centres were selected by invitation in six main
geographical clusters across the UK. Centres within each cluster included a mixture of cancer centres and
district general hospitals, to ensure that feasibility could be demonstrated in a representative selection of
UK centres.
A total of 12 out of 325 (3.7%, 95% CI 1.7% to 5.8%) consenting patients, for whom central review of
receptors was performed, were deemed ineligible after central retesting of their tumour ER and HER2
status. Reasons included discrepancy in HER2 status (n= 6), tumour heterogeneity (n= 2) and discrepant
ER status (n= 4, one of which was borderline positive according to local pathology).
Randomised patients were well balanced by age, menopausal status, tumour characteristics (grade,
histological subtype), tumour size and lymph node status.
Patient and public involvement
Three patient focus groups facilitated by members of ICPV were held, the final one taking place 7 months
after the study opened. All three groups reviewed the patient information sheet (PIS) and consent form.
The study was acceptable to the majority of participants. Some had clear preference for chemotherapy, as
that is what had been offered, and some discussed how they felt about not being offered chemotherapy.
The trial design using a ‘test’ to decide treatment was acceptable and most felt that a personalised
approach using multiparameter tests to be a preferred option. Comments made in the groups resulted in a
revision of the PIS and contributed to the ‘tips and guidance’ document, which was an output of the QRS.
DOI: 10.3310/hta20100 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 10
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Stein et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
xxvii
Qualitative recruitment study
A total of 14 semistructured interviews were conducted with research staff across six centres. Eight
telephone interviews with research nurses were also conducted to understand the recruitment pathway for
each centre. Thirty-six consultation recordings were obtained from 29 patients, involving 12 recruiters from
all geographical clusters.
Analysis of interview transcripts identified several key challenges to recruitment, particularly difficulties in
eligibility processes and clinician–patient communication. The latter included the quality and clarity of
explanations of the trial design and trial-specific processes. These had potential to limit the number
of patients approached, and/or ran the risk of threatening the trial’s acceptability to patients.
These observations led to a series of QRS interventions in phase 2, which took place between July 2013
and January 2014. These included facilitating discussions about eligibility criteria with the TMG and at visits
to recruiting centres, revision of the PIS, development and circulation of recruitment ‘tips and guidance’
sheets, delivery of group feedback meetings to address concerns collaboratively, and delivery of individual
confidential feedback and support.
Although it is difficult to assess the distinct impact of the QRS among other variables potentially
influencing study progress, recruitment improved as OPTIMA prelim progressed. Qualitative evidence
suggests that QRS interventions had an impact on some clinicians’ practices. The QRS has identified key
recruitment issues that will be incorporated into the main OPTIMA trial.
Pathology study
A total of 313 randomised patients were eligible for inclusion at the cut-off of 3 June 2014, from whom
302 samples were available for analysis. Data are available for: Oncotype DX, MammaPrint and BluePrint®
(Agendia Inc., Irvine, CA, USA), ProsignaTM (NanoString Technologies Inc., Seattle, WA, USA), IHC4, IHC4
automated quantitative immunofluorescence (AQUA®) (NexCourse Breast™, Genoptix Inc., Carlsbad, CA,
USA) and MammaTyper® (BioNTech Diagnostics GmbH, Mainz, Germany).
Key findings were that for those assays that provided risk categorisation, 18% of tumours were considered
high risk by Oncotype DX, 39% by MammaPrint, 34% by Prosigna, 28% by IHC4 and 18% by IHC4
AQUA. Despite the largely similar proportions in the risk categories, there was substantial disagreement
between tests at an individual tumour level, with agreement between all five tests in only 39% of cases.
For individual test comparisons, the highest kappa value was 0.60 between IHC4 and IHC4 AQUA, and the
lowest was 0.33 between IHC4 and MammaPrint.
Of the three assays that assigned subtype, the proportion of tumours classified as having a (favourable)
luminal A phenotype was 61% for BluePrint, 60% for Prosigna and 62% for MammaTyper (combined
low-risk luminal B and luminal A); the great majority of the non-luminal A tumours were classified as
luminal B. Similar to risk categorisation, agreement between all three tests at an individual tumour level
was limited to only 59% of cases. The best agreement was between BluePrint and Prosigna, but the kappa
value was 0.55, indicating only modest concordance. The lowest kappa value of 0.39 was for comparison
between MammaTyper and MammaPrint.
Economic analysis
The base-case analysis included Oncotype DX, MammaPrint and Prosigna but excluded IHC4,
MammaTyper and IHC4 AQUA. Inclusion criteria required both a defined test cost and adequate evidence
for analytical and clinical validity, which were not available for all tests.
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Multiparameter test-directed chemotherapy is expected to be cost-effective for all tests, although there
remains uncertainty. With a willingness-to-pay threshold of £20,000 per QALY, the probability that
multiparameter testing is more cost-effective than giving chemotherapy to all patients ranged from 77%
(MammaPrint) to 79% (Oncotype DX and Prosigna). The differences in both the expected QALYs between
the alternative tests and the expected overall costs were small. The probability of tests being cost-saving
compared with chemotherapy for all patients was 53% for Oncotype DX, 39% for MammaPrint and for
68% Prosigna.
The estimates of the value of further research for Oncotype DX, MammaPrint and Prosigna are sufficient to
justify studies capable of comparing long-term survival outcomes when using tests to direct chemotherapy.
It should be noted that from the perspective of the NHS, the value of information for further research into
Prosigna is higher than for the two other assays that were evaluated in this study. The analyses showed that
uncertainty in the cost-effectiveness of tests is attributable not only to the performance of each of the tests but
also the implications for long-term outcomes.
The recommendation of Prosigna as most valuable for further research withstood testing of the main
assumptions around the survival of patients after cancer recurrence and also when considering other
candidate or emerging tests such as IHC4 AQUA, IHC4 and MammaTyper. Further sensitivity analyses need
to be performed to understand which model parameters are driving the costs and value of information.
Conclusions
l OPTIMA prelim succeeded in its aim of demonstrating that a large-scale study of multiparameter
test-directed chemotherapy allocation in a high-risk population of patients with ER-positive
HER2-negative cancer is feasible in the UK.
l Receptor determination (ER and HER2) is accurate in local centres in this patient population with an
acceptable predicted error rate of 3.7%.
l Patient and public involvement and the QRS have contributed substantially, although in an
unquantifiable manner, to the success of the project and should continue into a large-scale study.
l There is considerable discrepancy between the outputs of a selection of multiparameter assays
performed on individual participant tumour blocks.
l There is considerable uncertainty regarding the cost-effectiveness of all tests considered. There is
substantial value to the UK NHS in comparative research into all tests, although Prosigna may currently
be considered the highest priority.
Trial registration
This trial is registered as Current Controlled Trials ISRCTN42400492.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research. The Government of Ontario funded research at the Ontario Institute for
Cancer Research. Robert C Stein received additional support from the NIHR University College London
Hospitals Biomedical Research Centre.
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Chapter 1 Background
The current treatment of breast cancer
Breast cancer is a major public health problem. It is the most commonly occurring cancer in the UK,
with an annual incidence of 50,000, and it is the second most frequent cause of cancer death in women,
with about 12,000 deaths in 2011.1 Of the women who develop breast cancer, 80% are over 50 years old
at diagnosis and most deaths occur in this age group.
The treatment of primary breast cancer, which is undertaken with curative intent, includes local (surgery
and radiotherapy) and systemic [chemotherapy, anti-oestrogen and human epidermal growth factor
receptor 2 (HER2)-targeted drugs] therapies. The goal of adjuvant systemic treatment is to eliminate occult
microscopic metastatic disease and thus prevent incurable distant relapse. Decisions on adjuvant therapy
are informed by an individual patient’s risk of developing future overt metastatic disease. This risk is a
function of both tumour stage (size and number of involved axillary lymph nodes) and tumour biology.
Relevant biological features include tumour grade, oestrogen receptor (ER) status and HER2 status. ER and
HER2 status also predict sensitivity to anti-oestrogen drugs and anti-HER2-targeted therapy, respectively.
Distant relapse, which affects a minority of patients, typically occurs after an interval of several years; later
relapse is a feature of both ER-positive and lower-grade tumours.2
Anti-oestrogen therapy with tamoxifen, and more recently aromatase inhibitors (AIs), is considered to be
the mainstay of systemic adjuvant therapy for post-menopausal women with ER-positive disease, the most
common presentation of breast cancer. AIs have been shown to be superior to tamoxifen in a number of
large randomised clinical trials,3 and current National Institute for Health and Care Excellence (NICE)
guidance recommends that these drugs should be offered to the majority of post-menopausal patients.4
During the 2000s, there was a large expansion in the use of adjuvant chemotherapy, especially for
post-menopausal women. Decisions on chemotherapy are based on perceived risk. In the UK, as in many
other countries, it has become standard to offer chemotherapy with anthracyclines and/or taxanes to
all women under 70–75 years of age with axillary node involvement. For those without nodal involvement,
who are at inherently lower risk, chemotherapy is usually reserved for those with ER-negative and/or
HER2-positive tumours or with high-grade tumours.
Although undoubtedly highly effective for some women, chemotherapy may be extremely unpleasant,
with common side effects such as hair loss, fatigue, nausea, painful mouth ulcers, weight gain, muscle
pain, diarrhoea or constipation, and loss of sensation in hands and feet. Rates of admission to hospital
with serious complications have mostly been reported to be in the range 20% to 25%5–7 and there is a
small risk of early death from treatment, reported to be in the range 0.2% to 0.3% in recent studies.8,9
Patients are frequently unable to work both during treatment and for some time thereafter,10 which has
considerable cost to society. Many are left with anxiety, fatigue and depression, which may severely affect
their quality of life for months or even years afterwards.11,12 There is also a small long-term risk of
treatment-induced leukaemia and cardiomyopathy13 (although there is considerable uncertainty about the
incidence of chemotherapy-induced cardiovascular complications).8,14 It does not seem beyond the bounds
of possibility that the overall mortality from early and late complications of chemotherapy lies in the range
1% to 2%.
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Chemotherapy itself is expensive. The cost of delivering a course of fluorouracil, epirubicin, cyclophosphamide
and docetaxel (FEC-T) or of fluorouracil, epirubicin and cyclophosphamide (FEC) alone, which are the two
most commonly used adjuvant chemotherapy regimens in the NHS, is estimated at £4600 and £3800,
respectively15 (updated to 2014 prices). This includes drug costs, outpatient visits and hospital admissions for
the management of complications. Approximately 18,500 patients with breast cancer (41% of diagnoses)
received chemotherapy in the UK in 2006.16 As a result, adjuvant chemotherapy treatment for breast cancer
imposes a financial burden of approximately £80M per year on the NHS.
Prognostic and predictive nomograms such as ‘Adjuvant! Online’ (Adjuvant! Inc., San Antonio, TX, USA;
www.adjuvantonline.com)17 and PREDICT (www.predict.nhs.uk)18 have been increasingly used since the
mid-2000s. These are derived largely from clinical trial-acquired follow-up data to inform decisions about
the use of systemic adjuvant therapy. However, such tools provide information only on what will happen
to groups of patients on average and are not reliable at predicting outcomes for individuals. Thus, within a
population of women with ER-positive tumours, who may, as a group, benefit from a statistically
significant and clinically meaningful reduction in the risk of relapse consequent to the addition of
chemotherapy to adjuvant endocrine therapy, there will be individuals who gain nothing as well as those
who gain everything.
The advent of new technologies that offer improved means to characterise the biology of individual
tumours heralds an era of more personalised medicine with respect to their potential to inform rational
treatment decisions on a patient-by-patient basis. The Optimal Personalised Treatment of early breast
cancer usIng Multiparameter Analysis (OPTIMA) trial is designed as a prospective test of the success of
these technologies in identifying that sizeable subgroup of women with breast cancer (among those who
might be expected to be routinely offered adjuvant chemotherapy based on conventional criteria) whose
tumours are intrinsically insensitive to chemotherapy. For these women, the benefit of receiving such
treatment would not outweigh the harm from treatment, as they would experience only toxicity and delay
in starting more effective adjuvant endocrine therapy and radiotherapy.
Redefining breast cancer
The traditional classification of breast cancer is based on morphology, most notably tumour grade, which
when combined with stage (tumour size and extent of nodal spread) provides valuable prognostic
information, as exemplified by the Nottingham Prognostic Index (NPI).19 In recent years, multiple additional
prognostic markers have been defined through studies of tumour protein and gene expression.
The best established of these are receptors for steroid hormones, specifically ER and progesterone receptor
(PgR), and HER2 gene amplification. Positive ER expression confers a good prognosis and also predicts
sensitivity to anti-oestrogen drugs. HER2 gene amplification with associated HER2 receptor overexpression
is an adverse prognostic feature but predicts sensitivity to HER2-targeted drugs such as trastuzumab
(Herceptin®, Roche). The value of Ki-67, a marker of proliferation which is not routinely measured, is more
controversial20 and is subject to difficulties in assay standardisation.21–24
Since 2000, with the emergence of gene expression profiling (GEP) using microarray technology, a new
molecular classification of breast cancer has been developed.25–27 This classification divides breast cancers
into four main ‘intrinsic subtypes’: luminal A, luminal B, HER2 enriched and basal-like. These subtypes
differ markedly in their clinical behaviour and response to therapy, as shown in the summary table (Table 1).
This goes some way to explaining the highly heterogeneous clinical behaviour of the disease. Among the
intrinsic subtypes, luminal A has a significantly better prognosis than the other subtypes.28,29 Luminal A
breast cancer is broadly recognised as having a low proliferation rate (typically grade 1 or 2), being strongly
positive for steroid hormone receptor expression and expressing HER2 at normal levels, although some
25% of such cancers have a different molecular subtype.30 Molecularly classified luminal A breast cancer
makes up 50–55% of all breast cancers diagnosed in the developed world.30
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The original research into intrinsic subtypes required complex microarray analysis of frozen tissue samples
to analyse the simultaneous expression of thousands of genes within each breast cancer, with associated
bioinformatics challenges. This GEP technology is widely regarded as too complex and variable to bring
into the clinical setting. Recently, progress has been made in mapping the original microarray-based system
onto immunohistochemical markers that can be used in routine pathology laboratories,2,31 although
correlation with molecular subtyping is imperfect.28 Several molecular assays which assign subtypes by
measuring expression of a subset of the genes identified as significant in the original GEP studies are now
marketed but are not in widespread clinical use. The four intrinsic subtypes do not provide a full
description of breast cancer, and recent work suggests that there may be as many as 1032 but, until a
more robust molecular classification is developed, the intrinsic classification provides an extremely useful
framework for thinking about breast cancer.
Differential sensitivity of breast cancer subtypes to chemotherapy
The strongest evidence for the effectiveness of adjuvant chemotherapy comes from the meta-analyses of
over 101,000 patients in 123 chemotherapy trials conducted around the world, known as the Oxford
Overview.9 For a post-menopausal woman with steroid hormone-sensitive breast cancer treated with
tamoxifen, the Oxford Overview suggests that 10-year breast cancer mortality is reduced from about 32%
to about 21% by anthracycline–taxane chemotherapy. Although this is clearly worthwhile, nine patients
need to be treated for one life to be saved.
Most published adjuvant chemotherapy trials have made the assumption that chemotherapy benefits are
similar for breast cancer, irrespective of tumour characteristics. Up to the mid-2000s, the majority have not
restricted patient entry by tumour grade or receptor status. The underlying assumption in these trials that
the proportional benefits of chemotherapy apply uniformly to all cancers irrespective of histological
characteristics of the tumour is supported by the Oxford Overview analysis, although limited histological
information is available from those older studies that included a no chemotherapy comparison.9 The
development of the intrinsic classification requires re-evaluation of all of the available evidence on adjuvant
chemotherapy treatment. Now that different subtypes of breast cancer that behave in different ways are
recognised, it is necessary to investigate the appropriate use of chemotherapy within the new classification.
It can be argued that the effectiveness of chemotherapy for luminal A breast cancer is low in comparison
with the other subtypes, irrespective of tumour stage.33 Retrospective ad-hoc subgroup analysis of a
number of large trials of taxane versus non-taxane chemotherapy regimens have mostly suggested that
there is no significant benefit for the newer and more toxic regimens for women with ER-positive
HER2-negative cancers (e.g. see Hayes et al.34), most of which would be luminal A tumours although not
TABLE 1 Characteristics of breast cancer intrinsic subtypes
Characteristics
Intrinsic subtypes
Luminal A Luminal B HER2 enriched Basal-like
Prognosis Good Moderate Poor Poor
Proliferation Low Moderate High High
Chemosensitivity Low/nil Moderate High High
ER Strong Variable Nil Nil
HER2 amplification Uncommon In subset Usual Nil
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all such analyses confirm this, most notably the Oxford Overview.9 Similar analyses of comparisons of
anthracycline chemotherapy with older cyclophosphamide, methotrexate and fluorouracil (CMF) regimens
suggest that the anthracycline benefit is limited to patients whose tumours expressed high-risk markers.35
A recent analysis36 of two pivotal trials37,38 of CMF chemotherapy with or without endocrine therapy versus
endocrine therapy alone in women node-negative cancers failed to demonstrate a clear chemotherapy
benefit in those women whose tumours were demonstrated to be ER-positive using modern assays,
in contrast to other subgroups. Furthermore, those trials of chemotherapy versus no chemotherapy that
included endocrine therapy predated AI therapy, which is a more effective treatment than tamoxifen.
A second line of evidence that chemotherapy sensitivity is influenced by tumour biology comes from
studies of presurgical (neoadjuvant) chemotherapy. Analysis of the outcome of treatment according to
intrinsic subtype of individual tumours is particularly striking, with a ‘pathological’ complete response rate
of 6% in luminal tumours compared with 45% in basal type.39 A separate study showed that the chances
of achieving a pathological complete response for patients with luminal B tumours was 2.4-fold greater
than for patients with luminal A tumours.28 Similar findings have been reported in the Investigation of
Series Studies to Predict Your Therapeutic Response With Imagine and Molecular Analysis (I-SPY) 1 trial,40
which systematically evaluated chemotherapy response in relation to a number of biomarker profiles.
The third and particularly relevant line of evidence comes from the retrospective analysis of historical trials
comparing chemotherapy plus tamoxifen with tamoxifen alone in ER-positive breast cancer according to
the results of the Oncotype DX® (Genomic Health Inc., Redwood City, CA, USA) test performed on archival
tumour tissue. The evidence that assays such as Oncotype DX are able to predict chemotherapy response
is discussed below.
Multiparameter assays in breast cancer
The development of the intrinsic classification has transformed our understanding of breast cancer and is
changing clinical management to a more individualised approach. In parallel, it is driving intensive research
efforts to develop simpler molecular tools that classify breast cancers and, more importantly, quantitate
the risk of relapse for individual patients following particular treatment. These new tests typically involve
the simultaneous measurement of expression of a number of genes either at the protein or messenger
ribonucleic acid (mRNA) level. Most of the better-validated assays are commercialised and are either
available or in the process of being marketed for clinical use. Although the early multiparameter assays
that relied on mRNA measurement required fresh tissue, all the commercialised assays now work on
formalin-fixed paraffin-embedded (FFPE) tissue. One of the main drivers for the development of
multiparameter assays is the clinical uncertainty surrounding the benefits of adjuvant chemotherapy for
women with ER-positive HER2-negative breast cancer, so the majority of assays have focused on this group
of patients. Most assays have been developed and validated in (largely) node-negative populations whose
prognosis is not complicated by the effect of lymph node involvement.
The output of the available assays takes the form of either a simple numerical score that can be used
against a calibration chart to estimate recurrence risk [e.g. Oncotype DX41 and Breast Cancer IndexSM (BCI)
(bioTheranostics, San Diego, CA, USA)]42,43 and/or assignment to either a predefined risk category or
subtype. The most common measure of relapse is the risk of developing metastatic disease by 10 years
from diagnosis. Most commercially developed assays are strongly influenced by steroid hormone sensitivity,
HER2 status and proliferation. A number of assays have been evaluated only in ER-positive populations.
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All of the available assays have been retrospectively tested on archival material, mostly from historical trials;
to date, no prospective evaluation of any multiparameter assay has been published. Although it has been
argued that retrospective analysis of tumour samples can provide satisfactory validation when used with
appropriate precautions,44 a recent consensus panel has argued strongly for prospective validation
studies.45 Four systematic reviews46–49 have examined the data supporting the validation of multiparameter
assays, particularly Oncotype DX and MammaPrint® (Agendia, Irvine, CA, USA) in detail. Table 2 lists most
of the multiparameter assays that have been described for ER-positive HER2-negative breast cancer. Several
of these are described in detail below (see Individual multiparameter assays).
TABLE 2 Summary of multiparameter tests for breast cancer
Assay (vendor)
Details of multiparametric
assay Output Availability Reference
Perou et al.25 and
Sorlie et al.26,27
(non-proprietary)
The original description of the
intrinsic classification using
495 genes (the most highly cited
papers in breast cancer)
Subtype – Perou et al., 200025
Sorlie et al., 200326
Sorlie et al., 200127
Oncotype DX (Genomic
Health Inc.)
A 21-gene qRT-PCR expression
assay (using 16 cancer-related
and five normalisation genes)
Risk score Central laboratory
(USA)
Paik et al., 200441
MammaPrint+ BluePrint
(Agendia, Irvine,
CA, USA)
A 70+ 80 gene microarray-based
expression signature
Risk category
and subtype
Central laboratory
(the Netherlands)
Glas et al., 200650
Mook et al., 201051
Rotterdam signature
(non-proprietary)
A 76-gene microarray-based
expression signature
Risk score Not in clinical use Foekens et al., 200652
Mammostrat (Clarient/GE
Healthcare, Aliso Viejo,
CA, USA)
A five-gene
immunohistochemical assay
Risk score Central laboratory
(USA)
Ring et al., 200653
Prosigna (PAM50)
(NanoString Technologies
Inc., Seattle, WA, USA)
A 50-gene expression assay
using the NanoString system
Subtype and
risk score
(± clinical data)
Regional laboratories Geiss et al., 200854
Dowsett et al., 201355
BCI (bioTheranostics,
San Diego, CA, USA)
A seven-gene qRT-PCR
expression assay
Risk score Central laboratory
(USA)
Ma et al., 200842
IHC4 (AQUA and
non-proprietary)
Quantitative immunohistochemical
assay for ER, PgR, HER2, Ki67
Risk score
(± clinical data)
Academic Cuzick et al., 201156
MapQuant (Genomic
Grade Index, Bordet
Institute, Brussels,
Belgium)
A 97-gene microarray-based
expression assay
Risk category Not currently
available
Sotiriou et al., 200657
EndoPredict (Sividon,
Sividon Diagnostics,
Cologne, Germany)
A seven-gene qRT-PCR
expression assay
Risk score
(± clinical data)
Regional laboratories Filipits et al., 201158
NPI+ A 10-gene immunohistochemical
assay
Subtype and
risk category
(± clinical data)
In development Rakha et al., 201459
MammaTyper (BioNTech
Diagnostics GmbH,
Mainz, Germany)
A five-gene qRT-PCR assay Subtype In development Aigner et al., 201260
AQUA, automated quantitative immunofluorescence; qRT-PCR, quantitative reverse transcriptase-polymerase chain reaction.
± clinical data indicates that test output may take account of clinical data.
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Individual multiparameter assays
Oncotype DX
This is a polymerase chain reaction (PCR)-based expression assay testing expression of 21 genes, 16 of
which are cancer related and five are for normalisation. The assay is used in FFPE specimens. The initial
study41 described the derivation of the 21-gene signature assay from expression array analysis of
tamoxifen-treated cancers and its translation and validation into a multiplex PCR diagnostic assay. The test
output is the continuously variable numerical ‘recurrence score’ (RS), which has a monotonic relation to the
risk of distant recurrence at 10 years following tamoxifen treatment of ER-positive node-negative breast
cancer. Individual patient risk can be estimated from the calibration provided with the results. Additionally,
the patients are divided into three risk categories (low, intermediate and high), where intermediate is
defined (from the initial validation study) as a 10–20% risk of developing distant metastases over 10 years.
Genomic Health performs this test centrally in a single US laboratory; the UK list price for the assay
is £2580.
Multiple additional studies,61–65 comprising the retrospective analysis of patients’ outcomes in Phase 3 trials
within ER-positive breast cancer, have confirmed the value of Oncotype DX as a predictor of residual risk
following endocrine therapy and have extended the original observations to patients with positive lymph
nodes, and also to patients with ductal carcinoma in situ.66 Oncotype DX has been demonstrated to
reclassify risk defined by Adjuvant! Online,17 which is a risk predictor that uses conventional histopathology
information.64,67 Oncotype DX has also been shown to predict chemotherapy sensitivity in the
neoadjuvant setting.68,69
Analysis of individual patient Oncotype DX RSs has been performed retrospectively on a subset of patients
included in two historical clinical trials of chemotherapy versus no chemotherapy. The analyses of the B-20
trial of the National Surgical Adjuvant Breast and Bowel Project (NSABP B-20) trial in women without
axillary nodal involvement61 and in the Southwest Oncology Group (SWOG) trial 8814 (SWOG88-14) trial
in women with node-positive disease62 have shown that there is no chemotherapy benefit for women
with an RS in the low- or intermediate- risk groups. The analysis of the SWOG88-14 trial is particularly
important as it shows that even in heavily (≥ 4) node-positive patients who have a poor prognosis by virtue
of stage, there is no benefit to the addition of chemotherapy to adjuvant endocrine therapy, compared
with endocrine therapy alone, if the RS is low. These data are widely interpreted to suggest that
Oncotype DX is able to predict whether or not tumours are likely to be sensitive to chemotherapy.
Incorporating clinical data (tumour stage, grade and age) for patients with node-negative disease into
the test improves its performance as a prognostic test but crucially does not improve its ability to predict
chemotherapy sensitivity.64,70
A number of studies (e.g. Ademuyiwa et al.71 and Albanell et al.72), including two conducted within the
UK,73,74 have shown that the use of Oncotype DX leads to changes in chemotherapy decisions in
about one-third of patients, although these studies involve small sample sizes and often have poorly
described protocols.
Limitations of Oncotype DX highlighted by the systematic reviews46–49 include the fact that there are
relatively few data about the performance of the test in node-positive patients and that the data
supporting the ability of the test to predict chemotherapy benefit are not robust.49 Additionally, Oncotype
DX, unlike some other tests, is only able to predict recurrence risk over the first 5 years after diagnosis.75
No prospective studies reporting the impact of Oncotype DX on long-term outcomes, such as overall
survival have been identified. In addition, the test has not been prospectively trialled against any
alternatives. There is no evidence that the Oncotype DX assay is any more informative than other gene
expression assays.76
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In 2007, an American Society of Clinical Oncology expert panel reviewed the evidence and recommended
the use of Oncotype DX in routine care.77 The test has proved to be popular with patients and clinicians,
and is undoubtedly the global market leader in the field. Genomic Health reported that as of 31 December 2014,
more than 500,000 tests have been preformed, the majority for invasive breast cancer, generating a total
revenue of US$1.4B for the company over a 7-year period.78
MammaPrint
The MammaPrint assay is based on 70 genes, identified by GEP, that were shown to predict outcome in a
mixed population of young breast cancer patients with node-negative disease, none of whom was treated
with adjuvant tamoxifen.79 Following an initial validation study performed in a similar population,80 the test
was commercialised. Initially it was performed using array technology on fresh-frozen tissue,50 but since
2012 it has been available for FFPE tissue samples.81 Currently the test is marketed by Agendia as part of
the SYMPHONY profile and is performed in central laboratories located in the Netherlands and in the USA;
the current list price of SYMPHONY is €2675. The output from MammaPrint is essentially a simple binary
division into low risk and high risk. The BluePrint® (Agendia, Irvine, CA, USA) assay provides subtyping
information (luminal type, basal type and HER2 type); combining the MammaPrint and BluePrint results for
patients with ER-positive tumours allows tumours to be divided into luminal A and luminal B subtypes.
Following the initial validation study,80 MammaPrint has been reported to provide valid prognostic
information in a number of additional studies, and evidence has shown that it is able to reclassify risk
against existing prognostic variables.51,82–85 Several studies40,86,87 have shown that MammaPrint is able to
predict response to neoadjuvant chemotherapy, including differentiating between high- and low-risk
ER-positive disease. A study of patients pooled from several data sets has provided evidence that
MammaPrint is able to predict chemotherapy benefit in patients with ER-positive disease and up to three
involved lymph nodes.88 There is evidence that MammaPrint results influence chemotherapy decisions
made by European oncologists (predominantly Dutch) in clinical practice89,90 without any apparent increase
in recurrence after 5 years.91
Overall, the evidence supporting MammaPrint is broad-based and convincing but, in comparison with
studies validating the use of Oncotype DX, it is less comprehensive, with individual studies tending to have
a lower quality. This is also the conclusion of the four systematic reviews of the field.46–49 The limitations of
the evidence in support of Oncotype DX also apply to MammaPrint. Although one study92 has purported
to show that MammaPrint is able to predict outcome beyond 5 years, it clearly does not predict
late relapse.
MammaPrint is widely used in clinical practice in parts of Europe but has never achieved the global
penetration of Oncotype DX. Its use in the UK is very limited, probably because the requirement for fresh
tissue up to 2012 was widely considered to be an obstacle by clinicians and, as such, it was ‘second
to market’.
IHC4
There is long-standing evidence that the conventional immunohistochemistry markers, ER, PgR, HER2 and
Ki67 (a marker for cell proliferation),33,93 are able to identify patients at increased residual risk following
endocrine therapy. The IHC4 test relies on quantitative immunohistochemistry for these four markers. The
component scores have been integrated into a viable predictor of residual risk in post-menopausal women
with ER-positive disease. The assay was developed using outcome data and stored tumour blocks from
women who participated in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial.56 IHC4, using
conventional manual colorimetric immunohistochemistry, has been developed in an entirely academic
setting and, as there are no proprietary data, there is limited incentive for its commercial development.
Genoptix, a US-based company, promotes the test using proprietary automated quantitative
immunofluorescence (AQUA®).94 The output from IHC4 is a numerical score, with a division into three risk
groups using the same definitions as Oncotype DX.
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The original IHC4 validation study was performed on a large patient cohort (n= 1125), and the report
included a second validation performed on an independent patient cohort.56 A completely independent
study has been performed on around 4500 patients recruited from the Tamoxifen Exemestane
Adjuvant Multinational (TEAM) study, using both conventional immunohistochemistry and quantitative
immunofluorescence.95 Both methods of detection provided significant prediction of residual risk
following endocrine therapy with reasonable correlation, although the performance of quantitative
immunofluorescence was superior on the basis of the c-index. One study96 has demonstrated that IHC4 is
able to reclassify risk defined by Adjuvant! Online or the NPI. In addition to these studies, a detailed
comparison has been performed between IHC4 and Oncotype DX in the transitional cohort of the ATAC
trial (transATAC).56 Correlation between the two was modest, but the two assays provide a similar
amount of prognostic information. As both tests are strongly influenced by measures of proliferation,
steroid hormone receptor signalling and HER2 status, and were developed with similar patient cohorts,
this is unsurprising.
The validation of IHC4 as a predictor of residual recurrence risk involves far more patients than validation
studies performed for any other multiparameter assay. Additionally, the similarity between IHC4 and
Oncotype DX implies that, by extension, the ability of Oncotype DX to predict chemotherapy sensitivity
is like to apply to ICH4. The low estimated cost of £150 for performing IHC4 using conventional
immunohistochemistry49 and its portability are potential strong advantages for IHC4 over other
multiparameter assays. However, its portability is also its principal weakness, as the reproducibility of manual
quantitative immunohistochemistry, particularly for Ki67, is limited.21–24 It remains to be demonstrated whether
or not quantitative immunofluorescence established in local laboratories is more reproducible.
Prosigna® (PAM50)
PAM5028 is a quantitative reverse transcriptase-PCR expression assay developed in an academic setting
using 50 genes selected from the original set identified by Perou et al. in their pioneering microarray
studies of intrinsic subtype.25–27 The assay provides subtyping information and additionally a numerical
risk of recurrence (ROR) score; there are several variants of the ROR score incorporating varying amounts of
clinical and conventional histological information.
The ProsignaTM test, which measures the expression of the PAM50 gene set using the NanoString
platform,54 has been developed by NanoString Technologies (Seattle, WA, USA).97 The assay can be
performed in suitable local laboratories using hardware and reagents provided by the company. The
analytical validity of the assay has been demonstrated in a distributed environment98 and the company was
granted the necessary US Food and Drug Administration approval in September 2013 for its marketing as
a prognostic assay in post-menopausal patients. Prosigna was independently trained and validated but
Prosigna and PAM50 subtype predictions and ROR scores are highly concordant.
PAM50, and by inference Prosigna, can be used in all subtypes of breast cancer, but detailed validation
studies have been performed on patients with ER-positive disease.28,55,75,99–101 PAM50 has been validated
as a predictor of residual risk in two studies28,99 and has been shown to reclassify risk defined by Adjuvant!
Online using conventional pathology. Similarly, Prosigna has been demonstrated to predict residual risk
and to reclassify risk in the large transATAC cohort and in approximately 1500 mostly node-negative
patients treated with endocrine therapy alone from the Austrian Breast and Colorectal Cancer Study Group
(ABCSG-8) study of endocrine therapy in post-menopausal women.55,100 Prosigna, in contrast to Oncotype
DX and IHC4, is able to predict late (beyond 5 years) recurrence in these two patient cohorts (transATAC
and ABCSG-8).75,101
Response rates to neoadjuvant chemotherapy have been shown to vary between both PAM50-28,40 and
Prosigna102-defined intrinsic subtypes. Response rates have been reported to be lower for luminal A than
for luminal B tumours and both luminal subtypes are less chemotherapy sensitive than non-luminal
subtypes. Additionally, Prosigna ROR scores have been shown to be predictive of chemotherapy
response.102 Three studies have explored the ability of PAM50 to predict outcome in trials comparing two
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chemotherapy regimens, two of which were conducted in early breast cancer103,104 and one in advanced
disease.105 None of the three studies selected patients by receptor expression, so the numbers of patients
with luminal disease analysed was comparatively small. None of the studies showed an overall statistically
significant benefit for patients with luminal B versus luminal A disease. One of the adjuvant studies
compared an anthracycline containing regimen with CMF with an overall positive result.103 The second
adjuvant study, which was also positive, showed that patients with luminal A breast cancers appeared to
benefit from paclitaxel treatment, unlike those with higher-risk subtypes,104 which is a counterintuitive
finding. In the study conducted in advanced disease,105 which showed no overall benefit for the addition of
gemcitabine to docetaxel, there appeared to be a significant benefit for patients with luminal B versus
luminal A disease, which was lost in multivariate analysis.
Mammostrat®
Derived following expression array analysis identifying markers of residual risk in early breast cancer, the
Mammostrat® assay (Clarient/GE Healthcare, Aliso Viejo, CA, USA) relies on immunohistochemical analysis
of five markers (p53, NDRG1, SLC7A5, CEACAM5 and HTF9C). The test classifies patients into three risk
groups. First described in 2006,53 this assay was validated across multiple retrospective institutional
and clinical trial cohorts, including the NSABP B-14 and NSABP B-20 trials, and the TEAM trial.53,106,107
One health economic analysis suggests that the test is cost-effective in US health care.108
Mammostrat was developed by Clarient and, following US Food and Drug Administration approval in
2007, the assay was commercialised in the USA as a marker of residual risk in early breast cancer.
GE Healthcare acquired Clarient in 2010. Clarient/GE Healthcare discontinued development of the
test in 2014. Although still commercially available in the USA, its future is uncertain.
MammaTyper®
This is a four-gene quantitative reverse transcriptase-PCR expression assay being developed commercially
by BioNTech Diagnostics GmbH. The assay measures ER, PgR, HER2 and Ki67 mRNA.60 These data are
combined to allocate tumours to an intrinsic subtype rather than provide a risk score as IHC4. The
definition of intrinsic subtype is based on an immunohistochemical definition, which does not map
accurately onto PAM50/Prosigna defined subtypes.99 Formal clinical validation studies of the assay are
currently being conducted.
Comparative performance of multiparameter assays
Very limited information on direct comparisons between multiparameter assays is available. Comparisons
have been performed between Oncotype DX, IHC4, Prosigna and BCI results from approximately
1000 post-menopausal patients treated with endocrine therapy from the transATAC cohort.43,55,56,75
These have focused on high-level statistical analysis of the prognostic value of different tests within this
population. Information on the proportion of patients testing ‘positive’ (i.e. high risk) for individual tests is
more opaque and, in particular, data on results at the individual patient level are lacking. Nonetheless
these comparisons have been of substantial value in allowing comparisons between tests, albeit limited to
comparing their overall prognostic impact. Taken collectively, the results of these pivotal studies support
the conclusion that all four assays provide similar prognostic information at the population level. They also
provide evidence that Prosigna and BCI provide statistically more prognostic information than Oncotype DX
and IHC4, and in contrast to Oncotype DX and IHC4, they provide information about the risk of late
(beyond 5 years) relapse. No conventional parameters of performance (e.g. area under the receiver
operator curve) have been presented at any time for any of the currently available assays, which makes it
difficult to evaluate their performance in this regard. However, the statistical improvements in performance
for Prosigna and BCI are modest, but important, leaving space for further improvement.
An alternative approach is to use published assay algorithms, or to ‘reverse engineer’ assays, and to apply
these to gene expression data sets, with associated outcome data as an ‘in silico’ experiment.109,110 Such
comparisons have, like the direct comparisons, shown that the results of the various multiparameter assays
are moderately correlated with respect to the prognostic information provided. The major limitations of
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this methodology are, first, that different array platforms lack probes that match to prognostic signatures,
such that ‘missing genes’ may compromise analysis, and, second, that the algorithms used by the assays
are calibrated according to the method used to measure gene expression and may not translate well into
semiquantitative analysis of microarray data sets used for this analyses. Signatures compared, in a similar
manner using arrays and reverse engineering, in the I-SPY 1 trial include MammaPrint and PAM50.40 There
was again a modest correlation between assay performance, and most provide predictive information
about response to neoadjuvant chemotherapy and outcome. Once again, the analysis of I-SPY 1 provided
no information on the comparative performance of assays at patient level.
Cost-effectiveness analyses of multiparameter testing
We performed a systematic review of literature on the cost-effectiveness of multiparameter testing; the
methods are described in Appendix 1. Six studies assessed the impact of Oncotype DX (one in each of
Canada,111 the USA,112 the UK,74 Germany,113 Australia114 and Japan115), and one assessed the impact
of MammaPrint in the Netherlands.116 No head-to-head comparisons of the alternative genomic tests have
been conducted. Four studies74,112,113 either were funded by the test manufacturer or were carried out by
researchers who worked for the manufacturer.114 All studies compared the given genomic test with current
conventional management, which consisted of current national guidelines and tools based on patient
clinicopathological data (such as Adjuvant! Online,17 PREDICT18 and the NPI19).
The majority of studies considered mixed populations, including patients with both lymph node-negative
and lymph node-positive disease.74,113,115,116 Two studies112,113 assessed populations that included only
patients with lymph node-positive disease, both of which evaluated Oncotype DX. Four studies reported
specific details of patients’ level of lymph node involvement;112,113,115,116 most restricted their populations to
patients with low levels (1–3) of lymph node involvement, with only one study111 including patients with
higher (1–9) lymph node involvement.
The single MammaPrint study estimated that the test would lead to a 0.21 decrease in quality-adjusted
life-years (QALYs) together with a US$2882 fall in costs, from a Netherlands societal perspective.116
Of the six studies assessing Oncotype DX,74,111,115 two estimated that the test would dominate standard
care strategies, with Oncotype DX found to produce a gain in QALYs and a reduction in costs.112,113 Both
of these studies were funded by the manufacturer. Vanderlaan et al.112 found that, from a health-care
payer perspective and using a lifetime horizon, Oncotype DX was estimated to produce a gain of 0.17
QALYS per patient and reduce costs by US$384 (based on 2009 costs). Eiermann et al.113 found that, from
a German health-care payer perspective and over 30 years, Oncotype DX was estimated to produce a
gain of 0.06 QALYS and reduce costs by €561 per patient.
The remaining four studies74,111,114,115 found Oncotype DX to be more costly and more effective than
standard care. The highest incremental cost-effectiveness ratio (ICER) value was estimated in the only study
that included patients with high levels of lymph node involvement (1–9 positive nodes). Lamond et al.111
found that, from a Canadian third-party payer perspective and over a lifetime horizon, Oncotype DX was
estimated to produce a 0.06 QALY gain at an incremental cost of CA$14,844 (based on 2011 costs)
[95% confidence interval (CI) CA$3616 to CA$25,646] per QALY. They found that there was almost a
100% probability of Oncotype DX-guided treatment being cost-effective, but that the results for the lymph
node-positive group were more sensitive to one-way sensitivity analyses than the results in a lymph
node-negative population. For the remaining three studies (which assessed mixed lymph node populations),
the ICER results were £6232/QALY,74 JP¥568,533/QALY (equivalent to US$5685)115 and AUD$9986/QALY.116
In addition to these studies, two studies15,49 have considered the likely cost-effectiveness of multiparameter
assays for use in the NHS. Hall et al.,15 who performed a cost–utility analysis of Oncotype DX in a
node-positive population by modelling outcome data from the SWOG88-14 Oncotype DX study62 to the
NHS, concluded that Oncotype DX is unlikely to be cost-effective for this population. Ward et al.,49 who
undertook the external evidence review for the NICE DG10 guidance117 in a node-negative population,
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concluded that Oncotype DX could be cost-effective if offered to a higher-risk subset of such patients.
They considered that MammaPrint and IHC4 may also be cost-effective, but the evidence was not
sufficiently robust to draw a firm conclusion, while limited evidence suggested that Mammostrat is unlikely
to be cost-effective.
The literature review also identified two budget impact analyses,118,119 both of which were funded by or
affiliated with the manufacturer of the test. Ragaz et al.118 assessed the impact of Oncotype DX on US and
Canadian health-care costs in both lymph node-positive and lymph node-negative patients, and estimated
that Oncotype DX could save US$330.8M in the USA and US$46.2M in Canada. Zarca et al.119 assessed
the impact of MammaPrint on health-care costs in France on node-positive (1–3) breast cancer patients,
and estimated that MammaPrint could save €9043 per 100 patients per year compared with
current practice.
Availability of multiparameter testing in the UK
Four multiparameter assays have been evaluated by NICE (Oncotype DX, MammaPrint, IHC4 and
Mammostrat) for potential use in the NHS. The resulting guidance117 was published in September 2013.
The guidance states that Oncotype DX ‘is recommended as an option for guiding adjuvant chemotherapy
decisions for people with ER-positive, lymph node-negative and HER2-negative early breast cancer’. The
recommendation was limited to patients at ‘intermediate risk’, defined as a NPI score of > 3.4, and relies
on a discounted price for Oncotype DX. The guidance and resulting funding decisions apply only to
England. The three other technologies evaluated were recommended for use only in research at this time.
Five additional technologies, including PAM50, BCI and NPI+, were removed from the scope in November
2011, almost 2 years before the final guidance was published, on the grounds that at that time there
was insufficient evidence to justify their inclusion in the economic analysis performed by the external
assessment group.120 The appraisal was also limited to patients with node-negative disease, as the
evidence for the use of the tests was considered less robust in the node-positive population. The NICE
committee recommendation for the use of Oncotype DX was made on the basis that the test provides
superior prognostic information to conventional clinicopathological risk assessment. The committee,
however, did not consider the evidence that Oncotype DX is able to predict the benefit of chemotherapy
above and beyond providing prognostic information to be robust and recommended further research into
this question for all four technologies.
The OPTIMA study
There are a number of important unanswered questions for clinicians and patients on the practical use of
multiparameter assays in making decisions about chemotherapy. These include whether or not tests might
be useful for patients with axillary node involvement, how best to use the tests, what threshold to use
where this is not clearly defined and which of the available tests provides the most reliable results. Three
ongoing international randomised controlled trials (RCTs) will generate prospective evidence for the validity
of test-directed treatment assignment.121–123
l Trial Assigning IndividuaLized Options for Treatment (Rx) (TAILORx).121 This US-based intergroup trial
randomised patients to chemotherapy followed by endocrine therapy, or endocrine therapy alone
based on an Oncotype DX test result. Eligible patients have ER-positive breast cancer without nodal
involvement. All patients undergo Oncotype DX, and those with a RS in the range 11–25 are eligible
for randomisation. Recruitment was suspended in October 2010, when 10,000 (out of a target of
11,000) patients had been enrolled. The primary analysis is expected in 2017. The majority of patients
randomised in TAILORx would not currently be offered chemotherapy in the UK.
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l Microarray In Node-negative and 1- to 3-positive lymph node Disease may Avoid ChemoTherapy –
European Organisation for Research and Treatment of Cancer Trial 1004 (MINDACT – EORTC 1004).122
This pan-European trial is comparing adjuvant chemotherapy treatment decisions based on genetic
profiling using the MammaPrint test run on fresh tissue, with decisions based on clinical parameters.
Eligible patients can have up to three involved axillary lymph nodes. The MINDACT study has met its
recruitment target of 6000 patients; the primary analysis is planned to take place in 2016.
l Rx for Positive Node, Endocrine Responsive Breast Cancer (RxPONDER).123 This is a US-based intergroup
study that opened to recruitment in 2011. Eligible patients will have ER-positive, HER2-negative
tumours with one to three involved axillary lymph nodes. All patients will undergo Oncotype DX testing
prior to trial entry. Patients with a RS of ≤ 25 are eligible to be randomised between chemotherapy
followed by endocrine therapy or endocrine therapy alone. The trial aims to test over 10,000 patients
and to randomise 4500. The primary analysis is currently intended to take place in 2022.
The lack of comparative data with other multiparameter tests means that it is possible that other existing tests
may allow more reliable identification of chemotherapy-sensitive disease than Oncotype DX or MammaPrint.
Although NICE has recommended that Oncotype DX may be used to guide adjuvant chemotherapy decisions,
it may not be the most cost-effective platform for making test-directed chemotherapy decisions in the NHS.
The OPTIMA trial seeks to advance the development of personalised treatment in breast cancer by
establishing an appropriate and effective method of multiparameter analysis, to identify which women
with ER-positive HER2-negative, lymph node-positive primary breast cancer are likely to benefit from
chemotherapy, and which are not. It is axiomatic to the study that the benefit of chemotherapy is not
evenly distributed among breast cancer subpopulations, contrary to the assumption made by NICE in
DG10,117 and that the multiparameter assays are able to predict chemotherapy sensitivity. The potential
ability of multiparameter assays to predict chemotherapy sensitivity was recommended as a topic for future
research in the DG10 guidance. The study population is similar to that included in the NICE appraisal in
respect of ER and HER2 status, but at higher risk, so would ordinarily be offered chemotherapy by virtue of
either axillary lymph node involvement or because other adverse clinicopathological features; the majority
of such patients would not be eligible for NHS-funded Oncotype DX testing. The OPTIMA study is an
adaptive trial that allows more than one technology to be evaluated. It is planned to run in two phases
with an initial feasibility study, now completed, to compare the performance of technologies in order to
establish which of these will be included in the main trial, and to evaluate the acceptability of the
approach to patients and its cost-effectiveness. The main study will use an end point of non-inferiority
after 5 years because events often occur late in breast cancer and no intermediate end point that allows
early prediction of recurrence has yet been identified.
OPTIMA prelim (the feasibility phase of OPTIMA) was funded by the Health Technology Assessment (HTA)
programme of the National Institute for Health Research (NIHR) in 2012 (reference 10/34/01) and
completed the primary phase recruitment on 3 June 2014. The main objectives of OPTIMA prelim were to
demonstrate that recruitment to a large-scale randomised trial of test-directed chemotherapy is feasible
in the UK and to select a multiparameter assay to use as the primary treatment discriminator in the main
OPTIMA study. This report describes the methodology used in OPTIMA prelim and the results of the study.
BACKGROUND
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Chapter 2 Methods: recruitment and study
conduct
Trial design
The OPTIMA trial is a multicentre, partially blind randomised clinical trial with a non-inferiority end point
and an adaptive design. The preliminary or feasibility phase of the study, which has the same structure as
the main trial, is referred to as OPTIMA prelim (Figure 1).
OPTIMA prelim aimed to establish whether or not a large trial of multiparameter test-based treatment
allocation (‘test-directed’ treatment) is acceptable to patients and clinicians, with 300 patients randomised in a
1 : 1 ratio. A 200-patient extension phase was built into the design of OPTIMA prelim to allow a smooth roll
through to the main trial. A second key aim of the study was to compare the performance of alternate
multiparameter tests to allow the selection of multiparameter tests to be evaluated in the main trial.
OPTIMA trial compares the standard treatment of chemotherapy followed by endocrine therapy with
multiparameter test-directed treatment allocation to either chemotherapy followed by endocrine therapy or
endocrine therapy alone. The randomisation of patients allocated to chemotherapy is concealed from
treating centres. In the main trial, it is expected that approximately 1860 patients will be randomised to
each arm in a two- or three-arm design (with either one or two test arms). Patients will be followed up for
10 years.
The OPTIMA trial is adaptive with respect to the technology used to make a chemotherapy treatment
assignment. The technology used in the OPTIMA prelim was Oncotype DX, which was chosen as the
best-validated test when the trial was designed. A RS cut-off point of > 25 versus ≤ 25 was selected
as the threshold for allocation of patients to chemotherapy or to no chemotherapy. To avoid any potential
confusion in the use of nomenclature, the two groups defined by this cut-off point are referred to either
by RS value or as RS low or high score. The value of 25 was chosen (1) as it is the mid-point of the predefined
intermediate-risk range (RS of 18–31), (2) because from the retrospective analyses of the NSABP B-20 and
SWOG88-14 studies,61,62 this is roughly the level at which there appears to be a clinically meaningful benefit
for adjuvant chemotherapy, and (3) because it is the upper limit at which randomisation is permitted in the
ongoing TAILORx and RxPONDER trials.123,124
Trial objectives
The OPTIMA prelim objectives were:
l to evaluate the performance and health economics of alternative multiparameter tests to determine
which will be evaluated in the main trial
l to establish the acceptability to patients and clinicians of randomisation to test-directed
treatment assignment
l to establish efficient and timely sample collection and analysis, which is essential to the delivery of
multiparameter test-driven treatment.
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Control arm
(n = 150)
Experimental arm
(n = 150)
Eligibility
Randomisation
Female aged > 40 years
Excised primary breast cancer
ER-positive, HER2-negative 
(local pathology)
pN1–2 OR pN0 and pT > 30 mm
Consent and registration
Specify intended chemotherapy
regimen
Tissue block sent to central 
laboratory to confirm eligibility
(ER-positive, HER2-FISH non-amp)
Oncotype DX test
Chemotherapy
(randomisation blinded)
Endocrine therapy
(5 years)
Endocrine therapy
(5 years)
Chemotherapy
(randomisation blinded)
Endocrine therapy
(5 years)
Treatment assigned according to test result
Preliminary study analysis
Performance analysis (oncotype vs. other tests) after 300 patients randomised
Patient acceptability analysis
Decision to proceed with main study if acceptability criteria met
Decision on main trial tests
Open prelim study extension (bridge to main trial; up to 200 patients)
FIGURE 1 The OPTIMA prelim trial schema. FISH, fluorescence in situ hybridisation; non-amp, non-amplified;
pT, pathological tumour size. Note that pN refers to the pathologically determined nodal status; pN1 represents
1–3 positive nodes; pN2 represents 4–9 positive lymph nodes.
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The OPTIMA main trial objectives are:
l to evaluate whether or not test-directed chemotherapy treatment and endocrine therapy is non-inferior
to chemotherapy followed by endocrine treatment for all patients in terms of invasive disease-free
survival (IDFS).
l to establish the cost-effectiveness of a test-guided treatment strategy compared with standard practice.
OPTIMA prelim success criteria
The prespecified criteria used to determine the success of OPTIMA prelim were recruitment of 300 patients no
more than 2 years from the first centre opening to recruitment, and, for the final 150 patients:
l patient acceptance rate should be at least 40%
l recruitment should take no longer than 6 months
l chemotherapy should start within 6 weeks of signing the OPTIMA prelim consent form for no less than
85% of chemotherapy-assigned patients.
Outcome measures
OPTIMA prelim
Patient acceptability
l Time between consent and starting chemotherapy.
l Recruitment time.
l Agreement between tests.
The OPTIMA main trial
Primary outcomes
l IDFS.
l Costs and QALY.
Secondary outcomes
l Quality of life as measured by the European Quality of Life 5-Dimesions (EQ-5D)125 and Functional
Assessment of Cancer Therapy (FACT) questionnaire for patients with breast cancer.126,127
l Distant disease-free survival.
l Comparative performance of multiparameter assays (if more than one adopted).
l Patient compliance to long-term endocrine therapy.
l Overall survival.
Eligibility criteria
Inclusion criteria
l Female, aged ≥ 40 years.
l Excised invasive breast cancer with local treatment either completed or planned according to
trial guidelines.
l ER-positive [Allred score of ≥ 3 or histoscore (H-score) of ≥ 10 or as otherwise established by the
reporting pathologist] as determined by the referring centre and centrally confirmed.
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l HER2-negative (i.e. immunohistochemistry score of 0–1+) or fluorescence in situ hybridisation (FISH) or
other in situ hybridisation non-amplified, as determined by the referring centre and centrally confirmed.
l Axillary lymph node status: (1) 1–9 involved (macrometastases, i.e. > 2mm OR micrometastases,
i.e. > 0.2–2mm) OR (2) node negative AND tumour size ≥ 30mm. Nodes containing isolated tumour
cell clusters only, that is ≤ 0.2mm in diameter, were considered to be uninvolved.
l Considered appropriate for adjuvant chemotherapy by treating physician.
l Patient assessed as fit to receive chemotherapy and other trial-specified treatments with no
concomitant medical, psychiatric or social problems that might interfere with informed consent,
treatment compliance or follow-up.
l Bilateral and multiple ipsilateral cancers were permitted provided at least one tumour fulfils the entry
criteria and none meet any of the exclusion criteria. Patients with bilateral tumours where both
tumours fulfil all eligibility criteria including size and nodal status were excluded. Note that for separate
synchronous primary cancers, whether ipsilateral or bilateral, it was anticipated that laboratories
would, as per standard good practice, assess ER and HER2 on the different lesions. Centres were
requested to send a block for each separately reported tumour for central eligibility testing provided
sufficient material was available. If there were multiple invasive foci deemed to derive from one main
cancer (satellite foci), which had the same histological features including, for example tumour type and
grade, it was not required that every focus has its receptor status reassessed.
l Written informed consent for the study.
Exclusion criteria
l Ten or more involved axillary nodes or involved internal mammary nodes.
l ER negative OR HER2 positive/amplified tumour on central eligibility testing.
l Metastatic disease. Note that formal staging according to local protocol was recommended for patients
where there was a clinical suspicion of metastatic disease or for stage III disease (tumour > 50mm with
any nodal involvement OR any tumour size with four or more involved nodes).
l Previous diagnosis of malignancy unless:
¢ managed by surgical treatment only and disease free for 10 years
¢ previous basal cell carcinoma of skin, cervical intraepithelial neoplasia or ductal carcinoma in situ of
the breast treated with surgery only.
l The use of oestrogen replacement therapy (HRT) at the time of surgery. Patients who were taking HRT
at the time of diagnosis were eligible provided the HRT was stopped before surgery.
l Presurgical chemotherapy, endocrine therapy or radiotherapy for breast cancer. Treatment with
endocrine agents known to be active in breast cancer including ovarian suppression was permitted
provided this was completed > 1 year prior to study entry.
l Commencement of adjuvant treatment prior to trial entry. Short-term endocrine therapy initiated
because of, for instance, prolonged recovery from surgery was permitted but had to be discontinued at
trial entry.
l Trial entry more than 8 weeks after completion of breast cancer surgery.
l Planned further surgery for breast cancer, including axillary surgery, to take place after randomisation,
except either re-excision or completion mastectomy for close or positive/involved margins, which could
be undertaken following completion of chemotherapy.
l Patients with more than two involved axillary nodes (as defined in the inclusion criteria) identified by
sentinel node biopsy or by axillary sampling where further axillary surgery was not planned.
METHODS: RECRUITMENT AND STUDY CONDUCT
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Study conduct
Ethical and regulatory approval
The South East Coast–Surrey Research Ethics Committee approved the trial on 22 June 2012. Local
research and development department approval was obtained at each participating NHS trust prior to
patients being enrolled into the trial. The trial was conducted in accordance with the principles and
guidelines of the International Conference on Harmonisation, Good Clinical Practice, UK legislation,
Warwick Clinical Trials Unit (CTU) standard operating procedures and the Research Ethics Committee
approved protocol. The trial is registered as Current Controlled Trials ISRCTN42400492.
Management of the trial
The Trial Steering Committee (TSC) provided overall supervision of the trial, with an independent
chairperson and majority of independent members. The Trial Management Group (TMG) comprised a
multidisciplinary team of clinicians, statisticians, a translational scientist and a patient advocate, all with
considerable expertise in all aspects of trial design, running, quality assurance and analysis. The Data
Monitoring and Ethics Committee carried out the independent monitoring of the trial. Details of the
membership of the TSC, TMG and Data Monitoring and Ethics Committee can be found in the
Acknowledgements (see Acknowledgements and Contributors).
Trial centres
A total of 35 hospitals from 31 NHS trusts and health boards in England, Scotland and Wales participated
in OPTIMA prelim. As the demonstration of recruitment feasibility was a major end point for OPTIMA
prelim, it was important to ensure that trial centres were broadly representative of the UK. Rather than
issue a general invitation to participate in the study, individual centres were approached in five main
geographical clusters: Scotland, the West Midlands, East Anglia, North London and South West/South
Wales. Both district general hospitals and cancer centres were included. A list of all participating centres
can be found in the Acknowledgements (see Acknowledgements and Contributors). Prior to activating a
centre to recruitment, a trial initiation meeting was held, in person or via teleconference, to provide
study-specific training to all staff members working on the trial. Continued support was offered to
existing and new staff at participating centres to ensure that they remained fully aware of trial procedures
and requirements.
Patient information and informed consent
Patients who were potentially eligible for participation in the study according to the criteria (see Eligibility
criteria) were identified at the multidisciplinary breast cancer meetings held at each of the centres. Patients
were invited to participate in the OPTIMA prelim study during the initial consultation with their oncologist,
where treatment options were discussed. Here the local principal investigator or their designee discussed
the trial with the patient and provided the patient with a copy of the patient information sheet (PIS)
(see Appendix 2). In many cases a research professional would be present in this consultation and/or
meet with the patient afterwards to continue discussing the trial. Patients were given sufficient time to
consider participation in the trial and subsequently the opportunity to ask any further questions and to be
satisfied with the responses. Patients who were willing to participate were asked to provide written
informed consent (see Appendix 2 for a copy of the consent form). Consent for the study included consent
for use of the participant’s tissue samples, removed at the time of surgery, as part of the OPTIMA prelim.
Participants were also asked to donate the remainder of their samples for future unspecified research
projects; however, this was optional.
Randomisation procedure
Trial entry was defined as the time consent was given, which started the randomisation procedure. Once
written informed consent had been given and chemotherapy selected from the regimens permitted in the
protocol (Table 3), the researcher registered the patient with the CTU. During registration, eligibility was
confirmed according to the results of local pathology testing and the patient was allocated a unique
participant registration number.
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Once the participant was registered, the centre sent relevant tumour block(s) from the surgical resection to
the central laboratory for confirmatory testing of ER and HER2 status as soon as possible.
In order to avoid unnecessary delays in the randomisation procedure, on receipt of the tumour block, the
central laboratory prepared samples for Genomic Health in parallel with undertaking eligibility testing. The
central laboratory informed the CTU of the patient’s ER and HER2 status, and those eligible were randomised in
a 1 : 1 ratio to standard treatment (control arm) or to test-directed treatment. Randomisation was performed
centrally by a computer using a minimisation algorithm stratified to ensure balance across trial arms by
chemotherapy regimen: anthracycline–non-taxane [FEC75–80, FEC90–100, epirubicin, cyclophosphamide,
methotrexate and fluorouracil (E-CMF)] vs. taxane–non-anthracycline [docetaxel and cyclophosphamide (TC)]
vs. combined anthracycline and taxane [FEC-T, fluorouracil, epirubicin, cyclophosphamide and paclitaxel
(FEC-Pw)], number of involved nodes (none vs. positive sentinel node biopsy without axillary surgery vs. 1–3 vs.
4–9 nodes), menopausal status (pre-/perimenopausal vs. post-menopausal). Oncotype DX testing proceeded
immediately for all participants [tumour blocks from participants randomised to the control arm underwent
Oncotype DX testing as part of the pathology study (see Chapter 3, Pathology research in the preliminary
studies)]. Genomic Health reported the test result to the CTU, which subsequently informed the research centre,
by fax and e-mail, whether or not the participant was to receive chemotherapy according to randomisation and
RS for those randomised to test-directed treatment. It was anticipated that the randomisation procedure, from
date of consent/registration to treatment assignment, would take between 3 and 4 weeks.
TABLE 3 Permitted chemotherapy regimens
Regimen Drugs Dose Cycle schedule
FEC75–80 Fluorouracil 500–600mg/m2 i.v. q. 3 weeks × 6 cycles
Epirubicin 75–80mg/m2
Cyclophosphamide 500– 600mg/m2
FEC90–100 Fluorouracil 500mg/m2 i.v. q. 3 weeks × 6 cycles
Epirubicin 90–100mg/m2
Cyclophosphamide 500mg/m2
FEC-Pw FEC100 (as above) i.v. q. 3 weeks × 3–4 cycles
Followed by paclitaxel 80–90mg/m2 i.v. q. 1 week × 9–12 cycles
TC Docetaxel 75mg/m2 i.v. q. 3 weeks × 4–6 cycles
Cyclophosphamide 600mg/m2
FEC-T FEC100 (as above) i.v. q. 3 weeks × 3 cycles
Followed by docetaxel 100mg/m2 i.v. q. 3 weeks × 3 cycles
E-CMF Epirubicin 100mg/m2 i.v. q. 3 weeks × 4 cycles
Followed by
cyclophosphamide
600mg/m2 OR 100mg/m2
p.o. daily × 14 days
i.v. D1, 8 q. 4 weeks × 4 cycles
Methotrexate 40mg/m2
Fluorouracil 600mg/m2
D, day; E-CMF, epirubicin followed by cyclophosphamide, methotrexate and fluorouracil; FEC-Pw, fluorouracil, epirubicin,
cyclophosphamide and paclitaxel; i.v., intravenously; p.o., per os (orally); q., quaque (every); TC, docetaxel
and cyclophosphamide.
Number after regimen (i.e. FEC75–80 and FEC90–100) refers to epirubicin dose.
METHODS: RECRUITMENT AND STUDY CONDUCT
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Blinding
OPTIMA prelim was a partially blinded trial. For participants who were allocated to receive endocrine
therapy alone, it was not possible to blind either the participant or the clinicians at the centre. However,
for participants allocated to receive chemotherapy followed by endocrine therapy, the participant and the
centres were blind to the participant’s randomisation. In order to maintain blinding, for participants
randomised to the standard arm, the CTU delayed informing the treating centre of the treatment
allocation by a time period equivalent to that taken to perform the Oncotype DX test for those randomised
to test-directed treatment. In practice this was on receipt of the Oncotype Dx test result as this was
performed for all participants in OPTIMA prelim irrespective of randomisation. To assess the success of the
OPTIMA prelim and perform a comparison of multiparameter tests, the randomised treatment allocation
remained blinded to the analyst, as it was not needed in the analysis of the OPTIMA prelim.
Trial treatment
With the exception of mandating whether or not a participant received chemotherapy, treatment
pathways for patients joining the OPTIMA prelim study were designed to be as similar as possible to those
for equivalent patients who were either ineligible or chose not to join the study. The process of consent
and subsequent Oncotype DX testing was expected to delay the start of systemic treatment (with either
chemotherapy or endocrine therapy) by about 3 weeks compared with non-trial-treated patients. This
delay is not expected to be clinically deleterious.128 Although the protocol contained recommendations for
the management of all aspects of patient treatment based on national/international guidelines (where
available) and consensus views on best practice, the expectation was that participating centres already
follow these and, therefore, that treatment would follow the local implementation of best practice and
national guidelines.
Chemotherapy
Chemotherapy was chosen at the time of registration from the list of protocol-permitted regimens
(see Table 3). The regimens included in the list were selected from those with good evidence for efficacy
and which are widely used in the NHS.
Endocrine therapy
The OPTIMA prelim protocol specified that endocrine therapy should be started no later than 2 weeks after
treatment allocation in participants assigned to receive no chemotherapy and 4 weeks after the final dose
of chemotherapy for all other participants. Concomitant endocrine therapy and chemotherapy was not
permitted in the OPTIMA prelim. It was also not permitted for endocrine therapy to be delayed until after
radiotherapy. Permitted endocrine therapy for participants in the trial was:
l post-menopausal at trial entry: AI (anastrozole, letrozole, exemestane permitted)
l premenopausal at trial entry: tamoxifen for 5 years and ovarian suppression with either
i. a gonadotropin-releasing hormone agonist for a minimum of 3 years or
ii. bilateral surgical oophorectomy (radiation menopause was not permitted).
Within the OPTIMA prelim study ovarian suppression was recommended for all premenopausal women (1) to
ensure that the patients within both arms received equally balanced endocrine treatment and (2) to eliminate
the risk of confounding from different rates of chemotherapy induced menopause between the arms.
Surgery
All participants received appropriate surgery, performed according to local guidelines. Primary surgery
consisted of a wide local excision or mastectomy. If breast conservation surgery was undertaken, then the
acceptable circumferential and deep/superficial margin widths were determined by local protocol. If
required, re-excision for clear margins was permitted to take place before or after chemotherapy.
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All participants underwent preoperative axillary staging with an ultrasound scan and needle biopsy or
fine-needle aspiration of any suspicious or indeterminate nodes. Participants with preoperative pathologically
proven axillary lymph node involvement underwent axillary clearance. Participants with involved axillary lymph
nodes identified at sentinel node biopsy (including macrometastases, micrometastases, and isolated tumour
cell clusters) received further management according to local protocol. Centres could choose to avoid axillary
clearance following a positive sentinel node biopsy for participants who had undergone breast-conserving
surgery and who fulfilled the following criteria:
l no palpable nodes
l no more than two involved nodes
l clinical tumour size T1–T2 (≤ 5 cm).
All planned axillary surgery was completed prior to randomisation to allow for stratification by the extent
of axillary involvement.
Radiotherapy
Radiotherapy was given in accordance with local guidelines. The protocol stated the following
recommended best clinical care as a reference for centres.
l Breast radiotherapy was required for all patients who had undergone breast-conserving surgery. Whole
breast, including the primary tumour bed, was the target volume. Centres could give a tumour bed
boost in conjunction with whole-breast radiotherapy as per local guidelines. Partial breast radiotherapy
was permitted, but only for patients who had a negative sentinel node biopsy or a full axillary clearance.
l Participants who had undergone a mastectomy were required to receive chest wall radiotherapy if
they had four or more positive axillary nodes or T3 tumours with any node positivity. Chest wall
radiotherapy was recommended for tumours with a positive deep margin. Centres could also consider
chest wall radiotherapy for patients with 1–3 positive axillary nodes or high-risk node-negative disease.
The chest wall was the target volume.
l Treatment of the supraclavicular fossa was required when four or more axillary lymph nodes were
involved and could be given according to local guidelines for patients with 1–3 involved axillary nodes.
Axillary radiotherapy, in addition to breast radiotherapy, was permitted using a four-field technique,
when patients with up to two involved sentinel nodes did not undergo clearance. The axilla was not
otherwise routinely irradiated. Internal mammary nodes were not routinely irradiated.
Recommended schedules after breast-conserving surgery or mastectomy were:
1. 40 Gy in 15 fractions, five fractions per week
2. 50 Gy in 25 fractions, five fractions per week
3. 45 Gy in 20 fractions, five fractions per week.
Dose fractionation for tumour bed boost and regional lymph nodes was given according to local protocol.
Screening information
In order to assess patient acceptability, each participating centre maintained a screening log to document
all patients considered for the trial but subsequently excluded. Where possible, the reason for non-entry
to the trial was documented. Screening logs were requested by the CTU on a monthly basis. No
patient-identifiable data were recorded on the screening log.
METHODS: RECRUITMENT AND STUDY CONDUCT
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Data collection
Clinical and resource use data generated by all centres were collected on study case report forms (CRFs),
which were monitored and entered into the trial database by the CTU. The participant’s details were
entered onto the local centre’s patient identification log; at no time was this log forwarded to the CTU.
To preserve participants’ anonymity, only their allocated trial number and initials were used on the CRFs
and any correspondence. With participants’ permission, their name, date of birth, address and NHS/
Community Health Index number were also provided to the CTU on the registration CRF to allow flagging
with the Office for National Statistics. Participants’ confidentiality was respected at all times.
Case report form completion guidelines were provided to all centres to aid consistency of completion. Data
management and monitoring were conducted in accordance with the CTU standard operating procedures,
which are designed to ensure that trial data are as complete and accurate as possible, and comply with
the Data Protection Act 1998.129 Data management practice included verification, database validation and
formal data checking following data entry. All missing and ambiguous data were pursued until resolved
or confirmed as unavailable. Monthly reminders were sent to participating centres in order to flag any
forthcoming or outstanding clinical visits or questionnaires.
Quality of life and health resource use assessment
The patient questionnaire was designed to assess quality of life and health resource use. The baseline
questionnaire was provided by the centre and completed by participants after they had given written
informed consent but before randomisation. Further questionnaires were administered at 3, 6, 12 and
24 months from date of consent. These further questionnaires were either given to participants at a clinic
appointment or sent by post. The OPTIMA prelim study used two instruments to gather information on
quality of life as the basis for evaluating both effectiveness and cost-effectiveness: EQ-5D124 and the FACT
questionnaire comprising FACT – General126 and FACT – Breast cancer.127
Follow-up
Participants are followed up annually for 10 years from trial entry. Annual follow-up appointments could
be conducted in the clinic or via telephone for participants who had been discharged from clinical review.
The method of follow-up is recorded on the CRF.
Withdrawals
Participants had the right to withdraw from the trial at any time and for any reason. Those participants
who were deemed ineligible by central review were not randomised and did not count towards the sample
size. Participants who were registered but not randomised were not classified as withdrawals. Owing to
the cost, the multiparameter assay was cancelled for those who withdrew consent post randomisation but
prior to treatment allocation. For the purposes of the preliminary study, randomised participants who had
not yet been allocated treatment and for whom an Oncotype DX result was not obtainable were not
followed up. Participants who declined to comply with their trial-allocated treatment remained on-study
and are followed up in accordance with the protocol.
Analysis of the OPTIMA prelim success criteria
The acceptability of the trial was assessed as the proportion of eligible patients consenting to participate in
the OPTIMA prelim. The characteristics of the patients for whom the trial and the concept of test-driven
therapy were acceptable were provided. The time from signing the OPTIMA prelim consent form to
starting chemotherapy was calculated and the proportion of chemotherapy-assigned patients starting
treatment within 6 weeks was determined. Compliance with the test-directed treatment decision was
assessed through the proportion of patients choosing not to follow the result of the randomisation.
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Decision to continue to the main trial
There were no formal stopping rules within OPTIMA prelim, as the ability to continue to the main trial was
dependent on a combination of patient acceptability, recruitment, number of alternative tests to consider
and cost-effectiveness. The decision on whether or not the main trial is feasible was dependent on
meeting the predefined success criteria for the study (see OPTIMA prelim success criteria).
Involving patients in developing a study
Recruitment into the OPTIMA trial was anticipated to be challenging because women who would normally
be offered immediate chemotherapy after surgery were to be asked to consider the possibility of not
receiving chemotherapy on the basis of a test. As reported elsewhere, trials with control, placebo or
‘no’/’yes’ treatment arms can be inherently difficult to recruit.130–133 Although the OPTIMA study is slightly
different, in that a personal genomic test will dictate the need for chemotherapy, it is not known how this
may influence perceptions of the study and whether, or how much, this will impact recruitment. Patient
and public involvement (PPI) is, therefore, integral to the design of the OPTIMA study in order to
understand the possible opportunities and problems that this might present from the perspective of people
with cancer. It is planned that data and insight from PPI will allow for ongoing protocol amendments, and
advice and training to be disseminated to recruiting staff so that appropriate information can be given to
potential participants. This will prevent recruitment being compromised by misunderstanding or
inappropriate concerns from either staff or patients.
Three complementary stages of PPI have taken place during OPTIMA prelim, consisting of:
1. engagement as a co-investigator and consequent contribution to the study design, and information by
a member of a patient advocacy group, Independent Cancer Patients’ Voice (ICPV)
2. representation of the same patient advocate on the TMG with full participation in the review of trial
conduct and progress
3. focus groups with people who have or have had cancer about their perspectives on being offered
participation in the OPTIMA trial or a similar study potentially offering less treatment than expected.
Focus group design
Three focus groups were held for people who had or were living after cancer. These were held in Coventry
in August 2012, in Cambridge in February 2013 and Guildford in April 2013. At least two members of the
OPTIMA trial team were in attendance to offer factual advice about the trial and to give administrative
support,134 but their contribution was kept to a minimum to allow free discussion at each focus group.
The focus groups were facilitated by trained facilitators and discussions were moderated independently by
members of the charity ICPV, of whom one or two attended each group. Participants were people who
lived locally and had been invited via a support group they attended or through ICPV. Twelve self-selecting
participants attended each focus group. The majority were women with primary breast cancer, but the group
in Guildford was made up of six women living after breast cancer and six people with other cancers, including
four men. Each focus group was audio-recorded to ensure that data were as complete and reliable as
possible, and a member of the study team took notes of the proceedings and main areas of discussion.
Potential focus group participants were given a précis of the trial protocol, copies of information given to
potential OPTIMA prelim trial participants (the PIS) and details of the focus group aims. Additionally, an
information leaflet about taking part in the focus group was provided for participants to read before each
meeting, and to advise them that they would be asked for consent to take part in the study and have their
contribution recorded if they attended. Each focus group meeting started with introductions and a
presentation of the trial with an opportunity to ask questions. Following this, the intended structure of the
meeting was explained. Ground rules were suggested by the study team members and agreed at each
meeting by attendees (Table 4). Participants were also asked for written consent to take part in the focus
group and for the focus group to be recorded; all participants gave consent. It was made clear that
documentation would not contain anything that would make individuals identifiable and that names should
not be used during the focus group to keep data reporting as confidential as possible.
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Each group then proceeded with an invitation for each member to give a brief introduction of why they
had attended the focus group and any other information that they felt was pertinent to the group.
The majority of people also gave details about their diagnosis and treatment at this point, if applicable.
Research aim
The research aim for the focus groups was to seek an understanding from people with personal
experience of cancer of the possible difficulties and/or opportunities involved in making a decision to take
part in the OPTIMA study. Owing to the complexity of the study, each focus group session started with
a brief 5-minute introduction to the trial and written material was handed out in a pack to each participant
including the flow diagram.
Each group discussion was loosely structured to allow participants to focus on the difficulties and
opportunities that were important to them. Each was opened with the question, ‘Do you think you would
take part in the OPTIMA study?’. This was clarified by questions from the interview schedule detailed
in Table 5.
Analysis
The analysis of focus group data has been criticised as being subjective, with methods often not explained
fully in publications.134–137 It is usually based on a ‘constant comparison’ approach, as initially used in
grounded theory research,138 and involves coding and categorising data to identify themes.
We followed a previously described approach to analysis,139 which incorporates eight key stages of
interpretation (Table 6).
TABLE 4 Agreed focus group rules of engagement
Rule number Rules of engagement
1 Everyone has the right to say what they want to say without interruption
2 Everyone’s opinion and point of view will be respected
3 No identifiable information will leave the room (except recorded data and
only personal identification by the speaker will be permitted)
TABLE 5 Schedule for loosely structured focus groups
Key question Related questions
What information would you need to make a
decision to consent to the OPTIMA trial?
l What would motivate you or discourage you from taking part
in OPTIMA?
l Are the pathways of information adequate to support
decision-making?
l Would anything about the consent procedure, participant
information leaflet or any other aspect of the trial design affect
your decision?
Should an independent organisation provide
information to potential participants?
l Do you think it would be helpful for independent information to be
provided (e.g. via ICPV)?
l What should this be?
l How should it be made available or marketed?
What do you think might motivate people
who have refused the main study to take part
in a qualitative study?
l What aspects of a qualitative study would encourage or discourage
you from taking part?
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The three focus groups were analysed separately and then combined to create a composite. Analysis was
iterative and did not follow a linear course. It involved listening to tapes, transcribing them and reading
the transcripts with the notes taken during the group. The transcripts were loaded into NVivo V.9
(QSR International, Warrington, UK), which supports qualitative methods by allowing the organisation and
analysis of unstructured spoken data. While scrutinising the data and highlighting content of interest, we
began to code the data line by line. During this stage, developing categories and themes began to
emerge. After this had been done separately for the three groups, they were amalgamated and coding
and data categorisation continued until there was consensus about the themes.
Qualitative recruitment study methods
As there were anticipated challenges to recruitment, in addition to PPI, the OPTIMA prelim incorporated an
integrated qualitative recruitment study (QRS). This used a refinement of the methods developed for the
ProtecT (Prostate testing for cancer and Treatment) study’s complex recruitment intervention.140 The QRS in
OPTIMA prelim aimed to work with the chief investigator (CfI), TMG and OPTIMA staff to identify and
address barriers to recruitment, in three phases:
l Phase 1 sought to identify and understand recruitment difficulties through use of multiple
qualitative methods.
l Phase 2 involved sharing phase 1 findings with the TMG and CfI, and working collaboratively to design
and deliver interventions to optimise recruitment and informed consent. Phase 2 interventions included
individual confidential and group feedback sessions to dissemination of tips and guidance for recruiters.
All forms of intervention were shaped on the basis of the findings from phase 1 and consideration of
how the OPTIMA trials specific set-up could accommodate the intended changes.
l Phase 3 was an evaluative process, consisting of careful mapping out of QRS interventions and
assessment of potential impact on recruitment figures and recruiters’ practices.
The methods outlined below follow the consolidated criteria for reporting qualitative research (COREQ)
checklist.141 A copy of the COREQ checklist can be found in Appendix 3.
TABLE 6 Analysis of focus groups (based on Rabiee139)
Stage What is interpreted What to consider
1 Words The actual words used and their meaning (e.g. metaphorical use)
2 Context The context in which things are said (by both participants and facilitators)
3 Internal consistency Any changes in opinion by the participants
4 Frequency How often a view is expressed (but also need to consider contrary but
relevant views)
5 Intensity of comments The ‘depth of feeling’ in which views are expressed
6 Specificity of responses Personal experience vs. hypothetical situations
7 Extensiveness The number of participants who express a view
8 Big picture Significant themes or concepts that emerge from an accumulation of data and
intersect various discussions (e.g. in all groups)
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Phase 1: understanding recruitment issues
The first phase of the integrated QRS sought to understand barriers to recruitment, with the intention of
developing interventions to support recruiters, improving the quality of information provision where
needed and optimising recruitment rates. The approaches used to identify recruitment difficulties followed
principles of ethnography, with a flexible approach to data collection and analysis of interviews,
observations and documentary data including PISs and screening logs.
Sampling and recruitment
The sampling frame consisted of all TMG members and OPTIMA prelim staff members from centres
participating in the QRS at the start of the study (9 out of the 25 centres open to recruitment).
‘QRS centres’ comprised those which agreed to take part in this ‘optional’ element of OPTIMA prelim.
Additional centres that opened in later stages of the trial were also approached to take part in the QRS
(contributing audio-recordings only).
Interviews with OPTIMA staff
The TMG and staff members at QRS centres were purposefully selected for interview based on their
involvement in recruiting patients or trial oversight, and with the aim of selecting individuals occupying a
range of professional roles relevant to the recruitment process (e.g. oncologists, research nurses). Some
informants were purposefully selected on the basis of emerging analytical insights that warranted further
investigation. Informants were invited via e-mail to take part in a semistructured research interview with
LR (the qualitative researcher working on OPTIMA) at a mutually convenient time/date. E-mail reminders
were sent 2 weeks after dispatch of the original invitation. There was also scope to approach further
individuals for interview as new centres opened throughout the course of OPTIMA prelim.
Following semistructured interviews, all research nurses at participating QRS centres were invited
(via e-mail) to take part in a short, structured telephone interview to answer a series of questions about
eligibility processes and patient pathways at their centre. The processes of organising a convenient time/
date and dealing with non-respondents were similar to those described above.
Audio-recorded consultations
All staff members involved in recruiting patients were asked to routinely record consultations at which the
OPTIMA prelim was discussed with patients. A research nurse or the principal investigator (all of whom
were oncologists) for each centre distributed staff information sheets about the recording process and
obtained one-off written consent that covered all subsequent recordings made throughout the study
period. Patients were ‘recruited’ through a two-step consent process, developed to ensure that they were
fully informed. Staff obtained initial verbal consent to record the patient’s first consultation, followed
by written consent in a follow-up consultation. An information sheet explaining the recording process
was handed to patients in the first consultation and patients were given sufficient time to consider their
participation (at least 24 hours). If the patient declined participation in their follow-up consultation,
any recording(s) obtained to date were destroyed and no further recordings made. If consent was
provided, the second and any subsequent consultations were also recorded.
Data collection
Interviews
Semistructured interviews with staff were conducted face to face on hospital trust premises or via
telephone if meeting in person was not feasible. A topic guide was used to ensure broad topics were
consistently covered, although questions were adapted according to the role of the informant and
sufficient scope provided for exploration of new topics that emerged through discussion. Topic guide areas
covered: informants’ summaries of the RCT design and protocol; views on whether or not the trial
conception/design were appropriate; thoughts on whether or not practices deviated from protocols;
equipoise in relation to the RCT arms, and experiences of recruitment successes and difficulties (final topic
guides shown in Appendix 4 and the original versions are shown in Appendix 5). All interviews were
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conducted by LR and JD (Jenny Donovan, the QRS lead) between January and June 2013, and lasted
between 40 minutes and 1.5 hours. Sampling of potential interview participants ceased once the QRS
team were satisfied that data saturation had been achieved, defined as the point at which no new themes
emerged from two consecutive interviews.
A series of structured, short telephone interviews (lasting up to 10 minutes) were conducted with research
nurses and notes were taken in response to the structured fact-based questions about eligibility processes
and patient pathways.
Audio-recorded consultations
Audio-recordings were collected throughout the duration of the QRS (April 2013–April 2014). Centres
were provided with audio-recording devices and instructions for recording, uploading and storing
recordings on a secure computer on trust premises. Staff were encouraged to routinely record all
interactions with patients (following receipt of written consent) and received monthly updates from LR.
Transfer of recordings was periodically arranged through postage of encrypted data storage devices
between the research nurses and LR. Consultations were deleted from trust computers once LR confirmed
safe receipt of each (set of) recording(s).
In addition to these data collection processes, LR joined in on scheduled ‘core TMG’ and wider TMG
meetings, occurring approximately biweekly and once every few months, respectively, to facilitate
understanding of recruitment issues and trial processes. The ‘core TMG’ consisted of select members of the
TMG with the greatest responsibility for trial oversight (e.g. the CfI, trial manager and other individuals
with leadership responsibilities).
Data analysis methods
Interview analysis
Interviews were audio-recorded, transcribed in full and analysed thematically using the constant
comparison method derived from grounded theory methodology.138 This involved line-by-line coding of
transcripts, categorising codes into themes, and developing codes and themes as transcripts were reread in
light of newly collected data. Analysis was primarily conducted by LR and supported through use of the
software package NVivo (version 9). A sample (10%) of transcripts from interviews were independently
analysed by a trained qualitative researcher working in trials methodology (SP) in the initial stages of data
collection. A basic coding frame was agreed, which evolved as data collection proceeded. The QRS
research team regularly discussed extracts of raw data in face-to-face meetings. A descriptive account of
interview findings was written towards the end stages of data collection and discussed by the research
team to fine tune the ‘key themes’. This document evolved as analysis progressed and discussions among
the research team developed over time. Major themes from interviews were presented in matrices, with
individual accounts arranged by centre and participant role to encapsulate patterns of meaning within
each set of accounts. There was an attempt to search for ‘negative cases’ in relation to particular themes
or theories; where present, these were fully reported in the evolving descriptive account. A final series of
Microsoft Word (Microsoft Corporation, Redmond, WA, USA) documents, each devoted to a particular
theme, were compiled towards the end of the analytical process to facilitate reporting of findings.
Screening log analysis
There was an intention to map the patient eligibility and recruitment pathways through analysis of
screening log data, with a view to producing detailed accounts of the numbers and percentages of
patients at each stage of the process. It emerged that screening logs did not provide the necessary data to
do this, as these only recorded information from the point at which the patient was approached about trial
participation; details of initial screening and eligibility were not captured in the logs. In light of this,
interview data were used to map out a broad outline of eligibility processes and recruitment pathways for
each site. Screening logs were referred to regularly to track recruitment rates, which, in turn, partially
informed targeting of centres that could benefit from intervention. Screening logs also provided useful
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details pertaining to recruiters’ reported reasons for patients declining the trial (see Chapter 4, Screening
and acceptability). These insights were considered alongside data emerging from interviews and
audio-recorded consultations.
Audio-recorded consultation analysis
A systematic and multifaceted approach was adopted for analysis of audio-recorded consultations.
Consultation transcripts were initially analysed thematically using the constant comparison methods
described above. Areas of interest were coded to a greater number of levels than sections that were not
directly relevant to the OPTIMA prelim (e.g. rapport-building conversation, family medical histories). Key
themes arising from interviews were used as a starting point for in-depth analysis. Recruiters’ explanations
and use of terminology in the lead up to points of ‘confusion’ were scrutinised and compared with
explanations of the same concepts in other consultations – particularly those that appeared to be easily
understood and accepted by patients. Approaches to analysis inspired by conversation analysis were used
in a targeted, practical manner, where there was an intention to interpret patients’ reactions to trial
explanations (e.g. intonation of words/noises and the meanings of silences/pauses in interaction).142,143
The audio-recordings were initially listened to by LR. She noted points of interest and preliminary thoughts,
and followed this with targeted transcription of consultations. Sections of speech that were not directly
relevant to the OPTIMA prelim were summarised by LR in brackets (with timings). This included non-clinical
discussions about patients’ life contexts and details of medical history. Speech that was directly or loosely
related to the OPTIMA prelim’s rationale, aims and processes was transcribed using standard notation.
Points of confusion or contention or ‘troubled’ speech were targeted for verbatim transcription
(i.e. including pauses, repetition of words and ‘ums’, ‘ahs’). The length of time before introducing the
OPTIMA prelim study was timed for all consultations. This was considered alongside patients’ engagement
and comprehension of trial-specific processes.
Analytic synthesis
Themes for the interview and audio-recording data sets were compared and considered alongside
screening log data describing patients’ reasons for declining the trial. Findings from the multiple data
sources were presented to the CfI and TMG as key findings for phase 1 of the QRS.
Phase 2: development and implementation of recruitment strategies
The findings from the QRS were developed into plans for feedback and training with the CfI and TMG
members. All materials used for guiding and supporting recruiters were based on findings grounded in
data collected in phase 1. Recruitment difficulties recurring across centres formed the basis of ‘generic’
interventions disseminated across all centres through ‘tips and guidance’ documents and regional feedback
meetings attended by multiple centres. Clinician-to-clinician meetings between clinical members of the
TMG and clinicians at recruiting centres were suggested where differences in clinical opinion had
implications for recruitment. Single-centre feedback sessions were also developed for those who requested
this or were unable to attend regional meetings. Difficulties experienced by individual recruiters were
tackled through development of individual feedback plans that were discussed in confidence with the
relevant individuals.
Phase 3: impact of qualitative recruitment study interventions
The final phase of the QRS drew on multiple approaches to evaluating the impact of the QRS on
recruitment. The time points at which QRS interventions were delivered were mapped out on graphs that
charted recruitment figures over time. Changes in the direction (or rate of increase/decrease) in recruitment
figures were assessed relative to the QRS interventions. Other approaches to analysis considered
recruitment rates in centres that received certain forms of intervention, compared with centres that did
not. Further qualitative analysis also featured in this phase, where recruiters’ practices were compared
before and after points of intervention. The varied approaches to evaluating the QRS were considered
collectively with a view to forming tentative conclusions about the QRS’s success in optimising recruitment
within OPTIMA prelim.
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Chapter 3 Methods: pathology and health
economic study
Pathology research in the preliminary study
Additional research testing of tumour tissue was planned for all confirmed eligible patients, irrespective
of randomisation, to enable the performance of alternative multiparameter assays to be evaluated.
This research is integral to the preliminary study, and all patients who joined the study were required
to consent to this research. Genomic Health performed Oncotype DX testing on samples from participants
randomised to the standard arm as part of this programme at the time of eligibility confirmation; these
results were not used to determine the participant’s treatment. Following Oncotype DX testing, residual
tumour tissues were stored in the OPTIMA tissue bank at the University of Edinburgh. This is a good
laboratory practice facility managed by Professor John Bartlett [University of Edinburgh and Ontario
Institute for Cancer Research (OICR) Toronto].
Patients were also asked to give additional optional consent for future (unspecified) research to be
performed on their tissue samples, which could include genetic testing. If such permission was given,
tumour samples were retained in the OPTIMA tissue bank beyond the completion of the study. Should the
treating centre require a sample for diagnostic use in the future, the stored tumour sample will
be returned.
Multiparameter assays performed
We set out to evaluate as many tests as possible through positive engagement with multiple partners.
Discussions with several vendors of tests, which owing to their characteristics might be candidates for
inclusion in the OPTIMA main study, were undertaken during the design phase of OPTIMA prelim to
secure collaboration. Strenuous efforts were made to secure collaboration with additional test vendors
during the recruitment phase. We recognised that for commercially available tests it was important that
evidence of quality of test performance was ensured. The possibility of centralising tests to a single
laboratory was considered but rejected because the performance of most tests was dependent on
commercial laboratories (e.g. Oncotype DX, MammaPrint) or expert readers (e.g. Mammostrat).
The vendors of the following tests were approached for support:
l BCI
l Endopredict (Sividon Diagnostics, Cologne, Germany)
l Genomic Grade Index (Bordet Institute, Brussels, Belgium)
l MammaPrint/BluePrint/TargetPrint
l Mammostrat
l MammaTyper
l Molecular Grade IndexSM (bioTheranostics/Qiagen, Limburg, the Netherlands)
l NexCourse Breast by AQUA
l Prosigna (PAM50).
Five tests were not taken forward for analysis in the OPTIMA prelim cohort following discussions with the
vendors/licensees: BCI, Endopredict, Genomic Grade Index, Molecular Grade Index and Mammostrat.
The reasons for rejecting these tests included OPTIMA prelim population not appropriate for the test in
question (n= 3); test licensing under negotiation/transfer (n= 1); and test withdrawn from study (n= 1).
The decision not to offer these tests for the OPTIMA population reflected commercial concerns about
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prematurely transposing tests into novel applications. Tests developed by two vendors who were
supportive during the design phase were not included because of changed commercial development plans.
It is noteworthy that all companies participating in these discussions were supportive of the collaborative
effort being undertaken and the OPTIMA trial in particular, and sought to ensure the broadest comparison
between testing approaches given commercial constraints.
The Prosigna assay was performed at Professor Bartlett’s research laboratory at the OICR, following staff
training and accreditation by NanoString Technologies. MammaPrint and BluePrint assays were performed
by Agendia technologies using sections provided by the University of Edinburgh. MammaTyper quantitative
PCR assays were performed by Stratifyer GmBH at laboratories in Mainz, Germany, using residual
ribonucleic acid (RNA) from the Prosigna assay extracted using the Roche mRNA extraction kit provided by
Prosigna. The NexCourse Breast IHC4 assay using AQUA (IHC4 AQUA) was performed by Genoptix
medical laboratories on replicate tissue microarrays (TMAs) provided by the University of Edinburgh.
In addition to the commercial assays, IHC4 was also performed by conventional pathology techniques
[HER2 testing by in situ hybridisation at the UCL (University College London) Advanced Diagnostics
Laboratory and ER, PgR and Ki67 on TMAs by quantitative image analysis (Ariol version 4.0 SL50, Leica
Microsystems, Wetzlar, Germany) using standard immunohistochemistry at OICR as previously
described].144 Quantitation of ER, PgR and Ki67 to the degree required to calculate an IHC4 is not standard
practice in NHS pathology laboratories and, indeed, Ki67 is not a standardised marker for routine testing in
breast cancer pathology assessment.
Results were calculated to established procedures for each assay or, in the case of IHC4, using the
published algorithm.56 Tumours were categorised into risk groups based on the predefined cut-off points
for the continuous Prosigna ROR scores, IHC4 and IHC4 AQUA (see Appendix 6 for details). These risk
groups were then compared with each other including those defined by Oncotype DX.
Some guidelines, including the internationally recognised St Gallen guideline,145 recommend the use of
breast cancer subtyping as a means of informing treatment options. Breast cancers can be subtyped into
four main molecularly defined intrinsic subtypes (see Parker et al.28 and references therein25–27), namely
luminal A, luminal B, HER2 enriched and basal-like.
Three tests (BluePrint, Prosigna and MammaTyper) provide information on molecular subtypes. BluePrint,
which is performed together with MammaPrint, and Prosigna additionally provide information about
recurrence risk, which is binary in the case of MammaPrint and takes the form of a categorised risk score for
Prosigna, while MammaTyper is specifically focused on providing subtype information including a
stratification of ‘luminal B’ cases into low and high risk based on the Ki67 result (see Appendix 6 for details).
Analytical methods
For the purpose of analysis, patients were divided by randomisation and by Oncotype Dx score (≤ 25 vs.
> 25). Patients’ individual predicted predicted risks of both recurrence and death were summarised using
median and ranges. The kappa coefficient and associated 95% CI was used to assess agreement between
tests. All statistical analyses were performed using the SAS statistical package (version 9.3; SAS Institute
Inc., Cary, NC, USA).
Sample size
OPTIMA prelim required 300 patients to be recruited over the first 2 years (a 6-month set-up phase and an
18-month recruitment phase). Oncotype DX was used prospectively to decide on patient chemotherapy
treatment in the research arm (using a RS cut-off point of ≤ 25 vs. > 25), while alternative tests were
applied retrospectively. The true efficacy of the tests will not be known until all patients have been
followed up for 5 years and IDFS is compared. Therefore, the study was powered to compare risk groups
from the multiparameter tests with Oncotype DX as well as with each other.
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To assess agreement between tests, the sample size calculations assumed that 70% of patients randomised
to test-directed treatment would be assigned to no chemotherapy as a result of the Oncotype DX test and
the true kappa value was 0.8. A sample size of 300 patients would provide stability around the kappa
estimate and provide a lower 95% CI of 0.73. These numbers were also sufficient to be able to detect
agreement between tests, taking into account the expected type of patients entered into the study,
if the assumed proportion of patients randomised to test-directed treatment would be assigned to no
chemotherapy varied from 55% to 80% (Table 7). The lower confidence limit for kappa varied from 0.74
to 0.72, when the proportion of patients assigned to having no chemotherapy varied from 55% to 80%.
Economic evaluation
Introduction to the economic analysis
There is currently interest in using decision modelling earlier in the research and development process
for new health-care technology.146 This is, in part, a response to the high costs and high failure rates
of pre-regulatory Phase III trials. A decision model can be used to analyse uncertainties in the current
effectiveness and cost-effectiveness evidence. The estimate can then be used to tailor a Phase 3
research design to address uncertainties that pose the most risk for clinical, regulatory and
reimbursement decision-makers.
The objective of the economic analysis for OPTIMA prelim was to establish the value of conducting further
research into the cost-effectiveness of Oncotype DX or alternative test-directed therapy in the UK in the
setting of a main OPTIMA trial. OPTIMA prelim also assesses the feasibility of resource use measurement
and the within-trial identification of appropriate health-care costs and health-related quality-of-life
information to inform the calculation of QALYs.
The economic model and methods developed for this analysis are described in this section. Details on the
interpretation of the results of the economic analysis are given in Chapter 5 (see Economic analysis).
Test selection for inclusion in the main economic (base-case) analysis
The factors that were considered when assessing alternative tests for possible inclusion in the main study
included analytical validity or reproducibility, biological plausibility and cost-effectiveness. Evidence must
exist that an assay produces reproducible results when it is run more than once on the same sample and
for distributed tests, that the results are reproducible between laboratories undertaking the assay. The
assignment of patients to chemotherapy or not by a test must also be plausible. For instance, if a HER2
test was used as the primary discriminator within the OPTIMA trial, no patient would be assigned
chemotherapy, which may make this test appear highly cost-effective. However, although HER2 is a binary
test that identifies a high-risk patient population, HER2-positive patients are excluded from the OPTIMA
trial, so the test is not plausible.
TABLE 7 Sensitivity of the lower 95% CI for a true kappa of 0.8 and a range of values of the proportion of patients
assigned no chemotherapy with a sample size of 300
Sample size
Proportion of patients assigned
to no chemotherapy
Lower 95% CI if the true
kappa is 0.8
300 0.55 0.735266
300 0.60 0.7341705
300 0.65 0.7322176
300 0.70 0.7291755
300 0.75 0.7246098
300 0.80 0.7176715
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A base-case model was specified as the main analysis and from which sensitivity analyses were performed.
Tests were selected for inclusion in the base-case analysis if they met all three of the following criteria:
1. sufficient evidence of analytical validity in support of an achievable rollout into routine care in the NHS
2. peer-reviewed evidence published in the public domain for clinical validity in a relevant clinical setting
3. existence of either (a) a global or UK list price in the public domain for the test or (b) a credible way
of estimating the cost of performing the test including a list price for all test components.
Tests meeting these criteria were Oncotype DX, MammaPrint and Prosigna. IHC4 was not included owing
to concerns about the analytical validity when used as a locally implemented test in NHS laboratories.
Further details about this rationale are outlined above (see Chapter 1, Individual multiparameter assays)
and elaborated on in the discussion. IHC4 AQUA and MammaTyper were excluded owing to a lack of
peer-reviewed published evidence for clinical validity in a relevant clinical setting. MammaTyper was also
excluded, as the manufacturer put no price forward. An additional sensitivity analysis (see Sensitivity
analysis number 3, all tests included) was conducted that included all tests. Where a price was not
available from the manufacturer (as with MammaTyper) this was estimated by the analyst.
Clinical risk prediction
The outcome of the OPTIMA prelim patients will be unknown for 5 years and, therefore, it was necessary
to forecast long-term survival outcome for the OPTIMA trial population as an assessment of the population
under study and to enable the calculation of lifetime expected QALYs for the economic model. The
population included in the OPTIMA prelim study are ER-positive, HER2-negative early-stage breast cancer
patients. The clinical risk prediction nomograms NPI,19 Adjuvant! Online (version 8)17 and PREDICT18 were
applied to each patient. Both Adjuvant! Online and PREDICT give an estimate of treatment benefit for
both endocrine therapy and chemotherapy over a 10-year period. PREDICT, but not Adjuvant! Online,
takes HER2 status into account, while only Adjuvant! Online provides an estimate of recurrence-free
survival (RFS). Chemotherapy benefits estimated with the nomograms used the intended regimen for that
patient, where FEC75–80, FEC90–100, E-CMF and TC are considered to be ‘second-generation’, and
FEC-T and FEC-Pw are ‘third-generation’ regimens.
Endocrine therapy was specified as AI for post-menopausal and tamoxifen for premenopausal patients in
Adjuvant! Online. Comorbidities for Adjuvant! Online were entered as ‘average for age’. No attempt was
made to apply a correction for the HER2-negative status of the OPTIMA population using the inbuilt
prognostic tool. Ki67 was entered as ‘unknown’ in PREDICT. Five-year RFS probability was also estimated
using both a ‘constant benefit’ model (which assumes that the benefit of chemotherapy is constant across
all risk scores and independent of tumour biology as determined in the Early Breast Cancer Trialists’
Collaborative Group meta-analysis)9 and a ‘variable benefit’ model (which assumes that the benefit of
chemotherapy varies according to the test risk score, as determined in the SWOG88-14 trial).62 These two
models are described in more detail in sections Model parameters and Sensitivity analysis. The additional
benefit that might be gained from having chemotherapy was calculated per patient as the difference in
the survival estimates obtained if they were to have both endocrine therapy and chemotherapy, and that
for if they only had endocrine therapy. The median and ranges of the estimates from each nomogram
for all patients within the RS low group and high groups separately were obtained.
The economic model
A model-based economic evaluation of Oncotype DX was conducted during the design period of the
OPTIMA prelim. This served a dual purpose: first, it allowed the model to inform the design of OPTIMA
prelim, ensuring that the design and data collection was pertinent for UK NHS decision-making; and,
second, it prepared a suitable model that could form the basis of an economic analysis at the end of the
feasibility period to aid in the design and selection of appropriate tests for inclusion in the main trial.
The original model is described in a separate publication.15
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For the OPTIMA prelim analysis, model parameters have been updated by a systematic literature search and
costs have been replaced by contemporary costs, where possible from 2014, adjusted to a common base year
of 2012–13 (with conversions for the list prices of tests into GBP made using www.xe.com). An additional
health state representing acute myeloid leukaemia secondary to chemotherapy has also been added.
The economic model comprises a time-dependent discrete-state transition model (modified Markov
model). A detailed explanation of these methods is provided by Sonnenberg and Beck.147 The model
was used to estimate mean differences in clinical effects, including life-years, QALYs and costs for a
hypothetical cohort of women with ER-positive, lymph node-positive breast cancer.
Overview and model structure
The methods for the economic model followed the NICE guidance.148 The structure of the model was
developed by consensus among clinical experts, health economists and medical statisticians. The structure
was developed from a previously published model.149 The first part of the model structure is an
instantaneous decision tree that allocates a patient cohort either to standard care, where all patients
receive chemotherapy, or to a test that is used to allocate patients to high- or low-recurrence risk groups
(Figure 2). Patients in the high-risk group, but not those in the low-risk group, are allocated chemotherapy.
The second part is a modified Markov model, with annual cycles, which is used to calculate mean
life-years, QALYs and costs per patient in each group (Figure 3). All patients were assumed to receive
identical non-chemotherapeutic adjuvant therapies.
Patients entered the model at the initiation of adjuvant therapy and were assumed to be disease free.
This time point is synchronous with randomisation into OPTIMA prelim. The model assumes that patients
then move into a disease-free (follow-up) state; develop a local recurrence (which includes locoregional
recurrence) or a distant recurrence; develop congestive cardiac failure, acute myeloid leukaemia; or die of
unrelated causes. It was assumed that patients remained disease free until they developed a breast cancer
recurrence, cardiac failure, acute myeloid leukaemia or died.
No chemotherapy
RS low
RS high
Chemotherapy
Chemotherapy
State-transition
model
State-transition
model
State-transition
model
FIGURE 2 Decision tree.
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The model assumes that patients who develop a local recurrence can be treated curatively and move into a
separate ‘disease-free after recurrence’ state, which carries distinct risks of further distant relapse. For
simplicity, the model assumes that patients can develop only one local recurrence. Patients remain in the
distant recurrence state until death from breast cancer or death from other causes.
Model parameters
Test allocation
Estimates of the proportion of patients assigned to high- and low-risk groups and recurrence estimates for
each group were initially taken from the SWOG88-14 Oncotype DX analysis and used in a validation
model.62 Proportional allocation was available for alternative Oncotype DX RS cut-off points of 18 and 25.
Patient allocation into risk groups identified by all Oncotype DX cut-off points and patient allocation by
alternative tests were subsequently replaced by data from OPTIMA prelim. In the SWOG88-14 trial,
40% [standard error (SE) 0.026] of patients were allocated to a group with a RS of < 18 and 59%
(SE 0.026) were allocated to a group with a RS of ≤ 25. These proportions were represented by a beta
distribution in the probabilistic model. Test allocation was subsequently estimated from the OPTIMA prelim
data for use in the base-case analysis and sensitivity analyses.
Cancer recurrence rates and chemotherapy effect sizes
Estimation of cancer recurrence rate is central to the model. A major challenge of using decision-analytic
modelling before the main OPTIMA trial is the uncertainty about recurrence rates and chemotherapy
effects given the scarcity and limited transferability of available published evidence. In parallel with the
OPTIMA prelim statistical analysis, five separate model specifications were proposed, each relying on
alternative assumptions about chemotherapy effect and population characteristics.
Validation model: update of published model based on the SWOG88-14 trial
(Oncotype DX)
In the original model, recurrence rates were taken from the SWOG88-14 trial for all patients treated with
or without anthracycline-containing chemotherapy.62 SWOG88-14 provides survival estimates over
10 years. It should be noted that the main limitation of the validation model is that the SWOG patient
population may not be representative of a UK OPTIMA population. For example, in the intervening years
since the SWOG88-14 trial, the NHS breast screening programme has been put in place; recruitment into
the OPTIMA trial is commencing nearly 20 years later than into SWOG88-14, the OPTIMA trial has
different eligibility criteria than SWOG88-14 (with HER2-positive disease excluded) and, therefore, there
is likely to be different distribution of test scores. In addition, because RFS was not available for this study,
IDFS was used as a proxy for RFS, justified by the low number of deaths during the first 5 years of follow-up.
Disease free
Start
Dead
Local recurrence
Disease free after
local recurrence
Distant recurrence Heart failure
Acute myeloid
leukaemia
FIGURE 3 State-transition model.
METHODS: PATHOLOGY AND HEALTH ECONOMIC STUDY
NIHR Journals Library www.journalslibrary.nihr.ac.uk
34
Recurrence rates were available for groups selected by Oncotype DX based on RS cut-off points of 18 or
25. In this updated analysis, RFS for each group was represented by an exponential survival distribution
(constant hazard), specified separately for years 1–5 years and 6–10 years. This uses 5- and 10-year IDFS
proportions with SEs taken directly from the SWOG88-14 trial data, which was kindly provided by the
investigators (Table 8). The annual hazard was calculated from the event rate over each 5-year period
represented by a beta distribution, the parameters of which were calculated from the moments, to allow
Monte Carlo simulation in the probabilistic analysis. An important additional parameter is the transition
probability from disease recurrence to death, referred to as post-recurrence survival; this is a major
component defining the relationship between RFS and overall survival. There is very little evidence to
inform this parameter in the relevant patient populations.
The OPTIMA prelim base-case model
Clinical outcomes from the OPTIMA prelim trial were estimated as described earlier (see Clinical risk
predication) using Adjuvant! Online. The economic model requires an estimate of RFS, and the analysis is
therefore restricted by the availability of this. Forecast RFS, assuming no chemotherapy, was derived for the
OPTIMA prelim patient population using baseline clinical parameters entered into Adjuvant! Online.17
The only evidence of a predictive (variable chemotherapy benefit) effect at the time of writing is based on
retrospective Oncotype DX testing of patients in the SWOG88-14 trial (Table 9).
This was represented in the economic model by a linear regression model,
logHR=α+βRS, (1)
where logHR= the log-hazard ratio for RFS, α= 0.4541 (SE 0.03749), β= –0.0238 (SE 0.00418),
RS= recurrence score and the correlation between α and β is assumed to be –0.5.
TABLE 8 Disease-free survival at 5 and 10 years from the SWOG88-14 trial
Patient group RS 5-year IDFS SE 10-year IDFS SE
All patients treated with chemotherapy All 0.79 0.028 0.61 0.038
Tamoxifen alone RS of ≤ 18 0.91 0.039 0.60 0.092
RS of ≤ 25 0.85 0.038 0.57 0.067
Tamoxifen and chemotherapy RS of > 18 0.74 0.039 0.58 0.049
RS of > 25 0.71 0.048 0.56 0.059
TABLE 9 Individual patient predicted hazard ratios for chemotherapy vs. no chemotherapy for 5-year IDFS62
Oncotype DX RS Hazard ratio Upper 95% CI Lower 95% CI
10 1.24 0.62 2.48
18 1.03 0.58 1.81
25 0.87 0.53 1.42
31 0.75 0.48 1.18
40 0.61 0.39 0.96
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The resulting hazard ratio was applied to the no chemotherapy recurrence rates for all individual patients
in the ‘chemotherapy for all’ standard care arm of the model over the first 5 years. In the test-directed arm
of the model, the same chemotherapy effect was applied only to patients in the high-risk groups. Where
there were no data providing evidence for the predictive ability of alternative tests, extra uncertainty was
introduced into the model for these alternative tests depending on the degree of discordance between the
test and Oncotype DX. For example, a completely concordant test will have identical predictive ability and
therefore no extra uncertainty is introduced. To achieve adequate representation of extra uncertainty,
a suitable prior for the chemotherapy effect of the alternative test was required. In the absence of any
informative information, this prior treatment effect was represented by a hazard ratio of mean 1 with a
very large standard deviation (SD), assumed to be log-normally distributed. The choice of prior was subject
to sensitivity analysis. In the base-case analysis, post-recurrence survival was assumed to be independent of
pretreatment with adjuvant chemotherapy; the annual post-recurrence probability of death was assumed
to be constant across groups with a mean of 0.30 (SD 0.22).
Chemotherapy treatment and toxicity
The chemotherapy regimens and toxicity rates were used to estimate treatment-related costs. The
proportions of patients treated with anthracycline plus taxane, anthracycline alone, or taxane alone were
estimated from the OPTIMA prelim data. Chemotherapy toxicity rates150 were estimated from landmark
chemotherapy clinical trials (Table 10).151–153 Toxicity rates for FEC-Pw were assumed to be equivalent to
FEC-T, and toxicity rates for epirubicin were assumed to be equivalent to FEC. Toxicity rates for FEC75
were assumed to be equivalent to two-thirds the rates for FEC100.
Late effects
Parameters are included in Table 11. The population age- and sex-specific incidence of congestive heart
failure was taken from Office for National Statistics published data as presented by the British Heart
Foundation.154 The lifetime relative risk of congestive cardiac failure after chemotherapy was based on data
from the Oxford Overviews and applied to the population incidence, to provide an estimate of excess
congestive heart failure because of chemotherapy.9 Mortality after onset of congestive cardiac failure was
taken from a UK population study.155
The age- and sex-specific incidence of acute myeloid leukaemia was taken from a large UK primary
care-derived population database.159 There is evidence for an increased relative risk of acute myeloid
leukaemia in patients treated with chemotherapy from a number of published pooled trial-based analyses,
but this was difficult to estimate reliably owing to the low absolute numbers of observed events.8,160,161
The relative risk of acute myeloid leukaemia was estimated at 7.6 (SE 7.1). Survival after a diagnosis of
acute myeloid leukaemia was based on UK Cancer Registry statistics, as provided in a report by the
Northern and Yorkshire Cancer Registration and Information Service.162
Other transition probabilities and proportions
The mean time from metastatic recurrence to death was estimated from a UK patient-level analysis of
1000 consecutive breast cancer patients in a single NHS trust with a minimum of 10 years’ follow-up.157
An estimate of the proportion of recurrences that are locoregional was taken from the ATAC trial, which
included a large number of UK patients with similar characteristics to patients enrolled into OPTIMA
prelim.156 Background age-specific non-breast cancer mortality was estimated by subtracting age-specific
breast cancer-specific mortality from the age- and sex-specific background mortality, obtained from the
UK Office for National Statistics.158
Costs
Costs were adjusted to a base year of 2012–13 using the Hospital and Community Health Service pay and
prices index published by the Personal Social Services Research Unit.163 In the probabilistic analysis, costs
were assumed to have a log-normal distribution. The additional expected health-care costs in patients
receiving chemotherapy were derived by combining the expected costs of chemotherapy procurement and
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TABLE 10 Chemotherapy toxicity rates from landmark trials
Toxicity parameter Probability Distribution
TC (USO-9735 trial, Jones et al. 2009,151 n= 506)
Febrile neutropenia 0.046 Beta(23,483)
Anaemia 0.010 Beta(5501)
Thrombocytopenia 0.005 Beta(2504)
Stomatitis 0.008 Beta(4502)
Diarrhoea 0.025 Beta(12,494)
Nausea and vomiting 0.030 Beta(15,491)
FEC100 (PACS-01 trial, Roché et al. 2006,152 n= 995)
Febrile neutropenia 0.084 Beta(84,911)
Anaemia 0.014 Beta(14,981)
Thrombocytopenia 0.003 Beta(3,992)
Stomatitis 0.04 Beta(40,955)
Diarrhoea 0 Beta(1,996)
Nausea and vomiting 0.205 Beta(204,791)
FEC-T (PACS-01 trial, Roché et al. 2006,152 n= 1001)
Febrile neutropenia 0.112 Beta(112,889)
Anaemia 0.007 Beta(7994)
Thrombocytopenia 0.004 Beta(4997)
Stomatitis 0.059 Beta(59,942)
Diarrhoea 0 Beta(1,1002)
Nausea and vomiting 0.112 Beta(112,889)
E-CMF (TACT2 trial, Cameron et al. 2010,153 n= 1029)
Febrile neutropenia 0.13 Beta(137,892)
Anaemia 0.03 Beta(31,998)
Thrombocytopenia 0.01 Beta(10,1019)
Stomatitis 0.00 Beta(1,1030)
Diarrhoea 0.04 Beta(46,983)
Nausea and vomiting 0.02 Beta(24,1005)
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delivery with those expected from follow-up. Assumptions were made about routine practice in the UK
NHS based on advice from oncologists in London, Edinburgh and Leeds:
l Chemotherapy regimens represented in the economic model are FEC100, FEC-T, FEC-Pw, E-CMF and
TC (see Table 3).
l Average body surface area 1.7m2.
l Relative dose intensity 92% (all planned cycles completed).
l No vial sharing permitted (remaining drugs in vials assumed to be wasted).
l Standard supportive medication, procurement, laboratory, pharmacy and administration costs are based
on electronic Market Information Tool,164 British National Formulary165 and NHS reference costs.166
l Two medical oncology clinic visits per regimen and one specialist nurse review per cycle.
l Granulocyte colony-stimulating factor (five doses of filgrastim 300 µg) for 50% of FEC, 100% of FEC-T,
and 0% of TC and E-CMF cycles.
l Aprepitant (Emend®, Merck Sharpe & Dohme Ltd) is used as a prophylactic anti-emetic in 20% of
FEC cycles.
l Grades 3 and 4 acute toxicity rates as per the PACS-01, US Oncology 9735 (USO-9735) and the trial of
accelerated adjuvant chemotherapy with capecitabine in early breast cancer (TACT2) trials [including
febrile neutropenia rates for TC (4.6%), FEC100 (8.4%), FEC-T (11.2%) and E-CMF (13%)].
TABLE 11 Transition probabilities and proportions
Parameter Mean SE Distribution Notes Source
Proportion
locoregional vs.
distant recurrence
0.31 0.015 Beta Proportion of
recurrences that are
local to the original
breast cancer primary
Baum et al., 2003156
Death after distant
recurrence
0.30 0.025 Beta Annual probability of
death after a distant
recurrence (ER-positive)
Walkington et al., 2012157
Background mortality Age specific Fixed Life tables Office for National
Statistics, 2009158
Chemo-associated
excess mortality
(first year)
0.0024 0.0019 Beta 2.4% aged 55–69 years Peto et al., 20129
Background rate CHF Age specific Fixed Annual age-specific
female incidence of CHF
Townsend et al., 2012154
Relative risk of CHF
with anthracycline
treatment
1.61 0.31 Log-normal Applied as a constant
lifetime risk
Peto et al., 20129
Death after CHF 0.6 0.033 Beta Hillingdon study Cowie et al., 2000155
Background annual
rate AML (female,
aged 60–79 years)
0.00296 Fixed Fixed Bhayat et al., 2009159
Relative risk of AML
after chemotherapy
2 4 Log-normal Uncertain estimate Azim et al., 2011160
Peto et al., 20129
Praga et al., 2005161
Relative 5-year
survival for AML
(female, aged
≥ 65 years)
0.0383 0.0048 Beta Assumes constant
relative survival,
applied to background
mortality rate
Oliver et al., 2013162
AML, acute myeloid leukaemia; CHF, congestive heart failure.
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l Fifty per cent of toxicity-related hospital admissions were assumed to be of more than 2 days’ duration
(long stay) and 50% were assumed to be of less than 2 days’ duration (short stay).
l Fifteen per cent of patients have a central line inserted (but associated complications of this are
not costed).
l Community health-care costs, out-of-pocket patient and carer costs and costs attributed to future lost
productivity are not included.
l Value-added tax (VAT) is not included on drug costs.
Unit costs for on-chemotherapy grade 3 and 4 toxicity were taken from the UK NHS reference costs.166
A full breakdown of chemotherapy costs is given in Tables 12–16.
The mean annual costs of disease-free and cancer recurrence health states were estimated from hospital
income recorded research157,167 (see Table 16). These costs are based on the national payment by results
tariff produced by the UK Department of Health specific to each year in which they were incurred,
adjusted for inflation to the base year for the analysis.168 Patient data were censored at last follow-up
contact and the Kaplan–Meier sample average cost method was used to adjust for censoring.169 The
annual cost of the disease-free state was based on year 2 onwards costs under the assumption that this
represents the costs of follow-up minus chemotherapy costs.
Test costs
Test costs were calculated on a per-sample basis using current list prices and data from manufacturers.
Where a list price was not available in the public domain, the manufacturers were asked for an expected
UK price. Any anticipated NHS discounts were not considered. Any assumptions used in the cost
calculations were based on expert opinion. Costs were converted to 2013 pounds sterling using the
following exchange rates: GBP to euros= €0.825, and USD to GBP= £0.60.
All tests were assumed to be exempt from VAT. For tests conducted within the NHS it was assumed that
all NHS purchasing was operated under a managed service contract (which excludes VAT); similarly tests
conducted by commercial institutions for the NHS are exempt from VAT.170 For tests conducted within NHS
laboratories, labour costs were calculated based on estimates of the overall time to run assay samples,
and did not include sectioning time, pathologist time to mark areas for extraction and for reporting.
A summary of the per-sample test costs of all tests is provided in Table 17.
A breakdown of the cost calculations for each of the tests is given below.
Oncotype DX: for Oncotype DX, tests are sent to the manufacturer (Genomic Health) to complete and
return, with no additional costs to the NHS. The cost for Oncotype DX is based on the manufacturer list
price at the time of analysis (£2580).
MammaPrint/BluePrint: tests are sent to the manufacturer to complete and return, with no additional
costs to the NHS. The advertised list price, confirmed by manufacturer at the time of analysis, was €2675
excluding VAT, equivalent to £2207.
Prosigna: testing requires the purchase or lease of a NanoString instrument in addition to individual assay
kits in order to process samples within the NHS. The cost per test, therefore, depends on the machine
capital costs (purchase and services), the assay cost, RNA extraction/preparation and the labour costs.
These are summarised below.
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TABLE 13 Supportive medications
Supportive medications Unit dose Unit cost (£) Units per cycle % use Per cycle (£)
Dexamethasone (oral)a 2mg 0.03 20 1 0.60
Dexamethasone (i.v.)a 3.3mg 0.40 8 1 3.20
Ondansetrona 8mg 0.15 1 1 0.15
Aprepitant (premade pack)b 1 pack 47.42 1 0.2 9.48
Metoclopramidea 10mg 0.01 7 0.5 0.03
Filgrastim (Zarzior®, Sando) (GCSF)b,c,d 300 µg 52.70 5 1d 263.50
Total cost of supportive medications per cycle (£)
FEC100+ 50% GCSF 145.21
FEC100+GCSF 276.96
T+GCSF 267.48
CMF 0.36
TC 3.98
P 0.08
E 0.03
E, epirubicin; GCSF, granulocyte colony-stimulating factor; i.v., intravenous; P, paclitaxel; T, docetaxel.
a Commercial Medicines Unit electronic Market Information Tool.164
b British National Formulary 2013.165
c GCSF is used for 100% of FEC-T cycles, 50% of FEC100 cycles and 0% of TC cycles.
d Refer to list of assumptions above (see Costs).
TABLE 14 On chemotherapy toxicity costs derived from the NHS reference costs166
Parameter Mean (£) HRG code
Toxicity (grades 3 and 4) HRG – short stay
Anaemia 644 PA48B
Febrile neutropenia 877 PA45Z
Allergic reaction 491 WA11C
Nausea 340 PA28B
Diarrhoea 356 PA26B
Thrombocytopenia 540 SA12K
Stomatitis 387 CZ23Y
Toxicity (grades 3 and 4) HRG – long stay
Anaemia 1099 PA48B
Febrile neutropenia 3485 PA45Z
Allergic reaction 1808 WA11C
Nausea 856 PA28B
Diarrhoea 1107 PA26B
Heart failure 2290 EB03E
Thrombocytopenia 1311 SA12K
Stomatitis 1551 CZ23Y
HRG, Healthcare Resource Group.
Note
In the analysis, toxicity-related inpatient stay costs were assumed to be 50% short stay and 50% long stay.
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TABLE 17 Test costs
Test Cost per test (£)
Oncotype DX 2580.00
MammaPrint/BluePrint 2207.00
Prosigna 1672.00a
MammaTyper 1277.00a,b
IHC4 AQUA 720.00
IHC4 152.00a
a Represented by an uncertain distribution in the model.
b Unavailable from manufacturer; therefore, estimated by analyst.
TABLE 15 Overall costs per regimen (assuming 50% short stay and 50% long stay for toxicity)
Drug regimen
(number of
cycles)
Central line
costs (£)
Drug
costs (£)
Delivery
costs (£)
Supportive
medication
Medical
oncology
costs (£)
Specialist
nurse
review (£)
Blood
tests (£)
Toxicity
costsa (£)
Total
cost (£)
FEC100 (6) 18.17 346.38 1284.58 871.27 310.81 613.10 62.32 359.53 3866.17
FEC-T
(3+ 3)
18.17 306.84 1284.58 1238.07 450.03 613.10 62.32 378.18 4351.30
TC (4) 18.17 211.20 856.39 15.91 310.81 408.74 41.55 158.16 2020.93
FEC75 (6) 18.17 346.38 1284.58 80.77 310.81 613.10 62.32 239.69 2955.82
E-CMF (4+ 4) 18.17 392.28 2569.16 1.54 450.03 817.47 124.64 360.10 4733.39
FEC-Pw (3+ 3) 18.17 274.53 2569.16 435.89 450.03 613.10 124.64 378.18 4863.70
a Refer to list of assumptions above (see Costs).
TABLE 16 Disease-free and cancer recurrence health state annual costs167
Parameter Mean (£) SE
Costs
Disease free (annual cost excluding chemotherapy-related costs) 1000.31 3.83
Disease free after local recurrence (annual, year 2 on) 1354.17 151
Local recurrence (first year) 6126.35 517
Distant recurrence (annual) 1681.53 32
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1. Capital costs: machine purchase, lifetime and service costs were communicated by the manufacturer at
the time of the analysis:
i. machine purchase – US$285,000= £171,000
ii. machine expected lifetime= 5 years
iii. service cost – US$15,000/year=US$75,000/5 years= £45,000/5 years
iv. total capital cost per site= £216,000 per 5 years.
The expected number of tests required is 4376 per year (Cancer Registry data171). Assuming five sites
within the NHS, 875 tests are required per year, per site. Capital cost per test (five sites) is, therefore,
£216,000/5 years/875 tests= £49.37. There is uncertainty around the number of instruments that would
be purchased across England. Assuming three sites there is a lower (25th) quartile value of £29.61 and
assuming 10 sites there is an upper (75th) quartile value of £98.72.
2. Assay cost:
i. Prosigna assay – £1277 (manufacturer quoted UK cost)
ii. cartridge sizes – four or 10.
Each cartridge pack includes one quality assurance sample, and an entire cartridge must be used at once;
any unused cartridges from the pack are wasted. Thus, a pack of four can run a maximum of three
samples plus one quality assurance test, and a pack of 10 can run up to nine samples.
Assuming a 5-day working week, 52 weeks per year, and excluding Christmas and New Year (3 days),
there are ≈257 [(52 × 5) – 3] working days in 1 year. Assuming that there are five sites, to complete
875 tests per year requires completing (on average) 3.4 tests per day per site, or 17 per week per site. It is
assumed that assays are batched on a weekly basis; therefore, running 17 tests per week requires two
cartridges of size 10, with wastage of one sample. We therefore assume that, on average, cartridge sizes
of size 10 are used with one sample wasted.
The expected assay cost is, therefore, £1596.25 per test (£1277 × 10/8).
There is uncertainty around the number of samples that would be wasted per cartridge. This is represented
in the model using a log-normal distribution with a lower bound of £1418.89 per test (assuming maximum
number of nine samples run using cartridge size 10, i.e. £1277 × 10/9) and an upper bound of £5108 per
test (assuming minimum number of one samples run using cartridge size 4, i.e. £1277 × 4/1), assuming
these bounds are 95% CIs.
3. Labour cost: biomedical scientist time – assuming ‘batching’ of tests in groups of 17 (plus two controls)
it is estimated that 11 hours of hands-on time is required for the macrodissection, RNA extraction and
assay set-up. This equates to 39 minutes of biomedical scientist time per test. Valued at an Agenda
for Change grade 7 technician hourly rate of £22.98, this equates to £14.94 labour cost.
4. RNA extraction/preparation materials:
i. US$500 for 25 isolations using the Roche kit (F. Hoffmann-La Roche Ltd, Basel, Switzerland)
(US$20/sample= £12 per sample; communication with manufacturer).
ii. Total cost per Prosigna test: capital cost per test (£49.37) plus assay cost (£1596.25) plus RNA
extraction cost (£12) plus labour cost (£14.94)= £1672.56.
iii. Incorporating uncertainties around the capital cost, assay cost and labour costs gives a log-normal
distribution, with mean £1672.50 and SD £50.94 (µ= 7.422, σ= 0.030).
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MammaTyper: testing requires the purchase or lease of a Roche LightCycler real-time PCR platform
(F. Hoffmann-La Roche Ltd, Basel, Switzerland). The cost per test therefore depends on the machine capital
costs (purchase and servicing), the assay cost, RNA extraction, preparation and the labour costs. These are
summarised below.
1. Capital costs: capital costs include a Roche Diagnostics LightCycler real-time PCR machine. Purchase
and service costs of the LightCycler machine were communicated by Roche at the time of the analysis:
i. LightCycler LC/Z480 (96-well) machine purchase (F. Hoffmann-La Roche Ltd, Basel, Switzerland) –
£23,500
ii. machine expected lifetime – 10 years
iii. service cost – 10% of purchase cost from year 2= £21,150 (to 10 years)
iv. total capital cost per site= £44,650 over 10 years.
The expected number of tests required is 4376 per year (bespoke analysis by Public Health England Cancer
Registry171). Assuming five sites within the NHS, then 875 tests are required per year, per site. Capital cost
per test (five sites) is therefore (£44,650 × 5)/(4376 × 10)= £5.102. There is uncertainty around the number
of instruments that would be purchased across England. Assuming three sites there is a lower (25th)
quartile value of £3.061 and assuming 10 sites there is an upper (75th) quartile value of £10.203.
2. Assay cost:
i. MammaTyper assay – £1277 (interquartile range £400–1400) (analyst estimated UK price)
ii. MammaTyper tests are purchased in batches of 10 (eight tests+ two controls).
Two controls need to be included with each real-time PCR run. Controls can be reused/thawed up to
three times.
Assuming a 5-day working week, 52 weeks per year, and excluding Christmas and New Year (3 days),
there are ≈257 [(52 × 5)–3] working days in a year. Assuming five sites, to complete 875 tests per year
requires completing (on average) 3.4 tests per day per site, or 17 per week per site. It is assumed that
assays are batched on a weekly basis. Therefore, running 17 tests per week in a single batch with
two controls.
The expected assay cost is, therefore, £1596 per test (price × 10/8) [interquantile range (IQR) £500–1750].
3. Labour cost: biomedical scientist time – assuming ‘batching’ of tests in groups of 17 (plus two controls)
it is estimated that 11 hours of hands-on time are required for the macrodissection, RNA extraction
and assay set-up. MammaTyper preparation, set-up of master mixes, distribution of master mixes and
set-up of real-time instrument is estimated at 1 hour. This equates to 42 minutes of biomedical scientist
time per test. Valued at an Agenda for Change grade 7 technician hourly rate of £22.98, this equates
to £16.09 labour cost.
4. RNA extraction/preparation materials:
i. £283 for 50 isolations using the Roche kit (£12 per sample).
Total cost per MammaTyper test: capital cost per test (£5.102) plus assay cost (£1596) plus RNA extraction
cost (£12) plus labour cost (£16.09)= £1629.19 (IQR £531.15–1788.29).
Incorporating uncertainties around the capital cost, assay cost and labour costs gives a log-normal
distribution, with mean £1629.19 and SD £1905.11 (µ= 6.991, σ= 0.899).
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IHC4 AQUA: price provided by the manufacturer in 2014 for in-house/central commercial testing was
US$1200 (£720).
IHC4: for IHC4 performed using routine staining methods, costs of staining are relatively simple to
estimate; however, owing to the quantitative nature of the IHC4 score, additional pathological assessment
is required to accurately estimate ER histoscores, and PgR and Ki67 percentage-positive cells within the
narrow bands (30 units or 10%) required.
Within the OPTIMA prelim study, IHC4 was performed in a central laboratory, using TMAs and image
analysis, which does not reflect routine diagnostic practice (where whole slides are assessed) and precludes
accurate assessment of test costs as they would be in a NHS setting. No formal measurement of the time
required by individual pathologists to perform the additional quantification required for this test is available
to provide a cost estimate was undertaken within OPTIMA prelim. For the purposes of the economic model,
the time taken for IHC4 was estimated by consultation with NHS pathologists and laboratory managers.
It was assumed that all IHC4 testing was conducted at local hospitals and laboratories, using currently
available technology. Block selection and retrieval was not costed, as these are already routinely conducted
within the NHS. The cost of consultant time was assumed to be £157 per hour based on Personal Social
Services Research Unit costs.163 The calculation of the IHC4 cost per test was as follows:
l ER – £26 (10 minutes) extra pathologist time
l PR – £15 consumables/laboratory costs plus £26 (10 minutes) pathologist time
l Ki67 – £20 consumables/laboratory costs plus £52 (20 minutes) extra pathologist time
l HER2 – no extra cost
l generation of IHC4 report via algorithm – £13 (5 minutes of pathologist time)
l total cost per test= £152.
As there remains uncertainty about this estimate, which is based on expert opinion, it will be represented
as an uncertain parameter in the OPTIMA model, with mean £152 and IQR £116–207 (SD £69) (implying
that there is a 50% chance that the true cost lies within this range). This is represented in the model
by a log-normal distribution with parameters µ= 4.93 and σ= 0.429.
Utilities
A literature review was carried out to update the relevant health utility values for the OPTIMA model.172
Full details of the literature review and data extraction for utility values can be found in Appendices 1
and 7. The utility parameters used in the model are shown in Table 18.
Sensitivity analyses
Sensitivity analysis number 1: variable survival after recurrence
It is likely that survival duration after a recurrence will be different in patients who receive adjuvant
chemotherapy and those who do not. In the base case, the annual post-recurrence probability of death
was assumed to be 0.30 (SD 0.22). In sensitivity analysis number 1, the annual probability of death after
recurrence varied depending on whether or not previous adjuvant chemotherapy had been given. Given
that overall survival is available for the SWOG88-14 trial, the post-recurrence survival parameter was derived
by calibrating the validation model against this outcome measure. The resulting annual probability of death
following recurrence is, therefore, 0.40 (SD 0.17) for patients treated with adjuvant chemotherapy and 0.14
(SD 0.17) for patients who did not receive adjuvant chemotherapy and who had a low Oncotype DX RS.
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TABLE 18 Utility parameters
Health state Mean SE Distribution Source
Starting utility Age group specific
l 60–64 years= 0.81
l 65–74 years= 0.78
l 75–100 years= 0.71
Fixed NA Kind et al., 1998173
Disease free (no chemotherapy)a –0.003 0.03 Log-normal Campbell et al., 2011174
Disease free (on chemotherapy)a –0.099 0.033 Log-normal Campbell et al., 2011174
Local recurrencea –0.108 0.04 Log-normal Campbell et al., 2011174
Distant recurrencea –0.303 0.16 Log-normal Campbell et al., 2011174
Congestive heart failure 0.528 0.047 Beta Kirsch and McGuire, 2000175
NA, not applicable.
a Decrement from age- and sex-matched controls (Kind et al., 1998173).
Sensitivity analysis number 2: constant chemotherapy effect
In this sensitivity analysis we assumed that multiparameter tests have only prognostic ability, with no ability
to predict the magnitude of benefit from chemotherapy. For this analysis the effect of chemotherapy was
taken from the Oxford Overview meta-analysis and was applied to the predicted RFS over a 5-year period
for patients receiving chemotherapy in the model. The hazard ratio for RFS for anthracycline chemotherapy
was taken to be 0.69 (SE 0.04) over the first 5 years with an additional benefit from the addition of a
taxane of 0.84 (95% CI 0.78 to 0.91).9 A limitation of this approach is that it allows only incorporation of
uncertainty around the forecast where full information is available about the prognostic model; such
information is not available for Adjuvant!. Therefore, in an attempt to represent probable uncertainty, the
sample SD of the Adjuvant! Online RFS estimates was taken as a proxy for the SE of individual estimates.
In this model, specification of annual post-recurrence probability of death was assumed to be constant
across groups with a mean of 0.30 (SD 0.22).
Sensitivity analysis number 3: all tests included
An additional analysis that included all tests was performed, ignoring barriers to implementation and
irrespective of the clinical evidence for the tests. Where list prices were unavailable, these were sought
from the manufacturers or estimated by the analyst.
Analysis and the handling of uncertainty
The cost-effectiveness analysis was conducted in accordance with the specifications of the NICE reference
case.148 Outcomes for effects are measured in life-years, which represent the mean number of years of life per
patient and are measured by the area under the survival curve. Life-years were weighted by estimates of
health-related quality of life, which are represented by utility values (such that death is represented by 0 and 1
is the best possible health), to produce QALYs. Cost outcomes were measured as the mean cost per patient.
The final cost-effectiveness outcome measure – the ICER – is the difference in expected costs for each cohort
divided by the difference in expected effects (cost per QALY). According to NICE, the threshold ICER for an
intervention to be considered cost-effective in the UK ranges from £20,000 to £30,000.148 The analytic
perspective was that of the UK NHS; thus, only direct costs to the NHS were considered. The base year for costs
was 2013. In the initial model based on the SWOG88-14 trial, the starting age of the patient cohort was
60 years, which is consistent with the average age of patients in the majority of trials in ER-positive, early-stage
breast cancer. This was modified in accordance with the findings of OPTIMA prelim. The time horizon was the
lifetime of the patient cohort, assuming that all patients had died by age 100 years. Both costs and benefits
were discounted at 3.5% as recommended by the NICE reference case. Mathematical programming was
implemented using the R statistical programming language (The R Foundation for Statistical computing,
Vienna, Austria). The University of Leeds Advanced Research Computing Cluster, which is part of the Yorkshire
White Rose High-Performance Computing Grid, was used for the analysis.
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Probabilistic sensitivity analysis
To characterise overall uncertainty in the output measures, a probabilistic sensitivity analysis was conducted
using Monte Carlo simulation.176 This method comprises, for repeated model simulations, a random draw
from statistical distributions of all model inputs to produce a distribution of model outputs. This distribution
allows characterisation of uncertainty in the ICER, which, owing to the mathematical properties of the ICER, is
expressed as a probability of cost-effectiveness rather than as CIs. The distributions from which this random
draw was made were fitted to each input parameter using reported means and variance according to
methods recommended by the NICE reference case. For example, the beta distribution was used for binomial
proportions and utility weights, the Dirichlet distribution was used for multinomial proportions, and the
log-normal distribution was used for relative risks, hazard ratios and costs. A further explanation of
probabilistic sensitivity analysis and the simulation techniques used can be found in Briggs et al.177 Analyses
were an average of 10,000 simulations unless otherwise specified.
Value-of-information analysis
Value-of-information analysis provides a useful framework for setting priorities for further research into
cost-effectiveness. This approach relies on the fact that resources that are spent on a new intervention will
not be available to spend on alternative interventions. If we invest in a new intervention that is not the
most cost-effective option, we could lose health (or money) that could have been gained by patients if we
had invested in a more cost-effective intervention. Research (i.e. the gain of more information), therefore,
has value if it reduces the risk of adopting an intervention that is not cost-effective. This value can be
quantified as either lost health (measured in QALYs) or lost health-care resources (measured in monetary
units). An overall maximum value can be calculated (the expected value of perfect information), which
represents the burden of uncertainty on the decision-maker for a defined decision. Alternatively, a
maximum value can be attributed to specific components of the evidence base [the expected value of
perfect parameter information (EVPPI)].
The expected value of perfect information can be thought of as the opportunity cost (lost benefit)
associated with the risk of making an incorrect decision. The value of information is related to both the
estimated cost-effectiveness and the current level of uncertainty about the cost-effectiveness estimate. It is
the value to society of reducing all uncertainty about a decision to zero and, therefore, represents a ceiling
on the value of further research. It is useful for determining if further research, including clinical trials and
test optimisation research, is worthwhile and, if so, the type of research that should be undertaken. The
value of a defined research proposal can also be estimated by calculating the expected value of sample
information (EVSI). EVSI calculation remains experimental and computationally expensive, which may limit
its ability to inform a research design question in a timely manner. For this reason, EVPPI will form the
main component of the analysis, supplemented, where possible, by EVSI.
Calculation of value of information in this study used the non-parametric methods that are well described
by Briggs et al.178 The results presented in this report were generated using a meta-modelling approach
implemented by the Sheffield Accelerated Value of Information tool (http://savi.shef.ac.uk/SAVI/).179 An
annual discount rate of 3.5% is applied over a 10-year time period, assuming that this is the time over
which the decision is relevant. Value is expressed as ‘net monetary benefit’ or ‘net health benefit’. This is a
composite scale that allows financial costs and health benefits to be expressed in common units and relies
on the decision rule for cost-effectiveness,
ΔC
ΔE
< λ, (2)
where ΔE and ΔC are the incremental effects and costs and λ is the willingness-to-pay threshold. This is
rearranged, for example, to give:
net monetary benefit: λ × ΔE−ΔC > 0: (3)
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Chapter 4 Results: recruitment and study conduct
Recruitment
The first centre opened to recruitment into the OPTIMA prelim study on 5 September 2012. There were
35 centres open to recruitment and, of these, 34 centres recruited participants. Between 16 October 2012
and 3 June 2014, when the database was locked, 350 participants were registered, of whom 313 were
subsequently randomised into the study (Figure 4). The final 150 patients were recruited within 6 months
at a rate of 28 patients consented (registered) or 25 patients randomised per month. The average
recruitment rate was 0.8 patients consented per open site per month in the final 6 months of recruitment
(0.7 over the whole recruitment period). The average recruitment rate for randomising patients was
0.7 patients randomised per open site per month in the final 6 months of recruitment (0.6 over the whole
recruitment period) (Figure 5). Recruitment rates for recruiting centres ranged from 0.1 to 2.2 patients
consenting (registered) per month open.
Screening and acceptability
A total of 968 patients were reported on the screening logs, of whom 795 were deemed eligible
according to local information; however, 45 of these were excluded by clinicians (Figure 6). Of the
750 patients approached by their clinicians about participating in OPTIMA prelim, 350 consented to join
the study. This equates to a 47% patient acceptance rate, which was above the target 40%. The
acceptance rate ranged from 0% to 100% across the 35 open centres, with 19 (54%) centres having
an acceptance rate above the target 40%.
Patients did not have to give a reason for declining to take part but when a reason was given it was
recorded on the screening log. Recorded reasons are summarised in Table 19. Of those who declined to
enter the study, 51% did so because they had a strong treatment preference (33% wanted chemotherapy
and 18% did not want to have chemotherapy). Some patients who declined to enter the study (8%) chose
to pay privately for the Oncotype DX test.
Registered patients who were not randomised
Of the 350 patients who consented to participate in the OPTIMA prelim, 313 had been randomised prior
to 3 June 2014 and 15 were undergoing central eligibility confirmation on that date (Figure 7).
A total of 22 (6%) registered patients were not randomised (see Figure 7) for the following reasons:
l referring site realised that patient did not meet eligibility criteria (n= 2)
¢ HRT was being taken at the time of breast cancer surgery (n= 1)
¢ repeat local receptor testing showed tumour to be ER negative (n= 1)
l insufficient invasive tissue to perform Oncotype DX test and therefore ineligible (n= 1)
l withdrawal of patient by their clinician (n= 2)
¢ underlying condition that made patient unsuitable for the trial (n= 1)
¢ axillary surgery had been delayed and needed to begin chemotherapy immediately (n= 1)
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Screened for eligibility
(n = 968)
Did not meet eligibility criteria
(n = 173)
Eligible according to
 local information
(n = 795)
Approached about
the study
(n = 750)
Consent given and
participant registered
into the study
(n = 350)
Excluded by clinician
(n = 45)
Declined to participate
(n = 400)
FIGURE 6 Screening of potential participants.
TABLE 19 Patient-reported reasons for declining to participate
Patient-reported reason
Number of patients
reporting this reason
Percentage of those
declining (%)
Wanted to receive chemotherapy 133 33
No reason given 98 25
Did not want to receive chemotherapy 70 18
Decided to pay for Oncotype DX test privately 30 8
Did not want to participate in a clinical trial 30 8
Did not want to delay treatment start 14 4
Declined any further treatment 4 1
PIS sounded too risky 5 1
Did not want to travel to the hospital participating in
OPTIMA prelim for treatment
5 1
Unable to make decision 3 1
Uncertain of the Oncotype DX test 2 1
Patient did not understand the PIS owing to poor
understanding of English
2 1
Able to have Oncotype DX test on NHS 1 0
Uncertain if want chemotherapy or not 1 0
PIS too complicated 2 1
RESULTS: RECRUITMENT AND STUDY CONDUCT
NIHR Journals Library www.journalslibrary.nihr.ac.uk
52
l patient withdrew consent (n= 5)
¢ sample submitted for central review did not contain sufficient invasive tumour for testing and
patient did not want to wait for another sample to be sent and tested (n= 3)
¢ decided to pay for an Oncotype DX test privately (n= 1)
¢ decided did not want to receive chemotherapy (n= 1)
l deemed ineligible on central review of receptor status (n= 12).
The discrepancy between local and central determination of receptor status was low at 3.7% (95% CI
1.7% to 5.8%), with only 12 of the 325 registered patients for whom central review of receptors was
performed deemed ineligible (Table 20).
Excluded prior to randomisation (n = 22)
• Deemed ineligible on central review, 
   n = 12
• Found to be ineligible by referring 
   centre, n = 2
• Insufficient tumour for testing, n = 1
• Withdrawn by treating clinician, n = 2
• Withdrawal of patient consent, n = 5
Randomised to arm A (n = 157)
• Withdrawn prior to treatment 
   allocation, n = 3
   • Withdrawal of patient consent, n = 2
   • Insufficient tumour for testing, n = 1
Randomised to arm B (n = 156)
• Withdrawn prior to treatment 
   allocation, n = 1
   • Withdrawn by treating clinician, n = 1
Treatment regimen allocated (n = 154)
• Withdrawn from study, n = 3
   • Withdrawn by treating clinician, n = 1
   • Withdrawal of patient consent, n = 2
Treatment regimen allocated (n = 155)
Registered
(n = 350)
Pending central eligibility confirmation
(n = 15)
Randomised
(n = 313)
Treatment allocated
(n = 309)
Follow-up
FIGURE 7 The CONSORT diagram.
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TABLE 20 Details of registered participants deemed ineligible on central review of receptor status
Case
Central ER results Central HER2 results
OutcomeStatus
Quick
score % positivity
HER2 gene
status
HER2 gene
ratio
Average
CEP17
copy
number
per cell
Average
HER2
copy
number
per cell
A Negative 0 0 Non-amplified
(≤ 1.79)
1.19 1.8 2.15 Heterogeneous
tumour. Part of tumour
strongly ER-positive
(which local receptor
status was determined
on) and part of the
tumour ER-negative
B Negative 0 0 Non-amplified
(≤ 1.79)
1 2.35 2.35 Local ER-positive result
owing to faulty
staining of slide. ER
repeated on core
biopsy using different
antibody clone, which
showed negative
staining for ER
C Negative 0 0 Non-amplified
(≤ 1.79)
1.21 2.15 2.6 Local ER-positive result
was because of local
error, the core biopsy
was retested and
ER-negative
D Negative 0 0 Amplified
(> 2.20)
3.59 1.1 3.95 Local difficulties in
retesting core biopsy.
However, decision
taken to treat patient
as HER2-positive
(according to central
test) and ER-positive
(according to
original biopsy)
E Negative 0 0 Non-amplified
(≤ 1.79)
– – – Heterogeneous
tumour. Tumour
shows two different
cell populations. One
completely negative
for ER and a second
one (probably lobular
carcinoma) strongly
positive in all the cells
F Positive 8 98 Borderline
amplified
(2.00–2.20)
2 2.78 5.55 FISH repeated locally;
remained HER2-negative
Ga Positive 8 98 Borderline
amplified
(2.00–2.20)
2.14 1.65 3.53 Local decision to treat
according to HER2
status from UCL-AD as
this was performed on
the excision specimen
and the local HER2
was performed on the
core biopsy
Ga Positive 8 98 Borderline
amplified
(2.00–2.20)
2.06 1.69 3.47
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Randomised participants
The characteristics of the 313 randomised patients are shown in Table 21. Patients were allocated to the
partially blinded trial arms (157 on arm A and 156 on arm B) and their characteristics were well balanced
across trial arms.
Withdrawal post randomisation
Four participants withdrew consent for the trial following randomisation but before receiving their
treatment allocation (see Figure 7). Of these, two patients withdrew consent because of the delay in
treatment allocation. One patient was withdrawn by her clinician because she had received preoperative
letrozole and was therefore ineligible. One patient was withdrawn because, prior to treatment allocation,
it was found that there was insufficient invasive tumour to obtain an Oncotype DX test and no additional
sample was available.
A further three participants withdrew following treatment allocation. One patient was withdrawn by her
clinician as a subsequent bone scan revealed metastatic disease and two patients withdrew consent as
they chose not to follow the results of the randomisation; one patient decided to pay for Oncotype DX
off-study and one did not accept her trial-allocated treatment (chemotherapy).
These seven patients are included in the baseline data, but no further information is available.
TABLE 20 Details of registered participants deemed ineligible on central review of receptor status (continued )
Case
Central ER results Central HER2 results
OutcomeStatus
Quick
score % positivity
HER2 gene
status
HER2 gene
ratio
Average
CEP17
copy
number
per cell
Average
HER2
copy
number
per cell
H Negative 0 0 Not done – – – Local ER repeated on
core and surgical
resection. Assessed
these as low positive;
Allred 5 on core biopsy
and Allred 3 on
resection. Decision
taken to treat with
chemotherapy and
endocrine therapy as
per local results
I Positive 7 95 Borderline
amplified
(2.00–2.20)
2.2 1.43 3.14 Unknown
J Positive 8 95 Amplified
(> 2.20)
2.7 2 5.4 Unknown
K Positive 8 95 Amplified
(> 2.20)
2.39 1.55 3.7 Unknown
L Positive 8 98 Amplified
(> 2.20)
2.81 1.35 3.8 Unknown
CEP17, chromosome 17 centromere. UCL-AD, University College London Advanced Diagnostics.
a Samples from two separate tumours were submitted for central eligibility testing for this participant.
Shading represents whether the patient was deemed ineligible because of (1) the central ER results, (2) the central HER2
results or (3) both the central ER and HER2 results.
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TABLE 21 Participant demographics and tumour characteristics
Characteristic Arm A,a n (%) Arm B,a n (%) Total, n (%)
Number of patients 157 (50) 156 (50) 313
Age in years, median (range) 57 (40–78) 58 (40–78) 58 (40–78)
Stratification variables
Menopausal status of participant
Pre-menopausal 52 (33) 50 (32) 102 (33)
Post-menopausal 105 (67) 106 (68) 211 (67)
Number of involved nodes
None 31 (20) 30 (19) 61 (19)
1–3 99 (63) 99 (63) 198 (63)
4–9 22 (14) 21 (14) 43 (14)
Positive sentinel node biopsy without clearance surgeryb 5 (3) 6 (4) 11 (4)
Intended chemotherapy regimen
Anthracycline–non-taxane 62 (40) 61 (39) 116 (39)
FEC75–80 42 (27) 50 (32) 92 (29)
FEC90–100 9 (6) 7 (4) 16 (5)
E-CMF 11 (7) 4 (3) 15 (5)
Taxane–non-anthracycline (TC) 17 (11) 18 (12) 35 (11)
Anthracycline–taxane 78 (49) 77 (49) 155 (50)
FEC-T 78 (49) 74 (47) 152 (49)
FEC-Pw 0 (0) 3 (2) 3 (1)
Tumour characteristics
Histological grade
1 9 (6) 11 (7) 20 (6)
2 105 (67) 105 (67) 210 (67)
3 43 (27) 40 (26) 83 (27)
Tumour size in mm, median (range) 28 (2–150) 27 (7–170) 28 (2–170)
≤ 30 91 (58) 90 (58) 181 (58)
> 30 66 (42) 66 (42) 132 (42)
Lymphovascular invasion reported
No 84 (54) 90 (58) 174 (56)
Yes 66 (42) 62 (40) 128 (40)
Not known 7 (4) 4 (2) 11 (4)
Tumour type
Ductal 110 (70) 113 (72) 223 (71)
Lobular 31 (20) 36 (23) 67 (21)
Tubular/cribriform 2 (1) 0 (0) 2 (1)
Mucinous 3 (2) 1 (1) 4 (1)
Micropapillary 1 (1) 0 (0) 1 (1)
Mixed 10 (6) 6 (4) 16 (5)
a Trials arms remain blinded, as the trial is ongoing.
b Of the 11 patients with positive sentinel node biopsy without clearance surgery, the largest node involved was
micrometastasis for nine patients and macrometastasis for two patients.
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Sample handling logistics
The median time between patients signing the OPTIMA prelim consent form to treatment being allocated
was 20 days (IQR 16–23 days, range 10–41 days). Treatment allocation took longer than 4 weeks from
date of consent for 25 patients (8%). The main reasons for these delays were staffing problems and
issues within the central laboratory (10 patients) and obtaining a suitable sample from centres for testing
(11 patients). Furthermore, central eligibility testing took substantially longer than the target timeline
for two patients and Oncotype DX testing took substantially longer for one patient.
The median time between patients signing the OPTIMA prelim consent form and starting chemotherapy
for those allocated to chemotherapy was 4.6 weeks (IQR 4.1–5.3 weeks, range 2.6–11.3 weeks). The
proportion of chemotherapy-assigned patients starting treatment within 6 weeks was 91% over the whole
recruitment period, but 92% within the last 6 months of recruitment. The delays with allocating
chemotherapy because of problems with the tissue samples led to the withdrawal of four registered
patients and two randomised patients prior to treatment allocation.
Recruitment conclusions
OPTIMA prelim had three pre-defined success criteria for establishing feasibility, namely that 300 patients
would be recruited in no more than 2 years from the first centre opening, and, for the final 150 patients,
(1) patient acceptance rate should be at least 40%; (2) recruitment should take no longer than 6 months; and
(3) chemotherapy should start within 6 weeks of signing the OPTIMA prelim consent form for no less than
85% of chemotherapy-assigned patients. All of these criteria have been met demonstrating that a large-scale
randomised trial to demonstrate the effectiveness of multiparameter test-directed chemotherapy allocation in
a high-risk population of patients with ER-positive HER2-negative chemotherapy is feasible in the UK.
Involving patients in developing the study
Three patient focus groups met to discuss the OPTIMA trial; two of these were held shortly before and
after the study opened (in August 2012 and February 2013) and the third discussion, which involved a
mixed patient group, took place in a non-participating centre in April 2013. Members of ICPV facilitated all
three groups. Although the conversations took different directions, it is possible to extrapolate certain
themes that recurred throughout and within the groups. These illustrated the ‘big picture’ and explained
some of the possible difficulties and opportunities that these groups felt would be involved in making a
decision to take part in the OPTIMA study. These are described below.
Personalised chemotherapy
Perceptions of chemotherapy and the move towards more test-guided treatment, such as that evaluated by
the OPTIMA trial, were discussed at length in all the groups. Although a small number of participants saw
the benefits in receiving no or less chemotherapy, they felt most patients would want to treat breast cancer
as thoroughly as possible, which meant having chemotherapy. Focus group participants acknowledged that
test-guided treatment was becoming more commonplace now (e.g. those mentioned by group members
included HER2 and ER status testing and tests required for treatment of haematological malignancy).
However, they felt that there was not always a clear understanding if and when chemotherapy was needed,
and that some patients ignored potential side effects in their enthusiasm for treatment.
Overall, it was felt that there was a need for contemporary information, both generally in the media and
more specifically, such as in the OPTIMA prelim participant information leaflet, so that the expectation of
chemotherapy, and the view that more chemotherapy is always better and that less is somehow deficient,
will be challenged by both patients and within society. One group felt that this was a view perpetuated by
health professionals and should be confronted through education. They felt that endocrine therapy, such as
tamoxifen, was not, as one participant described, ‘painted in the same light’ by health professionals and was
therefore seen to be less important and less effective. Participants stated that evidence-based information must
be made widely available to make people aware that every person is different; that there is a multiplicity of
DOI: 10.3310/hta20100 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 10
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Stein et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
57
breast cancer diagnoses and thus every treatment is different and ‘personalised’. They felt this would manage
expectations more appropriately and prevent inappropriate comparisons with other women. They also felt that
it needed to be explained that best practice changes over time.
Focus group participants felt that there should be more information made available in the news media and
magazines about personalised, test-guided treatments to make the public aware and change perceptions
generally about cancer always requiring chemotherapy.
It was agreed that the best way to introduce the study to potential OPTIMA participants would be to
explain that breast cancer treatment is always tailored to the individual woman and it should be stressed
that the OPTIMA trial involves personalised treatment, rather than less treatment, in any written
information about the study.
There was some concern from focus group participants that people would think that less treatment, as
prescribed in the OPTIMA trial, was simply a cost-saving measure by the NHS. They felt it should be made
explicit to potential study participants that this was not the case.
Deciding to take part in research and the OPTIMA study
There was a consensus that the OPTIMA study seemed to be an appropriate and helpful study from a PPI
perspective and focus group participants said they would take part in principle (one woman had actually
been offered and consented to OPTIMA prelim). The reasons why they would take part were both general
to research and specific to the OPTIMA study. For example, being invited to take part in research made
one feel valued and important, and it was seen to make a difference to treatment and potentially help
others. It also made individuals feel ‘looked after’ and the additional follow-up and ‘active monitoring’ that
was involved, even within the control group, was highly valued. Participants felt that this was specifically
the case in the OPTIMA study, in which the regular and active monitoring involved was seen as positive
and information given about individual risk was seen as constructive.
The hypothetical question of making an informed choice to take part in the OPTIMA study was appreciated
to be very difficult; focus group participants in all three groups wished this to be noted. Describing their
own experience of being invited to take part in RCTs, some participants had felt under enormous pressure
to make a quick decision. A minority felt that deciding to take part would have caused too much personal
anxiety and so they would have preferred to leave the decision to, as described by one participant, ‘those
that were qualified’. Another minority felt that they would be deterred from taking part because of the wait
to get results and consequent delay in starting treatment. There was a common misconception among
focus group participants that chemotherapy had to be instigated very quickly to have the most beneficial
effect but they were reassured that, in breast cancer, adjuvant chemotherapy could be delayed for up to
12 weeks.180 Participants felt that this should be made very clear to potential OPTIMA study participants.
Knowing this, they also felt that the complexity of the OPTIMA trial and the possibility of potentially
receiving less treatment would mean that the information and consent process would be likely to take
longer and research staff should be made aware and of this and trained, if appropriate.
The information provided for the OPTIMA study
Focus group participants from all three groups stressed the importance of an expert multidisciplinary team
to manage the OPTIMA study involvement and treatment in which potential study participants could have
ready access. In order for the OPTIMA study participants to have confidence in their treatment allocation
and in their decision to consent to the study, they agreed they would need confidence in the information
they were given and the person giving it.
All focus groups also agreed that an audio-recording of the initial consultation would be positive for
potential OPTIMA study participants to take away with them as discussions and information given in
consultations often, as one participant described, ‘went in one ear and out of the other’. It was also felt
that it was important for the OPTIMA study information to be made available so that it could be discussed
RESULTS: RECRUITMENT AND STUDY CONDUCT
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with family members and friends away from the hospital environment. Multiple formats, which would
allow patient choice and be appropriate for different people, were preferable and formats described
included digital versatile discs, leaflets, websites and podcasts. Independent information was also valued
and it was felt that this could be hosted by a neutral organisation such as ICPV or a cancer charity.
The provision of full information was felt to be important and would encourage rather than
discourage recruitment.
There was also some concern about the partial blinding in the OPTIMA study and the inherent lack of
information. For example, would trial participants allocated to no chemotherapy worry that they actually
had a borderline score? Focus group participants were reassured that borderline scores of the genomic test
had been lowered specifically for the purposes of the trial to ensure safety. Focus group participants felt
that if potential OPTIMA participants were told this, they might be more likely to consent knowing that
there was less risk of a false-negative score. They also felt strongly that potential study participants should
be made aware that chemotherapy could be offered at a later date if necessary, as many had been under
the impression that the test would predict chemotherapy use indefinitely, which is not the case.
The additional burdens of chemotherapy
Interestingly, focus group participants felt that the important additional burdens of treatment were often
ignored by health professionals and were under-reported and therefore not recognised. These were often
related to employment and financial issues. As such, the health economics questionnaire that is included in
the OPTIMA study was seen to be particularly useful and important. The additional burdens that were
discussed in the groups are reproduced in Box 1. The quality-of-life questionnaires that are included as part
of the trial were also perceived as highly relevant and valuable, although some individuals felt that certain
important and impactful information would not be gathered by the measures proposed, for example the
impact of tamoxifen and AIs on sexuality and sexual function.
BOX 1 Additional costs incurred with breast cancer treatment (as identified by focus group participants)
Additional costs
Wigs, scarves and hats.
Complementary therapy, for example counselling, reflexology.
Gym membership for exercise and physiotherapy.
Child care.
New clothes because of weight change/‘hot flushes’.
Extra washing/heating costs (owing to vasomotor symptoms).
Increased cost of food (more preprepared food, more fresh food, more wastage).
New shoes (to accommodate fallen arches).
Increased cost of skin care, for example moisturisers.
Increased cost of holidays (need for better accommodation, costly travel insurance).
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Patient and public involvement conclusion
Data from the three focus groups and the dissemination of these results have generated invaluable
in-depth information about the potential impact of taking part in the OPTIMA study from people who
have a direct experience of living with cancer. It has shown us that the study is supported and, in theory,
people would be keen to be involved and take part. However, it has highlighted the difficulties involved
in accepting randomisation to potentially less treatment than expected. The data that have been generated
by the focus group participants have been incorporated into the study design and, although they cannot
be truly quantified, have probably contributed to the success of the study.
Qualitative recruitment study results
The integrated QRS undertaken within the OPTIMA prelim study was based on a refinement of the
methods developed for the ProtecT study complex recruitment intervention.140 This section reports on the
details of the data collected and analysed, and presents the findings from each of the three phases of
the QRS. Detailed results from the analysis of phase 1 (including the recruitment difficulties identified
through interviews with the OPTIMA staff members and audio-recordings of recruitment consultations) are
reported in full in Appendix 8.
A summary of those findings is presented in this section, followed by the full findings from phase 2
(describing the delivery of interventions to address the barriers identified from phase 1) and phase 3
(considering the impact of the QRS interventions on recruitment during OPTIMA prelim).
Qualitative recruitment study data set
In total, 18 of the 32 staff contacted for interview responded: 14 agreed to participate (no withdrawals),
two declined outright and two declined the interview at the time, with the offer of being contacted at a
later more convenient date. The 14 semistructured interviews were conducted with participants across six
centres and included eight oncologists (three of whom were also members of the TMG), four research
nurses, one surgeon and a non-recruiting member of the TMG. Six interviews were conducted face to face
and eight were conducted via telephone. Interviews were conducted with staff from ‘mid-range’ centres by
chance rather than by design. One of the centres included in the QRS had failed to recruit any patients;
the remaining centres’ recruitment rates ranged from 0.32 to 1.85 patients per month compared with an
overall range of 0 to 2.20 in the study. At least one site from each of the OPTIMA prelim’s geographical
clusters participated in interviews.
Of the eight research nurses invited to take part in structured telephone interviews about patient
pathways, all agreed to participate and none withdrew.
A total of 36 audio-recordings were obtained from 29 patients’ consultations. First and second oncology
consultations were recorded for 7 of the 29 patients. First oncology consultations were available for
21 patients and the second oncology consultation was available for one patient. Twelve different recruiters
(10 oncologists and two registrars) led the consultations and audio-recordings were obtained from all
geographical clusters.
Phase 1: understanding recruitment issues
Detailed findings are reported in Appendix 8. In summary, the recruitment issues identified through the
QRS fell under three overarching themes:
l eligibility processes and patient pathways
l missed opportunities for discussing the trial
l opportunities for improving communication and information provision.
RESULTS: RECRUITMENT AND STUDY CONDUCT
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The sources of data outlined earlier (see Qualitative recruitment study data set) were considered in tandem
to identify key recruitment challenges in the OPTIMA prelim. Although there was some overlap in
identified recruitment challenges, which emerged through different methods of data collection, there was
also a tendency for certain methods to be better suited for uncovering certain challenges to recruitment.
For instance, challenges relating to communication were largely uncovered through audio-recorded
consultations, while issues relating to patient pathways were largely based on information derived from
interviews. Some themes, such as recruiters’ levels of equipoise, were supported through both interview
data and audio-recorded consultations.
Eligibility processes and patient pathways
‘Eligibility processes’ relate to clinicians’ and triallists’ decision-making about patients’ eligibility for
the OPTIMA prelim study, while ‘patient pathways’ refers to the series of OPTIMA prelim-related events
patients experienced in the lead up to entering (or declining) the trial. These processes had potential to
hinder recruitment and so provided an initial focus for phase 1. Obtaining an overview of these processes
from OPTIMA prelim staff also provided a useful framework for placing specific barriers to recruitment
into context. A summary of these processes is presented in the paragraphs below, with more detailed
descriptions shown in Appendix 8.
Although trial eligibility processes appeared straightforward, systems were not always in place to map
eligibility from the first point at which patients were considered for the study [i.e. within multidisciplinary
team (MDT) meetings]. At the commencement of the trial, screening logs recorded patients from only the
point of registration and randomisation, thus making it difficult to elucidate the full patient pathway. This
missing information pertaining to the screening process probably led to potentially eligible patients not
being offered the opportunity to consider the study.
Patient pathways were clear, simple and appeared successfully integrated into research nurses’ services.
However, patients sometimes gave decisions about participation via telephone conversations with research
nurses rather than in face-to-face consultations. Consequently, some patients may not have discussed
their thoughts or concerns about the OPTIMA prelim study with an oncologist. This had implications for
clinicians’ opportunities to resolve patient misunderstanding and/or concerns (if appropriate) and limited
scope for the QRS to capture discussions for or against trial participation (i.e. through audio-recordings).
Missed opportunities for discussing the OPTIMA prelim with patients
Interviews and early TMG meetings showed recurring concern among staff that fewer than anticipated
patients were being approached about OPTIMA prelim. Regular telephone conversations with research
nurses frequently suggested that no eligible patients had been identified. Six interview informants from
five different centres talked about the limited flow of eligible patients they had encountered at the time of
interview. This was the most frequently reported issue raised by informants when asked about their views
on the main barriers to recruitment:
I don’t know why we’re not actually identifying (any); it’s not that we’re deciding that we’re . . . no,
it’s not that we’re approaching patients and they’re saying ‘No’.
Research nurse (RN) 1
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With the starting pool of potential eligible patients unknown, little could be deduced with regards to the
numbers of patients deemed ineligible or the associated underlying reasons for ineligibility. This led to
TMG members producing broad, non-specific explanations of why the number of patients approached for
OPTIMA prelim was lower than expected when the study was conceived:
[Dr A] will probably tell you but at the meeting yesterday [they] said how surprised [they were] about
how small the pool of eligible patients is. It’s much smaller than (they) thought it would be [. . .]; that’s
like a change of tune, really, from before we started recruiting (they) were very positive about how big
the pool was [. . .]. So I think (their) experiences in trying to identify eligible patients have shown that
perhaps the expectation of how many eligible patients there would be, were a bit, perhaps slightly
over-enthusiastic.
TMG member
Further evidence supporting the theory that the full pool of eligible patients was not being offered
participation in the study came in the form of recruitment figures and acceptance rates. Actual recruitment
figures trailed behind target figures throughout the recruitment period, while ‘acceptance’ rates
consistently exceeded targets. Interviews with recruiters gave insight into potential attitudinal factors that
may have played a role in restricting the pool of eligible patients. In summary, these factors related to
the following.
Discomfort surrounding eligibility criteria
Recruiters’ unease surrounding various aspects of the eligibility criteria was widespread, reported by staff
members from every centre participating in interviews. OPTIMA prelim staff varied in their readiness to
accept increasing risk (in terms of disease status). Increasing lymph node involvement, tumour size and
grade caused discomfort surrounding the upper thresholds of the eligibility criteria stated in the protocol.
Concern about patients’ ability to handle information
Some clinical informants gave general or specific examples of refraining from offering the trial to patients
on the basis of their clinical judgement. Failure to approach patients at a clinician’s discretion would not
breach the study protocol; the eligibility criteria clearly stated:
Patient must be fit to receive chemotherapy and other trial-specified treatments with no concomitant
medical, psychiatric or social problems that might interfere with informed consent, treatment
compliance or follow up.
However, an issue that arises is whether or not the decision not to inform patients about the opportunity
to take part in the OPTIMA prelim study was always appropriate or well founded. Such judgements, if
applied differently across different centres, could have had implications for the numbers of patients being
approached for the OPTIMA prelim.
Priority of the OPTIMA study at multidisciplinary team meetings and among surgeons
Although research nurses were well versed in the inclusion and exclusion criteria, some felt that they did
not always have the necessary expertise or voice to flag a patient as an OPTIMA prelim candidate at a MDT
meeting. This suggested that potentially eligible patients were at risk of falling through the net at the
stage of initial eligibility screening.
Summary of missed opportunities to discuss the OPTIMA prelim study
To summarise, findings from QRS interviews and informal discussion/observation in meetings suggested
that there had been missed opportunities to approach eligible patients about the OPTIMA prelim study.
This was a key finding from the QRS and suggested that there would be clear opportunities to increase
levels of recruitment. These findings were supported through the observation that, although numbers
of eligible participants were falling short of targets, the study seemed very acceptable to patients
who were informed about it, as the percentage of eligible patients agreeing to randomisation consistently
exceeded targets (see Screening and acceptability).
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Opportunities for improving communication and information provision
Communication and information provision were largely explored through audio-recorded consultations,
although data from staff interviews sometimes provided a useful backdrop for exploring particular
challenges. Recruitment consultations varied in length and structure across and between centres, with
some formats more conducive to explaining the study than others. Difficulties emerged in relation to how
trial-specific processes were explained to patients, and staff attitudes also played a role in influencing the
direction consultations took – particularly when it came to exploring patients’ views and perspectives on
OPTIMA prelim participation.
Explaining randomised controlled trial processes and concepts of uncertainty
A fundamental challenge to recruitment identified by interview informants was the perceived difficulty in
explaining the OPTIMA prelim trial design. Having an arm that split into two further arms, combining
random and test-directed treatment allocations, and the partially blinded design were all thought of as
potentially confusing to patients. Some interview informants had directly experienced patients dismissing
the trial on this basis:
This particular lady just didn’t go into any detail at all she said, I just didn’t know what it was talking
about, and I said, and I tried to explain bits of it to her, but no, she said, I just, I don’t, I just want to,
I don’t understand it, she just said locked her mind off completely to it.
RN4
In the light of the above, analysis of audio-recorded consultations focused on recruiters’ explanations of
trial processes and scrutinised information exchange that led up to evidence of patient misconceptions or
confusion. Particular practices were identified as being potentially detrimental to patient understanding.
These included absent or incomplete explanations of ‘randomisation’, ‘blinding’ and unclear descriptions of
the treatment(s) provided in each trial arm. Explanations of the trial arms also revealed examples of loaded
terminology, including use of the words ‘standard’ and ‘experimental’ (see Appendix 8).
The issue of uncertainty was an important theme to arise from audio-recorded consultations, particularly in
relation to the discussions about chemotherapy benefits and the accuracy of the test. There were
differences in how recruiters framed chemotherapy provision at the start of the consultation, which in turn
had implications for patient understanding. Recruiters’ explanations ranged from presenting chemotherapy
as a treatment with definite benefits, to framing it as an uncertainty that required careful balancing of
benefits and side effects/complications. There were occasional examples in which patients still believed that
they would definitely benefit from and/or receive chemotherapy even after the trial had been explained.
Uncertainty surrounding use of the Oncotype DX test in treatment decision-making was another difficult
concept to communicate according to recruiters’ interview accounts (i.e. oncologists and research nurses).
Overselling the benefits of the test could prompt patients to pay for the test privately, whereas an overly
cautious approach ran the risk of obscuring any incentives for participating in OPTIMA prelim. These
considerations raised the dilemma of how best to reassure patients while conveying the inherent risk of
participating in a study in which treatment allocation may be determined by a test that requires
further research:
The trouble is if in our initial interview we sort of really down play the test as not being useful, then
nobody would want to go in the trial in the first place. And if we play it too much they think ‘well it’s
such a great test, I don’t want to risk not having it in the trial’ and go and find out the information.
So again, it’s that fine balance.
Oncologist (Onc) 4
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The TMG meetings revealed that a particular point of concern was a line in the PIS that highlighted the
uncertainty surrounding the test’s accuracy. Based on TMG members’ experiences (not audio-recorded),
patients had reportedly refused the trial once they had read the following statement:
The test might not work so well for patients with larger tumours or involved lymph glands. We do not
believe this to be the case. However if it was, then in the future we might realise that we should have
given you chemotherapy.
It was noted that this issue reportedly materialised after (rather than within) the first oncology consultation
(i.e. once the patients had read the information sheets). This prompted us to consider how the Oncotype
DX test was described in consultations, with a focus on how uncertainty was communicated and
responded to (see Appendix 8 for details). Overall, recruiters varied in how they conveyed uncertainty,
which in turn had implications for patients’ understandings of the trial aims and design.
Tailoring consultations to the OPTIMA prelim study
Recruiters varied in the extent to which they presented OPTIMA prelim as the primary focus of the
discussion. This was influenced by the extent to which they covered diagnostic information and
non-OPTIMA prelim-related treatments within the first oncology consultation. Some consultations were
particularly long (up to 52 minutes), covering non-trial-related information in some detail prior to
introducing the OPTIMA prelim study. In some ways, it could be considered that many appointments were
not ‘recruitment consultations’ at all. Although there was the opportunity to present the OPTIMA prelim
study, this opportunity was not always fully utilised in some consultations. In other cases, the study was
presented as a ‘next step’ in a series of ‘information blocks’, rather than the heart of the consultation.
Some recruiters successfully tailored information provision around explanations of the trial, whereas other
struggled to do this, resulting in the aims and key details of the trial becoming somewhat lost.
Patient preferences
Screening logs and interview informants’ accounts suggested that patients’ preference either for or against
chemotherapy was the most common reason for declining the trial (50% of reasons for decline in final
screening logs: 33% for and 17% against):
We have a very good functioning wider unit [. . .]. There’s nothing that’s blocking us from doing it
other than patient preference.
Onc3
There were few (if any) examples in consultations where patients expressed strong preferences, but there
were some examples where patients appeared to be influenced by other clinicians that they had seen prior
to the oncologist (e.g. surgeons). There were also examples of patients showing misunderstandings about
trial participation while explaining their decision to refuse the trial; however, the recruiters did not always
address these misconceptions, instead accepting the patients’ decisions without further discussion.
A common thread that ran throughout recruiters’ interviews was that breast cancer patients in particular
were thought likely to have set preferences given the influence of the media, peers and the well-publicised
nature of the disease. As such, some recruiters completely disassociated themselves from patients’
decisions about trial participation and many indicated that they would accept patients’ preferences with no
further exploration. Recruiters’ discomfort in exploring patients’ decisions and/or preferences stemmed
from concern that raising these issues would jeopardise their relationships with patients or leave them
susceptible to accusations of coercion.
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Delay
Patients’ concern about the delay attributed to waiting for the Oncotype DX test result was a dominant
theme to emerge from audio-recorded consultations. Almost every consultation analysed supported this,
with most patients asking about how long the testing process would take. Although some recruiters
reassured patients that the delays associated with OPTIMA prelim had no implications for treatment safety,
this was not consistently done across consultations. This, therefore, also represented a missed opportunity
to address patients’ concerns and provide reassurance.
Summary of opportunities for improving communication and
information provision
Analysis of audio-recorded consultations revealed opportunities to clarify and refine recruiters’ explanations
of trial-specific processes to patients, reconsider use of terminology and frame explanations of treatment
options around the OPTIMA prelim trial design. Both interview data and audio-recorded consultations
revealed recruiters’ discomfort and reluctance to explore patients’ decisions to decline the trial. These
attitudes stemmed from concerns of being seen to coerce and the belief that patients’ views are fixed at the
outset of consultations. We found no evidence of clear ‘fixed’ patient preferences in the consultations we
listened to, but there were examples of patient expectations for chemotherapy/no chemotherapy that had
stemmed from previous interactions with clinicians (e.g. surgeons) prior to the first oncology consultation.
Summary of findings from QRS phase 1 and opportunities for intervention
Phase 1 of the QRS identified a number of challenges to recruitment from the analyses of interviews and
recruitment consultations, including opportunities for improvement to discuss with the CfI and TMG with
a view to developing a plan of action to be implemented in phase 2. The potential opportunities included:
l Considering introducing screening logs at the stage of eligibility assessment. Screening logs could then
record the recruitment process in greater detail, from the first point of identifying a potentially eligible
patient, through to the patient’s decision to accept or decline the trial. This would reveal if as many
potentially eligible patients as possible were being approached and informed about OPTIMA prelim,
and help to identify centre-specific barriers to recruitment.
l Discussing ‘on the ground’ perceptions of equipoise – including discomforts around particular eligibility
criteria – to reach a consensus about the need to change the criteria or to discuss these issues
more widely.
l Considering whether or not the basis of decisions not to approach patients could be standardised or
measured and whether or not they were appropriate, with a view to increasing opportunities for
potentially eligible patients to decide for themselves whether or not to participate.
l Considering how to raise the profile of OPTIMA prelim at MDT meetings and among surgeons.
l Providing recruiters with support to explain the study design, justification and details more clearly;
promoting early mention of OPTIMA prelim in consultations and encouraging recruiters to frame their
explanations of treatment options around the OPTIMA prelim study design.
l Exploring with recruiters how best to conceptualise issues of uncertainty and discuss those with
patients in the context of the OPTIMA prelim trial.
l Raising issues about the use of terminology that might not help recruitment, including the use of the
words ‘standard’ and ‘experimental’, which suggest the trial arms are not equivalent.
l Exploring with recruiters how best to describe advantages and disadvantages of chemotherapy and the
Oncotype DX test so that patients could understand the key issues.
l Exploring with recruiters how best to present issues of delays with Oncotype DX.
l Exploring with recruiters opportunities to discuss the origin of patient preferences for or against
chemotherapy and, in appropriate cases, to provide additional information that might alleviate
inappropriate concerns – all with the aim of ensuring more informed decision-making about
participation in the study.
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Phase 2: developing interventions to address recruitment challenges
Identification of potential barriers to recruitment was an iterative process that spanned the entire
recruitment period. As themes emerged from data collection, interventions were designed in collaboration
with the TMG and delivered to centres as recruitment proceeded. This section will outline the timing and
nature of these interventions, and discuss their function relative to the recruitment challenges identified in
the previous section. A summary of the interventions delivered is shown below in Table 22.
Addressing issues of discomfort surrounding eligibility: Trial Management Group
discussion, circulation of interview findings and clinician-to-clinician centre visits
The QRS interviews provided strong evidence of discomfort surrounding the OPTIMA prelim eligibility
criteria, suggesting that the full pool of eligible patients was not being approached. The knowledge
acquired from interviews was fed back to the CfI and ‘core TMG’ over a prolonged period, initially through
comments on ‘preliminary’ findings from interviews and finally through more formalised written reports of
interview findings produced for the CfI (18 October 2013). Findings were also shared generically in wider
TMG meetings attended by oncologists from centres around the UK. TMG members’ responses to these
findings suggested familiarity with the issues raised and opened up discussions about how clinicians’
discomfort surrounding higher-risk status patients could be addressed. One early suggestion generated by
the core TMG was to reassure individual oncologists about high-risk cases by publicising their peers’
readiness to include these patients in the study. This suggestion was put into practice on the premise that
awareness of what oncologists around the country were doing might alleviate individual oncologists’
concerns – particularly those in ‘isolated’ centres. Following this, the QRS team revisited recruiters’
discomfort surrounding eligibility criteria at a wider TMG meeting, suggesting that open discussion with
non-recruiting centres might be beneficial (17 June 2013). In particular, the team felt it was important that
these took the form of peer-to-peer discussions among clinical experts who fully understood the realities of
embedded clinical practice. Clinical members of the core TMG made a series of centre visits following this,
targeting non-recruiting centres. The function of these meetings was to openly address recruitment
difficulties in a supportive and confidential environment. Centre visits continued throughout the duration of
the recruitment period.
TABLE 22 Timeline of QRS interventions
Date QRS intervention
17 June 2013 Updated TMG about eligibility criteria discomfort (emerging findings from interviews); suggested
clinician-to-clinician discussions
22 July 2013 Raw preliminary interview data on eligibility issues sent to CfI
9 September 2013 Reminded TMG about eligibility criteria concerns; raised importance of detailed records of entire
eligibility assessment process; advised on the benefits of exploring patients’ treatment preferences
4 October 2013 Tips/guidance document circulated to all centres
16 October 2013 Edited PIS distributed to all centres
18 October 2013 Descriptive summary of interview findings sent to CfI
8 November 2013 Group feedback presented to Scottish centres
14 January 2014 Group feedback presented to South West England and Welsh centres
31 January 2014 Recruitment tips presented to newly opening centre
10 February 2014 Individual feedback provided for Onc8
6 March 2014 Individual feedback provided for Onc9
13 March 2013 Group feedback presented to centre 5
14 March 2013 Individual feedback presented to Onc4
27 March 2013 Individual feedback presented to Onc1
27 March 2013 Group feedback provided for centre 3
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Amendments to the patient information sheet
Members of the TMG expressed concern that the PIS section outlining the ‘disadvantages’ of OPTIMA prelim
participation prompted patients to decline the trial. This prompted the QRS team to review the PIS. This
opportunity was used to review the PIS in its entirety, with a view to considering how patients could interpret
the information. Elements of the study arm descriptions were clarified, but most amendments were
concentrated on the ‘advantages’ and ‘disadvantages’ sections of the document. These sections needed to
provide an honest and clear description of the trial-specific advantages and disadvantages of participation, in
as balanced a way as possible. Visually, the disadvantages section of the document far outweighed the
advantages section, yet it became apparent that some of the details stated as ‘disadvantages’ were repetitions
of trial processes described elsewhere. Through discussion with the TMG, it was agreed that some of this
information was not a specific disadvantage of trial participation and it was removed.
The particular line in the PIS that had created most concern among recruiters informed patients that the
Oncotype DX test might not work and that they might find out that they ‘should have received chemotherapy’.
Audio-recordings of recruiters’ descriptions of uncertainty surrounding the test were used to inform how this
disadvantage could be conveyed. It was evident that some recruiters successfully communicated the same
idea stated in the PIS, but preceded this with information about the current use of the test (i.e. in other
countries and in different subgroups of breast cancer patients). Audio-recordings also showed examples of
recruiters reassuring patients that the test had not been ‘plucked out of the air’. It was on this basis that
information surrounding the test’s current use, and intended extended use, were added to the PIS. Similarly,
we found evidence of recruiters tentatively stating that they believed the test would work, balancing this
with the assertion that concrete evidence was not yet available. Similar information was added to the
‘disadvantages’ section of the PIS. Patient representatives and the Research Ethics Committee approved these
amendments made to the PIS and the updated version was circulated in October 2013.
Tips and guidance for recruiters
The challenges associated with structuring consultations and explaining trial-specific processes were
addressed through circulation of a tips and guidance sheet formulated by the QRS team (see Appendix 9).
This document provided recommendations on how recruiters might explain difficult concepts such as
randomisation, blinding and the events that occur in each treatment arm. Other details pertinent to the
study rationale were also included to help recruiters structure their consultations.
All information stated within the tips and guidance document was grounded in the data collected from
audio-recordings and based on the potential opportunities listed above. Suggestions about how to explain
concepts were based on clear, effective examples derived from the collection of recorded consultations.
The CfI contributed some key clinical concepts and the document as a whole was reviewed by the CfI prior
to finalising. A letter from the CfI accompanied the document, with the option for recruiters to contact the
QRS team if they had any questions. Importantly, the letter framed the tips and guidance as suggestions
that recruiters may wish to incorporate into their current practices. The document was circulated to all
open OPTIMA prelim centres in October 2013.
Group feedback sessions
A series of group feedback sessions was delivered to a range of QRS and non-QRS participating centres
around the UK. The purpose of these feedback sessions was to spark discussion to generate acceptable
solutions to recruitment challenges, using findings from the interviews and audio-recordings as prompts.
The QRS team guided this process by showing extracts from consultations deemed more or less effective,
with recruiters encouraged to comment on and evaluate the extracts themselves. Group feedback sessions
were particularly targeted to addressing broad topics relevant to incorporating the OPTIMA prelim study
into clinical practice rather than specific technical challenges (e.g. explaining difficult concepts, which were
better addressed by the tips and guidance sheet). Topics addressed included discomfort surrounding
eligibility criteria, approaches to structuring consultations and how to respond to patient preferences.
Presentations were adapted to each feedback session, using updated recordings or focusing in on topics
that were problematic for the centre in question. TMG members, particularly the CfI, assisted in the
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formulation and delivery of presentations; for instance, the CfI contributed a number of vignettes designed
to generate discussion about eligibility and took the lead for this part of the presentation at one of
the meetings.
Exploring patient preferences was covered in all feedback presentations. The widespread discomfort
surrounding this was still apparent in meetings, but the QRS team attempted to show the merits of
exploring preferences (through actual consultation data) and offered suggested ‘lead-ins’ to how recruiters
might respond to a patient preference.
An attempt was made to deliver group feedback to as many regional clusters as possible by organising
meetings that could be attended by representatives from multiple centres. Secondary to this option was to
target centres that requested feedback and centres that appeared to be struggling with recruitment.
Four group feedback sessions were conducted in total: two attended by multiple centres and two
directed at single centres. Meetings attended by multiple centres were conducted in Scotland and the
south-west of England. Both regional meetings had at least one representative from local centres
present. Centre-specific feedback meetings were conducted in a centre that requested feedback and a
centre that had been struggling with recruitment.
Individual feedback sessions
In addition to group feedback sessions, recruiters who provided at least three audio-recorded consultations
were offered confidential individual feedback, which was conducted over the telephone or in person. A
summary sheet of key points discussed was provided to recruiters following this session. Individual feedback
sessions were useful for discussing specific challenges individual recruiters faced, which might not have
been appropriate to discuss in a public context (e.g. concerns of coercion). Furthermore, these sessions were
an ideal opportunity to discuss challenges that were specific to the individual, rather than ‘recurring’
challenges addressed in group meetings. All guidance provided by the QRS team was offered in the form
of suggestions that were discussed with the recruiters, making it clear that the individual should proceed as
they feel best. In all cases, it was emphasised that recruiters needed to remain comfortable and confident
while speaking with patients about OPTIMA prelim. In total, individual feedback was provided to four
oncologists. These were delivered in the later stages of recruitment, given the need to base feedback on a
sufficient number of recordings and the relatively low numbers of recordings that were made.
Phase 3: impact of qualitative recruitment study interventions
There were a number of approaches taken to evaluate the impact of the QRS, although no single method
could definitively show the influence interventions had on recruitment. As a consequence, the discussions
that follow should be viewed as speculative, although viewing the problem from multiple angles could
contribute to a clearer picture than relying on one method alone. In the light of this, three approaches
were used to explore the potential impact of the QRS interventions: analysis of how recruitment figures
changed relative to interventions; analysis of recruitment figures for centres receiving group feedback
versus those that did not; and a qualitative analysis of changes in practice for individual recruiters.
Changes in recruitment figures with respect to qualitative recruitment study interventions
Figures 4 and 5 show overall recruitment with time and monthly recruitment rate adjusted for the number
of open centres. Recruitment rate fluctuated substantially from month to month but there was an overall
upwards trend. The month of early October to early November 2013 coincide with a series of general QRS
interventions that could have impacted all centres or large clusters of centres. It is apparent that the
recruitment figures immediately following these interventions changed the trajectory, as rates of increase
sped up and the gap between ‘target’ and ‘actual’ figures began to close. This trajectory continues for the
remainder of the recruitment period, while the difference between ‘target’ and ‘actual’ recruitment figures
continued to narrow. One would not expect recruitment rates to increase at the exact point at which QRS
interventions were disseminated. A lag is to be expected, to account for the time needed for knowledge/
advice to diffuse and for eligible patients to emerge.
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The observations described above are far from conclusive evidence that the QRS had a positive impact on
recruitment. Causality cannot be established based on these data, owing to the countless confounding factors
that could have influenced recruitment and/or uptake of the interventions. For instance, we cannot prove
definitively that recruiters took note of the interventions, and could speculate that the slight increase in
recruitment could be attributed to any number of reasons. It should be noted, however, that this slight boost
in recruitment could be considered unusual given the time of the year (December/Christmas shut-down).
Comparison of recruitment figures for centres with and without
group feedback
Comparing centres that did/did not receive non-generic interventions was problematic, given that feedback
sessions occurred at various points in time within each centre’s ‘recruiting trajectory’. Centres had been
open to recruitment for different lengths of time, resulting in different levels of experience and (possibly)
confidence among clinical staff. Comparing ‘feedback’ versus ‘no feedback’ centres was also problematic as
there were difficulties in grouping ‘feedback centres’ in a single category: some centres received both
individual and group feedback, while others received one or the other; some had their full clinical team
present at feedback meetings, while others had one or two individuals present; some centres were visited
by the QRS team or TMG, whereas others sent representatives to regional meetings; and, finally, the
professional roles and numbers of those attending feedback meetings varied by centre (sometimes
oncologists were present, sometimes research nurses, and sometimes both). Comparing recruitment rates
for centres with/without feedback was further complicated by extraneous factors that could influence
recruitment rates (e.g. centres size, location), including more elusive factors that were harder to measure
(e.g. ‘commitment’ to the trial). None of these factors could be controlled or accounted for. The distribution
of ‘generic guidance’ to all centres also raised the question of whether or not any ‘no feedback’ centres
truly existed, as generic guidance often overlapped with the advice and recommendations offered in
feedback meetings.
Despite these difficulties, there were some examples where QRS interventions or ‘clinician-to-clinician’
discussions had clear impact. For example, two centres that had not yet recruited, despite being open for
numerous months, consistently recruited immediately after ‘clinician-to-clinician’ visits took place. Looking
at changes in recruitment before and after group feedback sessions, it was noted that recruitment rates
(patients per month) were almost always higher after these meetings took place (9 out of 11 centres).
Once again, though, it is difficult to distinguish the impact of the QRS from the effects of ‘natural
increasing momentum’; crude comparisons of change in recruitment rates could have been made with
‘no feedback’ centres if there was a single point of QRS intervention, but as mentioned above, variable
timings of feedback delivery meant this was not possible.
Qualitative analysis of audio-recordings: do recruiters’ practices change?
One relatively straightforward approach to assessing the impact of QRS interventions was to look at
whether or not suggestions in the tips and guidance sheet and feedback presentations were adopted by
recruiters. Three recommendations were consistently covered in ‘generic’ QRS interventions (i.e.
widespread advice to all centres), and were, therefore, ideal points to evaluate across centres before and
after intervention. These were:
l advice to draw out the arms of the trial and explain each route separately (e.g. ‘option 1′ and ‘option 2′)
l recommendations to specify that randomisation means there is no control over allocation
l advice to reassure patients that treatment delays associated with OPTIMA prelim were safe.
These points were also deemed the most important advice generated by the QRS team, having considered
factors that most frequently appeared to lead to patient confusion or concern. Table 23 sets out whether
or not each of these suggestions were detected in consultations occurring before (no shading) and after
(green shading) the date of intervention. Examples occurring before intervention indicate that the recruiter
was already doing this. The date of intervention was defined as the first point at which these
recommendations were distributed (October 2013 – the ‘tips and guidance’ document). All feedback
DOI: 10.3310/hta20100 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 10
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Stein et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
69
TABLE 23 Recruiters’ demonstration of QRS recommendations by centre before and after intervention
Centre
Consultation
identifier
Draws diagram
of trial arms?
Specifies randomisation=no
control over allocation Reassures about delay?
Centre 1 OP8 No No No
OP9 No No Yes
Centre 2 OP1 No No No
OP2 No No No
OP10 No No No
OP12 No No No
OP13 No No No
OP14 Yesa No Yes
OP17 No No No
OP20 Yes Yes Yes
OP21 Yes Yes No
OP22 Yes Yes Yes
OP26 Yes No Yes
Centre 3 OP1 No No No
OP2 Yesa No No
OP4 No No No
OP13 No No No
OP14 No No NA
Centre 4 OP4 No No Yes
OP6 No No No
OP8 Yes Yes Yes
OP9 Yes No Yes
Centre 5 OP26 No No NA
OP27 No No NA
OP28 No No NA
OP30 No No NA
Centre 6 OP1 Yes Yesb Yes
OP1 Yes Yes Yes
NA, not applicable; OP, OPTIMA participant.
a Initiated by patient expressing confusion.
b Initiated by patient asking a question.
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meetings also covered these points, all of which took place after October 2013. The data summarised in
the table are based on targeted analysis of consultations (arranged by date) to focus specifically on the
topics of interest. The word ‘Yes’ showed that the recruiter spontaneously demonstrated the behaviour/
recommendation, while ‘Yesa/Yesb’ indicate that the behaviour was demonstrated in response to patient
confusion (a) or questioning (b).
There is a general pattern suggesting change in centres’ practices before and after the QRS intervention,
although there are a few exceptions where practices were present before intervention and not adopted
after intervention. Evidence to support real changes in practice was particularly strong where recruiters very
clearly altered their approaches to communicating concepts. This was most apparent in recruiters’
descriptions of the study design before and after QRS intervention (specifically, their tendencies to draw
out arms and describe each separately as two ‘options’). This is demonstrated through extracts from the
following oncologist’s pre- and post-intervention explanations (Box 2). The changes apparent were similar
for other recruiters who adopted the technique of drawing out the study arms.
Not all elements of the QRS guidance and advice could be evaluated through qualitative analysis.
Recruiters’ readiness to explore patient decisions and preferences was a clear opportunity for change,
but actual practices could not be assessed owing to the limited numbers of audio-recorded consultations
where patients voiced their decisions. On a more general level, there were limited opportunities to discuss
pre-/post-intervention changes in practices for individual recruiters, as few (if any) had contributed enough
recordings that could be compared before and after intervention.
BOX 2 Pre- and post-intervention explanations
June 2013 (pre QRS intervention)
What OPTIMA does, essentially, we do the Oncotype DX test on the tumour and then you get told
whether you’re going to have chemotherapy or not [. . .]. Optima is a randomised study, so 50% of the
women at random in this study will get standard treatment with chemotherapy, and the other 50% in this
study will have the treatment decision made according to the results of the Oncotype tests.
Onc1
Intervention
November 2013 (post QRS intervention)
So we feed details about you into a computer, and it tells us whether you get the standard treatment,
which is option 1, or the Oncotype test, which is option 2. So if you look at the diagram, the way it works
is that if you are allocated to option 1, you get the chemotherapy that I’ve described, followed by
hormone tablets for 5 years or 10. And you get your radiotherapy whilst you’re having your
hormone tablets.
Onc1
OK.
Patient
You have option 2, um we send the tumour for an Oncotype test, and if it comes back as a high score
then you get exactly the same as you would in option 1. But if it comes back as a low score, it says that
chemotherapy is not likely to benefit you, and we’ll manage with oestrogen tablets alone.
Onc1
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Qualitative recruitment study conclusions
Phase 1 of the QRS provided considerable information about the process of recruitment, as it was enacted
in clinical centres participating in OPTIMA prelim. Interviews, audio-recordings and screening logs all
provided insights that enabled a detailed and nuanced understanding of the challenges faced by recruiters
in explaining the complex issues inherent in the OPTIMA prelim study and its design. These understandings
were transmitted to the CfI, TMG and recruiters in a range of ways, including direct discussion of eligibility
and information issues with the CfI and TMG, and through individual feedback, group discussions, tips
and guidance documents and a revised PIS.
The methods used in this QRS were developed in a number of other RCTs.140,181,182 Several issues identified
as important barriers to recruitment in other trials were also found in OPTIMA prelim, such as recruiters’
discomfort in exploring patient preferences, and the use of problematic terminology in recruitment
consultations and trial documentation.182,183 However, there were also some original barriers to recruitment
that were specific to the OPTIMA prelim trial, including recruiters’ discomfort in eligibility criteria and
patients’ difficulties understanding the trial design.
The QRS was facilitated by a supportive CfI and TMG, but was hampered by clinical centres being given
the opportunity to opt out of the QRS, and by recruiters’ unwillingness to audio-record consultations.
These issues have also been found previously.184 If OPTIMA prelim proceeds to a main trial, clearer support
for the QRS as a fully integrated and study-wide recruitment support initiative should be considered and
attention given to encouraging (or perhaps expecting) greater commitment to recording consultations.
In particular, it was noted that most of the centres participating in the QRS in the current study were
mid-range recruiters. Future work would benefit from targeting centres for participation in the QRS on the
basis of purposeful sampling methods, where screening logs are used to select centres deemed as ‘high’
and ‘low’ recruiters. This approach depends on clear, complete screening logs that record the entire
recruitment process, from initial screening to trial participation. A more detailed discussion of the
limitations of the QRS methods, including ideas for optimising future integration of the QRS in the OPTIMA
main study, is presented in the Chapter 6, Qualitative recruitment study and Appendix 10.
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Chapter 5 Results: pathology and health
economic study
Pathology analysis
The objective of the OPTIMA prelim pathology analysis, in conjunction with the health economic analyses,
was to identify which test(s) should be taken forward into the main OPTIMA trial. This chapter addresses
this question by first discussing the data from several different multiparameter tests conducted on the
same samples and then looking at how those data and the predicted patient outcomes identify test(s) that
would be strong candidates for further research within the main OPTIMA trial.
Of the 313 patients randomised between 10 October 2012 and 3 June 2014, 302 tumour samples
were available for analysis at the central laboratory; four patients had withdrawn prior to Oncotype DX
testing, one patient was ineligible and a further six patients had insufficient sample for additional
multiparameter testing, although an Oncotype DX score was obtained. These 302 patients are the focus
of this section of the report.
Characteristics of patients included in the pathology analysis by Oncotype DX
recurrence score groups
Of the 302 patients, 247 (82%) had a RS of ≤ 25, 54 (18%) had a RS of > 25 and one patient had
insufficient tumour available for Oncotype DX testing, although the sample was suitable for alternative
testing. The characteristics of the 301 patients split by high and low RS are given in Table 24. Histological
grade (1 or 2 vs. 3) was the only characteristic that was significantly associated with a RS of ≤ 25 or > 25
(odds ratio 12.3, 95% CI 6.3 to 24.4; p< 0.0001).
Comparison of Oncotype DX with ‘conventional’ prognostic risk assessment tools
The actual outcomes for the patients recruited into OPTIMA prelim will not be known for several years and
were therefore estimated using a variety of nomograms and models as described above (see Chapter 3,
Clinical risk prediction. Table 25 provides the median (range) estimates of overall survival and RFS by RS for
the 301 patients with available data, predicted using the nomograms, PREDICT18 (www.predict.nhs.uk),
Adjuvant! Online17 (www.adjuvantonline.com) and NPI,19 and also 5-year RFS from a constant benefit model
and a variable benefit model.
As expected, both the median predicted overall survival and median RFS rates were poorer for the
Oncotype DX high-score group than for the low-score group for all nomograms, although the ranges
overlapped between the two groups (Table 25). The median predicted additional benefit of chemotherapy
compared with that predicted from endocrine therapy alone was consistently greater for the Oncotype DX
high-score group for all nomograms although, again, the ranges overlapped with the low-score group. The
variable benefit model, which assumes that the benefit of chemotherapy varies with Oncotype DX scores
shows, as expected, the most difference in the benefit of chemotherapy between the categories.
DOI: 10.3310/hta20100 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 10
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Stein et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
73
TABLE 24 Participant demographics and tumour characteristics of participants by Oncotype DX RS groups
Characteristic RS ≤ 25, n (%) RS > 25, n (%) Total, n (%)
Number of patients 247 (82) 54 (18) 301
Oncotype DX RSa
< 18 163 (66) 0 (0) 163 (54)
18–25 84 (34) 0 (0) 84 (28)
26–31 0 (0) 20 (37) 20 (7)
> 31 0 (0) 34 (63) 34 (11)
Age in years, median (range) 58 (40–78) 57 (42–76) 58 (40–78)
Menopausal status of participant
Pre-/perimenopausal 82 (33) 14 (26) 96 (32)
Post-menopausal 165 (67) 40 (74) 205 (68)
Number of involved nodes
None 46 (19) 11 (20) 57 (19)
1–3 158 (64) 34 (63) 192 (64)
4–9 32 (13) 9 (17) 41 (13)
Positive sentinel node biopsy without clearance surgery 11 (4) 0 (0) 11 (4)
Intended chemotherapy regimen
Anthracycline – non-taxane 94 (38) 22 (41) 116 (39)
Taxane – non-anthracycline 30 (12) 4 (7) 34 (11)
Anthracycline – taxane 123 (50) 28 (52) 151 (50)
Tumour grade
1 19 (8) 0 (0) 19 (6)
2 185 (75) 15 (28) 200 (67)
3 43 (17) 39 (72) 82 (27)
Largest tumour size in mm, median (range) 26 (2–170) 31 (8–70) 28 (2–170)
Lymphovascular invasion reported
No 147 (60) 22 (41) 169 (56)
Yes 90 (36) 31 (57) 121 (40)
Not known 10 (4) 1 (2) 11 (4)
Number of active comorbidities, median (range) 0 (0–4) 0 (0–7) 0 (0–7)
ER score – Allred
≤ 6 6 (2) 5 (9) 11 (4)
7–8 241 (98) 49 (91) 290 (96)
a The predefined classification of Oncotype DX risk includes an intermediate group with a RS of 18–31. This information is
included for illustration.
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Risk categorisation by different molecular tests
One of the key end points for OPTIMA prelim is the selection of one (or more) multiparameter assay(s) to be
used as the primary discriminator for chemotherapy allocation in the main study. Tumour specimens from
the 302 patients were therefore analysed using additional tests to help inform this decision. Two groups
of multiparameter assays were used. The first group of tests discussed in the section, Oncotype DX,
MammaPrint, Prosigna ‘risk of recurrence’, which is weighed for proliferation score and tumour size
(ROR_PT; NanoString Inc.) IHC4 and IHC4 AQUA, measure aspects of tumour biology and, based on
previous clinical data sets, provide numerical scores for individual patients that reflect recurrence risk. The
tests also provide predefined risk categories that divide the population into three to four groups based on
the numerical risk score that is part of the test output; MammaPrint provides only a binary risk category but
no numerical score. The Prosigna assay alone among the tests incorporates some tumour stage information,
namely tumour size (but not nodal status). For the purposes of this analysis, the Oncotype DX scores were
TABLE 25 Patients’ clinical risk by Oncotype DX RS groups
Risk and treatment groups RS ≤ 25 RS > 25 Total
Number of patients, n (%) 247 (82) 54 (18) 301
NPI
Median (range) 4.5 (2.8 to 8.2) 5.4 (3.6 to 6.8) 4.6 (2.8 to 8.2)
≤ 3.4, n (%) 12 (5) 0 12 (4)
> 3.4 to ≤ 5.4, n (%) 196 (79) 29 (54) 225 (75)
> 5.4, n (%) 39 (16) 25 (46) 64 (21)
PREDICT 10-year overall survival, median (range)
ET only 78.4 (31.4 to 94.6) 69.4 (25.1 to 86.0) 77.0 (25.1 to 94.6)
CT and ET 83.8 (39.8 to 95.9) 76.1 (41.6 to 91.2) 82.6 (39.8 to 95.9)
Additional benefit of CT 4.9 (1.2 to 25.8) 8.0 (2.3 to 22.6) 5.5 (1.2 to 25.8)
Adjuvant! Online 10-year overall survival, median (range)
ET only 69.4 (25.4 to 90.4) 63.1 (38.8 to 78.6) 68.6 (25.4 to 90.4)
CT and ET 77.3 (31.0 to 93.6) 73.4 (43.6 to 86.9) 76.4 (31.0 to 93.6)
Additional benefit of CT 6.3 (1.2 to 25.8) 8.8 (2.1 to 18.3) 6.8 (1.2 to 25.8)
Adjuvant! Online 10-year RFS, median (range)
ET only 61.7 (22.0 to 82.1) 55.2 (35.4 to 72.9) 60.5 (22.0 to 82.1)
CT and ET 73.1 (29.1 to 89.4) 70 (41.4 to 80.9) 72.9 (29.1 to 89.4)
Additional benefit of CT 10 (2.7 to 31.0) 12.5 (3.6 to 33.3) 10.5 (2.7 to 33.3)
Constant benefit model for 5-year RFS, median (range)
ET 78.5 (46.9 to 90.6) 74.3 (59.5 to 85.4) 77.8 (46.9 to 90.6)
CT and ET 85.8 (61.8 to 93.9) 82.8 (71.9 to 90.5) 85.2 (61.8 to 93.9)
Additional benefit of CT 7.2 (3.3 to 14.9) 8.5 (5.1 to 12.4) 7.5 (3.3 to 14.9)
Variable benefit model for 5 year RFS, median (range)
ET 78.5 (46.9 to 90.6) 74.3 (59.5 to 85.4) 77.8 (46.9 to 90.6)
CT and ET 76.4 (46.2 to 88.9) 82.2 (66.0 to 89.8) 77.2 (46.2 to 89.8)
Additional benefit of CT –1.9 (–11.0 to 4.0) 6.2 (2.6 to 21.7) –1.0 (–11.0 to 21.7)
CT, chemotherapy; ET, endocrine therapy; RFS, recurrence-free survival.
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divided into two groups (rather than the manufacturer’s three predefined risk groups) with the same RS
cut-off point of ≤ 25 versus > 25 used for chemotherapy allocation in the OPTIMA prelim. It must be
emphasised that predefined risk categories provided by the tests are specific to that test. Although some
have been defined using similar boundaries, the tests have been developed in different patient populations
and therefore the actual definitions of the risk category boundaries may not translate between assays.
The second group of assays, BluePrint, Prosigna and MammaTyper, divide tumours into the intrinsic
subtypes (see Parket et al.28 and references therein25–27). MammaTyper further divides luminal B cancers
into ‘low’ and ‘high’ risk based on proliferation. The subtype of breast cancer identified by these tests
reflects the tumour biology, which in turn influences recurrence risk. These tests do not directly ‘measure’
risk but classify tumours into subtypes, which are known to have different drug sensitivities and natural
histories. There is extensive literature that shows that luminal A breast cancer is associated with a
significantly better prognosis than the other three intrinsic subtypes. Tumours have, therefore, mostly
been divided into luminal A and non-luminal A subtype in this analysis. In practice, the great majority of
non-luminal A tumours are categorised as luminal B. Again it must be emphasised that the precise
definition of subtype is specific to the relevant assay. MammaTyper classified far fewer OPTIMA prelim
patients as luminal A than Prosigna and BluePrint; therefore, on the grounds of clinical applicability
(plausibility) we chose to combine the MammaTyper luminal A and low-risk luminal B groups [referred to
hereafter as MammaTyper Int. (intermediate)].
The proportion of low-risk tumours predicted by Oncotype DX was higher (82%, 95% CI 78% to 86%)
than the proportion predicted as either low or intermediate risk using Prosigna ROR_PT (66%, 95% CI
61% to 71%) or IHC4 (72%, 95% CI 67% to 77%). MammaPrint and IHC4 AQUA identified the fewest
low-risk tumours, 61% (95% CI 55% to 67%) and 62% (95% CI 56% to 68%), respectively (Table 26).
Prosigna ROR_PT identified 36% (95% CI 31% to 41%) as just low risk, compared with 24% (95% CI
19% to 29%) for IHC4 (see Table 26).
A comparison of kappa statistics between tests with risk categorisation (i.e. Oncotype DX, MammaPrint,
ROR_PT, IHC4 and IHC4 AQUA) showed the highest agreement between IHC4 and IHC4 AQUA grouping
low/intermediate (κ=0.60; 95% CI 0.50 to 0.70), but this is only slightly higher than the agreement
between the classifications using MammaPrint and ROR_PT (low/intermediate, κ= 0.53; 95% CI 0.43 to
0.63) and Oncotype DX and IHC4 (low/intermediate, κ= 0.53; 95% CI 0.41 to 0.65) (Table 27).
What is clear from the data is that discordance between different tests in assigning individual tumours to
risk categories is common. For the five tests [Oncotype DX, MammaPrint, Prosigna ROR_PT (low/
intermediate), IHC4 (low/intermediate) and IHC4 AQUA (low/low–mid)], only 93 (31%) tumours were
classified as low/intermediate risk by all five tests and only 26 (8%) tumours high risk by all five tests.
Discordant results between the tests were seen in 183 (61%) tumours although there was agreement
between four tests for 94 (31%) tumours. The rates of agreement with other tests were similar for all tests
(Table 28). This is consistent with what is known about both (1) the similar prognostic information
provided by different tests and (2) differences in which each test measures residual risk (see Chapter 6).
TABLE 26 Risk categorisation by each test
Risk group
Oncotype DX
RS ≤ 25 vs. > 25 MammaPrint Prosigna ROR_PT IHC4 IHC4 AQUA
n 301 (99.7%) 298 (99%) 299 (99%) 257 (85%) 271 (90%)
Low risk 247 (82%) 183 (61%) 108 (36%) 62 (24%) 87 (32%)
Intermediate
(low–mid) risk
– – 88 (30%) 123 (48%) 80 (30%)
Mid risk – – – – 55 (20%)
High risk 54 (18%) 115 (39%) 103 (34%) 72 (28%) 49 (18%)
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Intrinsic subtypes
While the above tests simply measure biological parameters in order to predict outcomes, the growing
recognition that breast cancers can be categorised into discrete biological subgroups (or subtypes) has led
to the development of multiparameter prognostication based on these subtypes. Table 29 shows the
division of tumours into luminal A or non-luminal A for those multiparameter assays that provide intrinsic
subtype information. For illustration, the results for both MammaTyper luminal A and MammaTyper Int.,
which extends the luminal A group to a combination luminal A and low-risk luminal B, are included.
All further analysis involving MammaTyper were performed using MammaTyper Int.
Interestingly, despite all the patients in this study being screened by central testing as ER-positive,
HER2-negative, a small proportion of tumours (15 in total) were classified by molecular subtyping as either
‘HER2 enriched’ or ‘basal-like’ by different testing methods. This phenomenon is well recognised,28 although
its significance is unclear. Two tumours were classified as basal-like tumour by Prosigna; one of these was also
identified as basal by BluePrint and as triple negative by MammaTyper. The six tumours classified as HER2
enriched by Prosigna did not include the seven categorised as HER2 type by either MammaTyper only (n= 4),
BluePrint only (n= 2) or both (n= 1). The subtype tests (BluePrint, Prosigna and MammaTyper Int.) identified
approximately 60% of tumours as luminal A [BluePrint: 61% (95% CI 55% to 67%), Prosigna 60% (95% CI
54% to 66%) and MammaTyper Int. 62% (95% CI 56% to 68%)].
TABLE 27 Kappa statistics and 95% CI for tests providing risk predictions
Kappa statistic
(95% CI)
MammaPrint
(low)
ROR_PT
(low/intermediate)
IHC4
(low/intermediate)
IHC4 AQUA
(low/low–mid)
Oncotype DX
(RS of ≤ 25)
0.40 (0.30 to 0.49) 0.44 (0.33 to 0.54) 0.53 (0.41 to 0.65) 0.40 (0.30 to 0.51)
MammaPrint – 0.53 (0.43 to 0.63) 0.33 (0.21 to 0.44) 0.42 (0.30 to 0.53)
ROR_PT
(low/intermediate)
– – 0.39 (0.27 to 0.50) 0.43 (0.31 to 0.54)
IHC4
(low/intermediate)
– – – 0.60 (0.50 to 0.70)
TABLE 28 Agreement between tests
Number of other tests agreed with test Oncotype DX ROR_PT MammaPrint IHC4 IHC4 AQUA
4 119 (39%) 119 (39%) 119 (39%) 119 (39%) 119 (39%)
3 84 (28%) 77 (26%) 73 (24%) 67 (22%) 75 (25%)
2 54 (18%) 52 (17%) 47 (16%) 36 (12%) 33 (11%)
1 31 (10%) 33 (11%) 34 (11%) 25 (8%) 27 (9%)
0 13 (4%) 18 (6%) 25 (9%) 10 (4%) 17 (6%)
Missing 1 (1%) 3 (1%) 4 (1%) 45 (15%) 31 (10%)
For each tumour result obtained with a particular test, the number of other tests agreeing with that result is shown.
TABLE 29 Intrinsic subtype predictions
Subtype group BluePrint (n= 298) Prosigna (n= 299) MammaTyper Int.a (n= 298) MammaTyper (n= 298)
Luminal A 181 (61%) 178 (60%) 186 (62%) 53 (18%)
Non-luminal A 117 (39%) 121 (40%) 112 (38%) 245 (82%)
a MammaTyper Int. combines luminal A and low-risk luminal B.
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Despite the close similarity in the proportions of tumours identified as luminal A, only 121 (40%) tumours
were classified as luminal A subtype by all three tests and 58 tumours (19%) as all other subtypes.
Discordant results across these three tests for subtype classification were seen in 123 (41%) tumours.
Given the data outlined above on subtyping across different test platforms, it is unsurprising that, as
predicted, moderate kappa statistics between different tests were observed (Table 30). In a comparison
between subtype assignment by BluePrint, Prosigna and MammaTyper Int., kappa statistics ranged from
0.39 (95% CI 0.29 to 0.50) for the comparison of BluePrint and MammaTyper Int. to 0.55 (95% CI
0.45 to 0.64) for the comparison of BluePrint and Prosigna.
Assessing the relationship between the continuous Prosigna subtyping and
Prosigna risk of recurrence risk score
Prosigna is unique among the multiparameter assays evaluated in providing both a subtype (luminal A,
luminal B, HER2 enriched and basal-like) and a continuous risk score (ROR_PT) with predefined risk
categories. It is interesting to compare the information provided by these two measures that are derived
from measurement of the expression of an identical set of genes.
All 178 tumours classified as luminal A by Prosigna had a ROR_PT score less than the predefined high-risk
cut-off point (see Table 31); 108 (61%) of these lay in the low-risk group and the remainder, 70 (39%),
were in the intermediate-risk group. None of the 113 luminal B tumours was classified as low risk;
97 (86%) of these lay in the high-risk group (ROR_PT ≥ 61) (see Table 31), with the remainder in the
intermediate-risk group. Interestingly, eight tumours, all of which were centrally confirmed as ER-positive/
HER2-negative, were grouped into either the basal-like (n= 2) or HER2-like (n= 6) subtypes by Prosigna,
and were intermediate or high risk, respectively, according to ROR_PT score (Table 31).
TABLE 30 Kappa statistics and associated 95% CIs for the tests providing intrinsic subtype
Kappa statistic (95% CI) Prosigna subtype MammaTyper Int.a
BluePrint subtype 0.55 (0.45 to 0.64) 0.39 (0.29 to 0.50)
Prosigna subtype – 0.44 (0.34 to 0.54)
a MammaTyper Int. combines luminal A and the low-risk luminal B groups.
TABLE 31 Summary of the ROR_PT scores across Prosigna subtypes
Test result
Prosigna subtypes
Luminal A, n (%) Luminal B, n (%) Basal-like, n (%) HER2 enriched, n (%)
Number of patients 178 (59) 113 (38) 2 (1) 6 (2)
ROR_PT median
(interquartile range)
37 (28–44) 70 (63–78) 53 (47–58) 76 (72–78)
Range 5–59 43–96 47–58 64–84
ROR_PT
Low risk (0–40) 108 (61) 0 0 0
Intermediate
risk (41–60)
70 (39) 16 (14) 2 (100) 0
High risk (61–100) 0 97 (86) 0 6 (100)
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Assessment of patients’ tests results according to Oncotype DX recurrence
score group
Tumours were classified as low score or high score according to Oncotype DX for the purposes of
treatment allocation. Table 32 shows how tumours were categorised by the other multiparameter assays
according to this division. Of the 247 tumours with an Oncotype DX RS of ≤ 25, 177 (72%) were classified
as low risk by MammaPrint, 175 (71%) were classified as luminal A by BluePrint subtype 172 (70%)
tumours were categorised as luminal A by Prosigna and 168 (68%) were classified as luminal A by
MammaTyper Int. (see Table 32). Conversely, of the 54 tumours with a high-risk RS, 44 (88%) were
classified both as high risk by MammaPrint and as non-luminal A BluePrint subtype and 36 (66%)
were classified as high-risk luminal B by MammaTyper Int.
Economic analysis
In order to calculate the health economic aspects of the various tests, given that we do not know the
actual outcomes of the enrolled patients, these have to be estimated. As discussed in Chapter 3, Clinical
risk prediction, there are different views on whether or not the benefit of the chemotherapy is dependent
on the test score, and this section will present the health economics analysis using different assumptions
within alternative sensitivity analyses.
The tests meeting eligibility for inclusion in the base-case analysis were Oncotype DX, MammaPrint,
Prosigna Subtype and Prosigna ROR_PT. The base-case analysis excluded IHC4 and IHC4 AQUA because
of concern about their analytical validity in the context of a possible national NHS roll-out as outlined in
Chapter 1, Individual multiparameter assays. Although MammaTyper has demonstrated analytical validity,
there were no published clinical validation data and no cost information was available. No clinical
validation data have been published for IHC4 AQUA, which was also excluded on these grounds.
Validation model: Oncotype DX versus standard care based on the
SWOG88-14 trial
The validation model represents an update of the model, which was originally published in 2012, and
which compared Oncotype DX with chemotherapy for all.15 Results of the validation analysis comparing
standard care (chemotherapy for all patients or ‘chemo-for-all’) to Oncotype DX are shown in Table 33.
Two potential RS cut-off points for Oncotype DX have been considered: ≤ 25 and cut-off score of < 18,
hereafter referred to as Oncotype DX_25 and Oncotype DX_18. The results indicate that Oncotype DX
increases QALYs regardless of which cut-off point is used; however, Oncotype DX_25 proves more
cost-effective than Oncotype DX_18, as Oncotype DX_25 produces additional QALYs at a lower cost per
QALY rate than using a cut-off point of 18. That is, Oncotype DX_25 has a lower ICER than Oncotype
DX_18 and, therefore, Oncotype DX_25 is preferred to Oncotype DX_18, thus supporting the cut-off point
of 25 used in the OPTIMA prelim trial on health economic grounds.
Results of the analysis including only Oncotype DX_25 versus chemotherapy for all are shown in Table 34.
Compared with chemotherapy for all, Oncotype DX_25 is associated with a cost per additional QALY
of £2166.
Main economic analysis (base case)
The base-case comparison includes four tests (Oncotype DX, MammaPrint, Prosigna Subtype and Prosigna
ROR_PT) and assumes that the relative benefit of chemotherapy is dependent on risk groups and test
score. For the analysis we used cut-points dividing tumours into high- or lower-risk groups as follows:
Oncotype Dx, RS > 25 vs. ≤ 25; MammaPrint, vendor pre-defined; Prosigna subtype, non-luminal A vs.
luminal A; Prosigna ROR_PT, vendor pre-defined score of ≥ 60 vs. < 60. Post-recurrence survival is
assumed to be constant regardless of pretreatment with adjuvant chemotherapy and the benefit from
chemotherapy is assumed to depend on the test scores. The costs, QALYs and net health benefit of all
tests are shown in Table 35 along with the probability of producing more QALYs or costing less than
chemotherapy for all.
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TABLE 32 Comparisons of tests results with Oncotype DX RS groups
Test result
Oncotype DX
RS ≤ 25, n (%)
Oncotype DX
RS > 25, n (%) Total, n (%)
Number of patients tested by
Oncotype DX 247 (82) 54 (18) 30 (100)
Number of patients tested
by MammaPrint/BluePrint 247 (83) 50 (17) 297 (100)
MammaPrint
Low risk 177 (72) 6 (12) 183 (62)
High risk 70 (28) 44 (88) 114 (38)
BluePrint subtype
Luminal A 175 (71) 6 (12) 181 (60)
Luminal B 70 (28) 43 (86) 113 (38)
Basal 0 (0) 1 (2) 1 (1)
HER2 type 2 (1) 0 (0) 2 (1)
Number of patients tested by Prosigna 246 (83) 52 (17) 298 (100)
Prosigna subtype
Luminal A 172 (70) 5 (10) 178 (59)
Luminal B 74 (30) 39 (75) 113 (38)
Basal-like 0 (0) 2 (4) 2 (1)
HER2 enriched 0 (0) 6 (11) 6 (2)
ROR_PT, median (range) 43 (5 to 91) 77 (32 to 96) 47 (5 to 96)
ROR_PT
Low risk 106 (43) 2 (4) 108 (36)
Intermediate 81 (33) 6 (11) 87 (29)
High risk 59 (24) 44 (85) 103 (35)
Number tested by MammaTyper 243 (82) 54 (18) 298 (100)
MammaTyper Int. subtypea
Luminal A 168 (69) 18 (33) 180 (62)
Luminal B 72 (30) 34 (63) 106 (36)
HER2 positive 3 (1) 1 (2) 4 (1)
Triple-negative breast cancer 0 (0) 1 (2) 1 (1)
Number tested by IHC4 207 (80) 50 (20) 257 (100)
Median IHC4 score (range) –2.6 (–90.0 to 110.0) 54.0 (–37.8 to 143.7) 7.5 (–90.0 to 143.7)
IHC4
Low risk 61 (29) 1 (2) 62 (24)
Intermediate risk 113 (55) 10 (20) 123 (48)
High risk 33 (16) 39 (78) 72 (28)
Number tested by IHC4 AQUA 223 (82) 47 (18) 270 (100)
Median IHC4 AQUA score (range) –23.3 (–141.9 to 121.6) 28.7 (–40.3 to 133.7) –16.6 (–141.9 to 133.7)
IHC4 AQUA
Low 86 (38) 1 (2) 87 (32)
Low–mid 75 (34) 5 (11) 80 (30)
Mid 42 (19) 12 (25) 54 (20)
High 20 (9) 29 (62) 49 (18)
a MammaTyper Int. combines luminal A and low-risk luminal B as luminal A. The luminal B group is the same as high-risk luminal B.
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Considered in isolation, all tests are more cost-effective than standard care alone, since they all lead to an
increase in QALYs and all except MammaPrint result in an overall reduction in costs (see Table 35). The net
health benefit from all tests is higher than chemotherapy for all, although is fairly similar between tests.
Uncertainty in the cost-effectiveness is represented graphically for each test in comparison with
chemotherapy for all in the scatterplot on the incremental cost-effectiveness plane (Figure 8) and the
cost-effectiveness acceptability curves in Figure 9.
The results of an incremental analysis, in which tests included in the base case compete with each other,
rather than just competing with chemotherapy for all, is presented in the cost-effectiveness acceptability
curves in Figure 10. At a willingness-to-pay threshold of £20,000 per QALY Prosigna ROR_PT has the
highest probability of being cost-effective at 39%.
TABLE 33 Validation analysis cost-effectiveness results: three-way analysis of chemotherapy for all, Oncotype DX
(RS cut-off point of < 18) and Oncotype DX (RS cut-off point of ≤ 25)
Strategy Mean cost (£) Mean QALYs Incremental cost (£) Incremental QALYs ICER (£/QALY)
Chemotherapy
for all
13,565 7.76 – – –
Oncotype DX_18 15,364 8.19 1799 0.43 4184a
Oncotype DX_25 15,061 8.45 –304 0.27 Dominate
a Externally dominated strategy: a strategy that has an ICER higher than the next most costly alternative (and, therefore,
the next most costly alternative is preferred).
TABLE 34 Validation analysis cost-effectiveness results: two-way analysis of Oncotype DX_25 vs. chemotherapy for
all (externally dominated strategy Oncotype DX_18 removed)
Strategy Mean cost (£) Mean QALY Incremental cost (£) Incremental QALY ICER (£/QALY)
Chemotherapy for all 13,565 7.76 – – –
Oncotype DX_25 15,061 8.45 1495 0.69 2166
TABLE 35 Base-case analysis
Treatment strategy
Mean
cost (£)
Mean
QALYs
Net health benefit
(QALYs)
Probability more
effective than
chemotherapy for all
Probability cost-saving
vs. chemotherapy
for all
Chemotherapy for all 13,961 7.69 6.99 – –
Oncotype DXa 13,853 7.89 7.20 0.73 0.53
MammaPrinta 14,156 7.87 7.16 0.73 0.39
Prosigna subtypea 13,680 7.87 7.19 0.74 0.62
Prosigna ROR_PTa 13,487 7.88 7.20 0.73 0.68
a Tests included in base-case analysis.
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FIGURE 9 Cost-effectiveness acceptability curves: tests compared with chemotherapy for all.
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FIGURE 10 Cost-effectiveness acceptability curve for the base-case analysis: tests compared with each other.
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Sensitivity analysis number 1
In sensitivity analysis number 1, it is assumed that post-recurrence survival is dependent on previous
treatment with adjuvant chemotherapy. Results of sensitivity analysis number 1, including only tests
included within the base-case analysis, are shown in Table 36 and in the accompanying cost-effectiveness
acceptability curve (Figure 11). It should be noted that this analysis favours Oncotype DX over the other
tests on the basis of expected cost-effectiveness, with Prosigna ROR_PT falling into second place in terms
of both expected net health benefit and the probability of cost-effectiveness.
Sensitivity analysis number 2
In sensitivity analysis number 2, it is assumed that the effect of treatment (i.e. hazard ratio for RFS with
chemotherapy compared with no chemotherapy) is constant across test-defined risk groups. It is also
assumed that post-recurrence survival is constant across all patients, regardless of pretreatment,
as in the base-case analysis. The mean costs, QALYs and net health benefit are presented in Table 37.
Chemotherapy for all is more cost-effective than any of the testing options, although there is some
uncertainty about this as demonstrated in the cost-effectiveness acceptability curve (Figure 12).
TABLE 36 Sensitivity analysis number 1: costs, QALYs and net health benefit
Treatment strategy Mean cost (£) Mean QALYs Net health benefit (QALYs)
Chemotherapy for all 13,079 7.47 6.81
Oncotype DX 15,320 8.28 7.52
MammaPrint 15,008 8.10 7.35
Prosigna Subtype 14,437 8.07 7.35
Prosigna ROR_PT 14,437 8.13 7.41
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FIGURE 11 Cost-effectiveness acceptability curve for sensitivity analysis number 1.
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Value-of-information analysis for the base-case analysis and sensitivity
analyses numbers 1 and 2
The expected value of perfect parameter information is calculated for the 5-year RFS parameters and other
parameters that would be informed by the proposed OPTIMA trial (including benefit from chemotherapy
and the proportion allocated to high risk). This represents a ceiling on the value of research into these
parameters. Each EVPPI calculation is the EVPPI for a comparison between chemotherapy for all and
chemotherapy directed by a single alternative test. Tests with higher EVPPI are, therefore, a higher priority
for inclusion in further randomised research which has 5-year RFS as an outcome. The EVPPI is presented
in Figure 13 and is high for all tests included in the base-case analysis, suggesting high value in further
research into test-directed chemotherapy. The expected net benefit, probability of cost-effectiveness and
the EVPPI all favour Prosigna (ROR_PT) as the preferred test for both current adoption and inclusion in
further research. The EVPPI for MammaPrint is higher than for Oncotype DX, suggesting that this may be
the second priority, but that it should not be prioritised over Prosigna. The ranking of tests is similar in
sensitivity analysis number 1. For sensitivity analysis number 2 (constant benefit from chemotherapy,
irrespective of test score) the EVPPI is much lower for all tests except MammaPrint (see Figure 13).
TABLE 37 Costs, QALYs and net health benefit for sensitivity analysis number 2
Treatment strategy
Mean
cost (£)
Mean
QALYs
Net health
benefit (QALYs)
Probability more
effective than
chemotherapy for all
Probability cost-saving
vs. chemotherapy
for all
Chemotherapy for all 13,917 7.99 7.30 – –
Oncotype DX 13,826 7.89 7.21 0.34 0.58
MammaPrint 14,139 7.92 7.22 0.34 0.41
Prosigna Subtype 13,665 7.93 7.25 0.35 0.66
Prosigna ROR_PT 13,472 7.92 7.25 0.34 0.71
Chemotherapy for all
Oncotype DX
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FIGURE 12 Cost-effectiveness acceptability curve for sensitivity analysis number 2.
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Sensitivity analysis number 3
Sensitivity analysis number 3 includes all tests, irrespective of eligibility for inclusion in the base-case
analysis. The costs, QALYs and net health benefit are shown in Table 38. The probabilistic results are
shown in Figure 14. The results of the probabilistic analysis are presented as a cost-effectiveness
acceptability curve compared with chemotherapy for all in Figure 15 and with each other in Figure 16. It
can be seen that all three additional tests have a net health benefit higher than that of the tests included
in the base-case analysis, suggesting that they would be more cost-effective if adopted at the present
time. The results of a value-of-information analysis, which includes all tests as comparators, presented in
Figure 17, confirms the base-case conclusion that Prosigna ROR_PT remains the priority for further
research, although it is now closely followed by IHC4.
Prosigna
ROR_PT
Prosigna Subtype
MammaPrint
Oncotype DX
0 500 1000 1500
Population EVPPI over 10 years (QALYs)
2000 2500 3000 3500
Base-case analysis 
SA1 (variable survival 
after recurrence)
SA2 (constant 
chemotherapy benefit)
FIGURE 13 Value-of-information analysis for the base-case comparison and sensitivity analyses numbers 1 and 2.
SA, sensitivity analysis.
TABLE 38 Results from sensitivity analysis number 3, with all tests included
Treatment
strategy
Mean
cost (£)
Mean
QALYs
Net health
benefit (QALYs)
Probability more effective
than chemotherapy for all
Probability cost-saving
vs. chemotherapy for all
Chemotherapy
for all
13,961 7.69 6.99 – –
Oncotype DXa 13,853 7.89 7.20 0.73 0.53
MammaPrinta 14,156 7.87 7.16 0.73 0.39
Prosigna
subtypea
13,680 7.87 7.19 0.74 0.62
Prosigna
ROR_PTa
13,487 7.88 7.20 0.73 0.68
MammaTyper 13,017 7.88 7.22 0.73 0.80
IHC4 12,846 7.87 7.22 0.73 0.90
IHC4 AQUA 12,069 7.87 7.27 0.73 0.84
a Tests included in base-case analysis.
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FIGURE 15 Cost-effectiveness acceptability curves for sensitivity analysis number 3: all tests included and compared
with chemotherapy for all.
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FIGURE 16 Cost-effectiveness acceptability curves for sensitivity analysis number 3: all tests included and compared
with each other.
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Relationship between Adjuvant! Online survival prediction and test scores
The relationship of the Oncotype DX scores and ROR_PT scores with the Adjuvant! Online 10-year overall
survival for endocrine therapy is displayed in Figures 18 and 19. These data are presented because of the
reliance on outcomes forecast by Adjuvant! Online in the cost-effectiveness model. There is a slightly
higher negative correlation between the Adjuvant! Online 10-year overall survival for endocrine therapy
and ROR_PT scores (r= –0.39) compared with Oncotype DX RS (r= –0.19), which may be contributing to
the higher QALYs in the Prosigna analysis.
Prosigna ROR_PT
IHC4
IHC4-AQUA
MammaTyper
Prosigna Subtype
MammaPrint
Oncotype DX
0 500 1000 1500
Population EVPPI (QALYs)
2000 2500 3000
FIGURE 17 Sensitivity analysis number 3: value-of-information analysis, all tests included.
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FIGURE 18 Scatterplot of the Adjuvant! Online 10-year overall survival for endocrine therapy only against risk
scores: Oncotype DX.
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FIGURE 19 Scatterplot of the Adjuvant! Online 10-year overall survival for endocrine therapy only against risk
scores: ROR_PT.
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Chapter 6 Discussion
Recruitment and study conduct
Recruitment and study design
OPTIMA prelim opened to recruitment in late September 2012. The first patient consented to join
the study in October 2012. By 3 June 2014, 350 patients had been registered, of whom 313 had been
randomised from 35 recruiting centres. The OPTIMA TMG, and the NIHR HTA programme as study funder,
always considered that patient recruitment might prove to be difficult. Previous experience of clinical trials
involving an experimental arm in which less treatment is given than is standard clinical practice, such as
the ProTect trial,140 have experienced difficulties in recruitment.185,186 Prespecified success targets were
designed to demonstrate that recruitment into the proposed main trial was feasible once the number of
recruiting centres was scaled up. Most of these applied to the final 6 months of recruitment to allow time
to open the requisite number of sites and for research staff to learn how to recruit potential participants.
Site selection for the OPTIMA prelim was on the basis of individual invitation rather than an open call.
Five main geographical clusters were established, namely North London, East Anglia, the South West,
the West Midlands and Scotland. Sites within each cluster included a mixture of cancer centres and
district general hospitals. This policy was designed to ensure that feasibility could be demonstrated in a
representative selection of UK centres rather than in those that are best described as enthusiasts.
All predefined feasibility conditions have been met, demonstrating that a large-scale effectiveness trial of
the use of multiparameter assays as a decision tool for patients with primary ER-positive HER2-negative
breast cancer in the UK is indeed achievable. This is despite approximately 80% of patients having lymph
node involvement, which places them at comparatively high recurrence risk.
Two of the three other international trials of test-directed chemotherapy decisions have met their
recruitment targets.121,124 The MINDACT study estimated patient risk using information from a clinical risk
prediction nomogram, Adjuvant! Online, and a biological test, MammaPrint.122,186 Patients with discordant
risk assessments were randomised to a decision based on one of the two. Eligible patients could have up
to three involved axillary lymph nodes but there was no restriction on receptor status. Patients with
high-risk disease, determined on the basis of test concordance or by randomisation, were treated
with chemotherapy and offered an optional further randomisation between one of two chemotherapy
regimens. Similarly, those who had ER-positive disease, whether or not they received chemotherapy, were
eligible for optional randomisation between two endocrine treatment regimens. A formal feasibility
analysis was published after 800 patients (including a small number from the UK) had been registered,
at which time 25% of registered patients had discordant test results.187 The MINDACT design is very
complex, which inevitably created difficulties in explaining the study to patients. There is no published
information on the acceptability of the study to patients, although the use of a risk score provided by
Adjuvant! Online is likely to have been reassuring. The study recruited approximately 6600 patients.
The first analysis is expected to be published in 2016.
The TAILORx trial was conducted in the USA. Eligible patients had ER-positive, HER2-negative tumours no
larger than 5 cm in diameter and without lymph node involvement. Registered patients underwent
Oncotype DX testing.121,124 Those with a RS in the range 11–25 were eligible for randomisation between
chemotherapy followed by endocrine therapy versus endocrine therapy alone. Non-randomised patients
with low or high scores were followed up in registry arms. The study, which has a non-inferiority end
point, aimed to enrol 11,248 patients and to randomise approximately 4500; no information is available
on the number of eligible patients who accepted randomisation. Most of the patients randomised in the
study would be considered at too low a risk to be offered chemotherapy in routine UK clinical practice.
The primary analysis is planned to take place in December 2017.
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The RxPONDER study is similar in design to TAILORx but includes patients with one to three involved
lymph nodes; those with an Oncotype DX RS of ≤ 25 are eligible for randomisation.123,188 In potential
study participants, tumour testing may be performed either through trial registration or independently.
An estimated 9400 patients will need to be screened to achieve the randomisation target of 4000.
Cost-effectiveness research is an integral component of RxPONDER, which is largely funded by the USA
private health insurers. The primary analysis of the study, which began recruitment in 2011, is expected
in 2022. No information has been published on the acceptability of the study to patients.
The OPTIMA study has significant design differences to these three studies. Patients with up to nine
involved axillary nodes are eligible for randomisation, which by virtue of tumour stage is a higher-risk
group than the other studies have allowed. The study is partially blinded to minimise the likelihood of bias
in clinician behaviour and to reduce the risk of non-acceptance of treatment allocation; thus, participants
allocated to chemotherapy are not informed if they have been randomised to the control arm or have a
high-score Oncotype DX test result. Although patients allocated to no chemotherapy are aware that they
have a low-score Oncotype DX result, the actual RS is not disclosed to the site or patient. Patients who are
premenopausal at diagnosis are routinely treated with ovarian suppression regardless of whether or not
they receive chemotherapy, as otherwise a chemotherapy-induced menopause, which is difficult to identify
reliably, would be a potential source of inequality between the treatment arms. All of these features have
been identified in screening logs as reasons for potential participants choosing not to join the study.
Despite this, overall patient acceptance identified from the screening log was 47%, which exceeds the
protocol-defined target of 40%. Of those patients who went on to be randomised, 20% of patients had
node-negative disease while 15% had four or more involved nodes. A total of 31% of participants were
reported to be pre- or perimenopausal at the time of randomisation. Thus, the OPTIMA prelim has
demonstrated that it is possible to conduct a study with design features that will maximise the chances
that the study will deliver an unbiased result despite their difficulties for potential participants.
The reasons for the choice of an Oncotype DX RS cut-off point of ≤ 25 vs. > 25 for chemotherapy have
been explained in Chapter 2, Methods. To put this into context, a RS of 25 equates to a 16% risk of
developing metastatic disease over 10 years in a node-negative breast cancer population treated with
tamoxifen for 5 years but not chemotherapy,41 often termed residual risk. Any estimation of chemotherapy
benefit at this level of risk, however, must take into account that approximately one-third of this risk
relates to chemotherapy-insensitive late (beyond 5 years) relapse.9
Clinical decisions on chemotherapy use are influenced by residual risk and the predicted likelihood of
chemotherapy benefit, meaning the prevention of distant recurrence and death, which is related to
residual risk. There is no universally accepted level of predicted benefit that informs practice. Perception
of clinical risk and what constitutes a meaningful benefit from medical treatment is very much a matter of
individual judgement for both patients and clinicians. In the UK, most oncologists will discuss breast cancer
chemotherapy with patients who have a 3–5% predicted chance of benefit and recommend its use for
those with > 5% chance of benefit. At this level, although there is a significant population-wide treatment
benefit, the probability that an individual patient will benefit is modest.
Risk of recurrence is influenced by clinical stage as well as by tumour biology, and adding stage information
to multiparameter assay output improves the prediction of residual risk (e.g. see Tang et al.64,70). Should the
hypothesis underlying the OPTIMA study prove correct, however, then patients with tumours with a low
multiparameter risk score are unlikely to benefit to a meaningful degree from chemotherapy despite a
potentially high risk resulting from adverse stage, particularly lymph node involvement. This is the conclusion
from the retrospective analysis of the NSABP B-20 trial.64,70 It is difficult to make a direct estimate of the likely
level of chemotherapy benefit in the largely node-positive OPTIMA population at the RS threshold of 25.
Estimates based on NSABP B-2061 and SWOG88-1462 studies performed in node-negative and node-positive
populations, respectively, suggest a reduction in 10-year breast cancer mortality risk of in the order 5%. If a
RS of 25 is indeed close to the score at which the Oncotype DX predicts significant chemotherapy sensitivity,
then nodal status and other stage information are unlikely to have much influence on this estimate.
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In contrast, for patients at risk by virtue of adverse stage and whose tumours have higher scores predicting
chemotherapy sensitivity in addition to risk, chemotherapy is likely to offer a very substantial benefit. Similar
considerations should apply to other multiparameter assays.
Patient focus groups
Three patient focus groups were held to assess the acceptability and decision-making for women who
may have been offered randomisation into the OPTIMA prelim. These groups also reviewed the patient
information, leaflets and consent form. The study was acceptable to the majority of participants. Some had
clear preference for chemotherapy as that is what they had been offered and some discussed how they
felt not being offered chemotherapy. The trial design using a ‘test’ to decide treatment was acceptable
and most felt that a personalised approach using these multiparameter tests would be a preferred option.
The results of the focus groups provided some triangulation on the QRS for the TMG.
Qualitative recruitment study
Key findings from the qualitative recruitment study
The QRS was designed as an integral part of the OPTIMA prelim and identified a number of key challenges
to recruitment. It devised and delivered interventions to address these difficulties in collaboration with the
TMG and CfI. The most prominent identified themes that recurred across interviews and audio-recorded
consultations related to difficulties in eligibility processes and issues of clinician–patient communication.
These challenges had the potential to limit the number of patients approached about the trial, and/or ran
the risk of affecting the trial’s acceptability to patients.
In terms of difficulties in eligibility processes, some clinicians showed discomfort with the OPTIMA prelim’s
eligibility criteria, which deviated from embedded clinical practice. For instance, some clinicians felt patients
with the extensive lymph node involvement or higher tumour grade required chemotherapy, leading to
reluctance to enter these individuals into a trial where they may not receive this treatment. Equipoise issues
in some cases therefore had implications for whether or not certain high-risk patients were offered the
trial at all. Discomfort surrounding eligibility criteria also had potential to influence how clinicians
communicated with patients. For example, audio-recordings revealed that the prospect of chemotherapy
was sometimes (possibly inadvertently) presented as the preferred choice by clinicians. Recordings of
consultations also revealed examples of patients holding treatment expectations based on advice they had
received from other clinicians they had encountered in their care pathway. Clinicians’ discretion played a
role in determining whether or not patients would be approached about the trial; these judgments were
sometimes based on subjective criteria, such as clinician assessments of whether or not patients could
cope with additional information. As patient advocates, clinicians clearly felt they were protecting patients’
interests. However, these reported practices implied that patients themselves did not always make
decisions about trial participation.
A number of recruitment challenges uncovered by phase 1 of the QRS related to matters of
communication, such as the quality and clarity of explanations provided to patients. Recruiters experienced
difficulties in explaining the OPTIMA prelim trial design – particularly the unconventional way in which the
‘test-directed treatment’ arm split into two further arms. Audio-recordings of consultations showed
occasional use of problematic terminology to describe arms, and challenges in explaining trial-specific
processes such as ‘randomisation’ and ‘blinding’. Concepts such as ‘uncertainty’ and ‘risk’ were also
communicated in a variety of ways, to different levels of detail. Interviews uncovered recruiter discomfort
in exploring patients’ decisions to decline the trial for fear of jeopardising relationships with patients, or
being accused of coercive behaviour. While these scenarios should be handled sensitively, recruiters found
it easier to avoid exploring decisions about trial participation altogether. However, analysis of audio-recordings
provided some evidence to suggest that this avoidance could lead to missed opportunities to address patients’
misconceptions and concerns.
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Identification of the above challenges led to a series of QRS interventions, designed and delivered in
collaboration with the TMG and CfI. Key interventions included promotion of clinician-to-clinician
discussions to address concerns about eligibility criteria; circulation of generic ‘tips and guidance’ sheets to
help recruiters explain trial-specific processes within the context of the OPTIMA prelim; organisation of
group feedback meetings to share QRS findings and address concerns collaboratively; and delivery of
individual feedback, to provide tailored advice and consider solutions to challenges experienced by
individual recruiters.
Recruitment into OPTIMA prelim continued to improve as the study progressed. However, it is difficult to
assess the impact of the QRS, as claims of causality are problematic considering the multiple variables that
could have influenced recruitment at any given time. Nonetheless, we found some qualitative evidence
to suggest QRS interventions had an impact on some clinicians’ practices, although these findings were
based on a small sample of audio-recorded consultations.
Strengths and limitations
There were a number of limitations to the QRS methods. In terms of sampling, the full range of the
OPTIMA prelim centres were not available owing to some centres’ decisions to decline participation in the
optional QRS. The QRS consisted of mainly mid-range recruiting centres, not those with the highest and
lowest recruitment rates. Inclusion of centres with more extreme recruitment figures would have been
beneficial for comparison purposes, and may have contributed to further advice and recommendations to
optimise information provision and recruitment. Furthermore, questions should be raised about possible
differences between centres that opted for and against QRS participation (e.g. differences in commitment
to the trial, differences in resource availability).
Despite encouragement from the QRS team and TMG, recording of consultations did not occur as a matter
of routine, and the full range of interactions with patients was not captured. This is particularly true for
second oncology consultations (where patients sometimes gave their decisions about participation).
Incomplete recordings of each patient’s pathway made it difficult to track events and made deciphering
patients’ reasons for declining the trial problematic. In addition, limited numbers of audio-recordings for
each individual recruiter restricted opportunities to assess the impact of QRS interventions through
‘before/after’ comparisons. Reluctance to routinely record consultations may have been an indirect
consequence of recruiters perceiving the QRS as an optional additional task. The main trial, if funded,
will need to frame the QRS as a fully integrated component of the trial.
Although not a limitation of the qualitative methodology, questions remain with regards to the impact of
QRS interventions on recruitment rates and recruiters’ practices. We saw some evidence of recruiters
changing their practices and can be certain that recruitment improved over time. However, we cannot
make claims of causality between QRS interventions and recruitment rates. Further research by the QRS
team will consider this in more detail by exploring innovative ways in which this type of work can be
evaluated in the context of RCTs.
The above limitations are being addressed in future applications of integrated qualitative work by the QRS
team, and will be in the main trial, if funded. However, the practical (rather than theoretical) applications
of the QRS to the OPTIMA study need to be considered foremost; it is this applied nature of the QRS that
distinguishes it from traditional qualitative studies.
A clear strength of the QRS was its mixed-method, flexible approach to investigation. This enabled the team
to understand recruitment difficulties during enrolment in the trial, leading to identification of challenges that
were specific to the OPTIMA prelim (e.g. eligibility concerns), as well as difficulties that have been previously
reported in most trials (e.g. difficulties explaining trial-specific processes). The opportunity to feedback findings
quickly to change participants’ practices was a key strength of this research, highlighting its direct practical
applications. This process of sharing findings with participants also allowed for further exploration of
‘challenges’, thus reinforcing the iterative nature of the work undertaken and providing an informal form
of participant validation.
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The QRS work undertaken was a collaborative process that was designed to build on the support and
expertise of the TMG to help design and deliver interventions. This element of the QRS is an important
strength, as interventions were refined through input from a truly multidisciplinary team.
Lessons learnt from the qualitative research study: implications for a main trial
In the light of the above challenges and interventions in the OPTIMA prelim, there are a number of
key lessons that could be carried forward to the main trial. As new centres are likely to open, issues
of equipoise and discomfort surrounding eligibility criteria are likely to present again. The TMG could
pre-empt these difficulties by providing time for clinicians to discuss eligibility criteria at site initiation
meetings. One option may be to present clinical vignettes to prompt discussion about eligibility
concerns – a technique adopted in some of the group feedback meetings in the OPTIMA prelim.
A clear lesson from the QRS is the need for continued effort to use qualitative methods to optimise the
quality of information provision and address recruitment challenges in the main study. Experiences of
the QRS within OPTIMA prelim will help inform ways in which the QRS can be better integrated to ensure
it is used to its maximum potential. First, a more purposeful approach to sampling centres will be used,
with a view to including a maximum range of centres that vary by size, geographical location and
recruitment rates (based on screening log analysis). As suggested above, this process will work best if the
QRS is presented as an integrated component of the main study. Recruiters will be encouraged to record
routinely all interactions with patients who have given consent; this may call for the QRS team to offer
further support with the recording process (e.g. by making site visits where needed) and for recruiters to
prioritise face-to-face (rather than telephone) consultations whenever possible. Even if telephone
consultations are a necessity, additional equipment can be provided to ensure these discussions are
also captured.
Finally, a key consideration of the QRS within a main trial will be to compare recruiters’ practices before
and after feedback. This will help in the development of strategies to evaluate the impact of QRS
interventions. Promotion of routine audio-recording of consultations will be a cornerstone of this work.
Pathology and health economics
Characteristics of the OPTIMA prelim population
An important consideration is whether or not the population recruited represents those to whom the research
question is relevant. Although the prevalence of high-grade tumours in the OPTIMA-eligible population is
unknown, there seems to be an excess of histological grade 2 lesions compared with grade 3 tumours in the
OPTIMA prelim; 6%, 67% and 27% of lesions were reported to be grade 1, 2 and 3, respectively. For
reference, in an historic and completely unselected series of patients presenting with symptomatic early breast
cancer the ratio of grade 1, 2 and 3 lesions was reported to be 2 : 3 : 5.189 In mixed screening and symptomatic
series of ER-positive tumours, lower proportions of high-grade tumours (e.g. 3 : 4 : 3190) have been described.
It is likely that the proportion of high-grade tumours in the OPTIMA-eligible population lies between these two
proportions. Certainly the 18% of tumours with an Oncotype DX score of ≥ 25 was lower than the predicted
30% in our population. There appears, however, to be little difference from that expected in tumour type
distribution, with 70% of cancers of no special type/ductal in large series, compared190 with 71% in the
OPTIMA prelim. One possible explanation for the apparently lower than expected recruitment of patients with
more aggressive tumours is an element of patient selection by recruiting clinicians. It is important to ensure
that the study is not skewed towards patients with very low-biological-risk tumours if it is to be relevant
to the entire population. Recruiting clinicians therefore need to be reassured that multiparameter assays
reliably classify tumour risk irrespective of histological grade; going forwards to the main trial, this will
require education.
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Central review of receptor status
We undertook routine central retesting of receptor status in the OPTIMA prelim because of concern
about a potential for bias if patients with either ER-negative or HER2-positive disease based on local
histopathology testing were included in the study. There are many possible causes for this scenario,
including a well-recognised low incidence of HER2 gene amplification among tumours that are considered
HER2-negative by immunohistochemistry in first step of the standard two-stage HER2 testing procedure
recommended in UK guidelines.191 Any participants with ER-negative or HER2-positive disease would be
disadvantaged if allocated to endocrine therapy only, and such imbalance in treatment allocation would be
a potential source of confounding. To minimise this risk, central review to confirm the referring pathology
laboratory results for ER positivity and HER2 negativity was undertaken with immunohistochemistry for ER,
and with FISH for HER2 status. The former was scored using the Allred system (% staining and average
intensity; range 0–8) with a cut-off point of ≥ 3 defined as positive. HER2 positivity with FISH was defined
as a ratio of HER2 to chromosome 17 centromeric probe copy numbers of > 2.0 (2.0–2.2 defined as
borderline but amplified). This confirmed the eligibility of all but 12 of 325 patients (96.3%) tested on
central review of receptor status.
Reassuringly, in the OPTIMA prelim, only 1.2% (n= 4) of patients who locally were thought to have
ER-positive disease were found centrally to have ER-negative tumours. A total of 2.2% (n= 7) had tumours
with at least borderline amplification HER2 (three borderline but amplified, four amplified). Of these, one
woman had a tumour that was both ER negative and HER2 positive centrally. Two additional tumours
were heterogeneous, with discrete subpopulations of ER-positive and ER-negative cells and were, for this
reason, deemed ineligible (< 1%).
This level of discrepancy is lower than reported in the majority of clinical trials of early breast cancer,
although many of these have documented central review of HER2-positive (rather than HER2-negative)
disease. For example, among cases regarded locally as ER-positive, 4% and 16%, respectively, were
centrally redefined as ER-negative in two reviewing centres in Italy and the USA in the BIG 2-06/NCCTG
N063D trial.192 Similarly, in a centrally reviewed consecutive series of node-negative breast cancer from the
Netherlands, 4% and 5% disagreement was seen for ER and HER2, respectively, between local and central
tests (n= 694).193 The low level of disagreement in receptor status between local and central laboratories
that we report in this study reflects improvements in standardisation of receptor testing and the high levels
of quality assurance in the UK including, for example, mandatory participation in National External Quality
Assessment Service for Immunohistochemistry.194
The overall 3.7% (95% CI 1.7% to 5.8%) incidence of discrepancy between local and central laboratories
is reassuringly low. Although none of these cases underwent Oncotype DX testing, it is likely that such
cases would generate high-risk RS and consequently be allocated chemotherapy. Of the seven (2.2%)
patients who were found to have tumours that were HER2 amplified, three were classified as borderline
while four were clearly amplified. Such patients would ordinarily be treated with adjuvant trastuzumab but
received this treatment only by virtue of agreeing to join the OPTIMA prelim. The evidence of benefit for
adjuvant trastuzumab treatment for cases with equivocal HER2 amplification195 is controversial.
Therefore, based on the experience in 325 tumours centrally tested for ER and HER2, given the discordant
rates of ≤ 2.2% for each receptor separately, our experience with central review of ER and HER2 status
suggests that this is unnecessary in a large Phase 3 trial.
Multiparameter assays
Oncotype DX was chosen as the primary discriminator for decisions on treatment allocation for OPTIMA
prelim as this was judged most likely among the available tests to be acceptable to patients and clinicians
alike. The evidence supporting the use of Oncotype DX was and remains significantly stronger than for
potential alternatives. There is widespread familiarity with the test as the result of its successful marketing in
the UK private health-care sector. This has been reinforced by the NICE DG10 guidance,117 which provides it
with a stamp of authority that its competitors lack. Nevertheless there remain significant uncertainties in
relation to the use of Oncotype DX and other multiparameter assays that justify the OPTIMA study.
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One particular issue in relation to Oncotype DX is the choice of a cut-off point above which patients should
be advised to have chemotherapy treatment. The test output is calibrated as risk of distant recurrence at
10 years in patients with ER-positive disease treated with tamoxifen alone. The Oxford Overview has clearly
shown that there is no evidence that the recurrence risk in breast cancer patients who remain disease free
5 years after diagnosis is any different between those who did or did not receive adjuvant chemotherapy.
This is despite the observation that one-third of the recurrences during the 10 years after diagnosis occur in
the second half of this period.9 Therefore, estimation of likelihood of chemotherapy benefit in relation to
test output is inherently difficult. In the absence of robust data on the effectiveness of chemotherapy in
relation to Oncotype DX RS, the choice of a cut-off point is always going to be somewhat arbitrary. The
rationale for selection of a cut-off point of 25 is described above (see Chapter 2, Methods).
As there is no established method for the comparison between multiparameter assay platforms being
attempted in the OPTIMA prelim, the analysis has required the development of a methodology. There is
much uncertainty inherent in this, which is discussed in Chapter 6, Pathology study results. A particular
issue is that the assays have mostly developed to indicate residual risk of relapse after 10 years of
endocrine therapy and their predefined risk groupings reflect this. The limitations of this definition in
relation to decisions on chemotherapy use are described in the previous paragraph. As there is no
standardised definition of risk of relapse, the equivalent cut-off points for the available assays differ.
This means that the proportions of cases assigned by the assays to low-risk (or not high risk where there
are multiple divisions) and high-risk groups differ, which for the purposes of OPTIMA means that
proportions of patients advised chemotherapy differ. Consequently, the assumptions for treatment benefit
made in the health economics analysis are uncertain. As a result of this, any conclusions that can be drawn
from this analysis are, at best, an estimate and require formal testing in a prospective study.
Pathology study results
This study within the OPTIMA prelim represents, to our knowledge, one of the few and certainly the most
comprehensive ‘head-to-head’ comparisons of multiple tests designed to utilise tumour biology to predict
patient residual risk. Rarely has there been the opportunity to compare results of multiple tests on a
patient-by-patient basis to explore differences in risk categorisation. However, it should be remembered in
the interpretation of these data that this study was designed with limited and focused goals. We are
aware of the intense interest around this study and wish to ensure that results are interpreted in the
appropriate context.
The second objective of this study, after demonstrating feasibility, was to aid the selection of candidate
biological risk stratification tools for inclusion in the main OPTIMA trial. The OPTIMA trial aims to test
whether or not, for ER-positive HER2-negative patients deemed to be clinically high risk, an additional
biological predictor of risk can inform treatment. Specifically, for the clinically high-risk population is it
appropriate to assign biologically low-risk patients to endocrine therapy without chemotherapy while
retaining chemotherapy for clinically and biologically high-risk patients?
A key challenge for the OPTIMA triallists remains: which of the several validated diagnostic assays that
assess biological risk should be used to address the trial question?
In addressing this second goal, we recognise a number of important factors, which both inform and limit
the interpretation of results from the OPTIMA prelim pathology analysis.
(a) OPTIMA prelim was neither designed nor powered to evaluate or compare the prognostic value of the
tests included in the study. The tests that have been evaluated in the study have been extensively
validated prior to inclusion in this study for their ability to inform risk, mostly following endocrine
treatment. In addition, a number of elegant studies from the transATAC study group have shown that
each test provides broadly similar risk discrimination in luminal breast cancers.43,55,56 However, all tests,
while of significant value in informing patient choice, are only modestly predictive of the risk of
relapse at the individual patient level. Within the validation studies for each test there are patients
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assigned to ‘low-risk’ groups who relapse and die of their disease, and in all cases the majority of
patients who are ‘high-risk’ do not in fact relapse and die from their disease. These tests therefore
represent a significant step towards personalised medicine but are not yet perfect. This is important
since it implies that discordance in risk estimates between tests that measure risk in different ways
may not be unexpected.
(b) The OPTIMA prelim study sought to evaluate diagnostic tests in a high-risk patient group as defined
by tumour stage; for some tests this means that results from the OPTIMA prelim are using risk scores
designed for node-negative disease in a predominantly node-positive population. This is in line with
current thinking that ‘biological’ risk measures are informative across, and to a degree independent
of, stage of disease. This thinking is supported by the fact that only grade, in the current study, is
significantly associated with biological risk defined by multiparameter assay. This association may be
explained by the fact that both grade and most biological risk tools assess tumour proliferation.
The key end point required for an appropriate choice between tests for the OPTIMA trial, which was also a
key objective of the current OPTIMA prelim analysis, was to identify the proportion of cases assigned as
high risk (or low risk) by each test, accepting that for each test this was a ‘true result’. As regards
biological risk, since we cannot assess outcome, each test must function as its own gold standard.
Each test for which data are available provides an individual patient risk assessment. If all, or indeed any,
of the candidate tests were 100% accurate in predicting risk (recurrence) it would be appropriate to use
concordance estimates or kappa statistics to compare tests. However, in the absence of such a ‘gold
standard’, kappa comparisons between tests simply reflect agreement between multiple modestly accurate
tests. The low concordance between tests reflect the fact that the tests are measuring different genes,
using different technology and highlight the problems of predicting recurrence risk based on the biology
and management of the tumour.
We have presented comparisons between two different types of test results: (1) molecular subtype
comparisons that group tests into luminal A, luminal B, etc. and (2) risk assessments where tests have
included a risk prediction (either categorical or continuous). For tests generating continuous risk scores we
have grouped patients into ‘low risk’ (patients who might safely avoid chemotherapy in the OPTIMA study)
or ‘high risk’ (patients for whom their biological risk would suggest that chemotherapy should be given).
For example, Oncotype DX provides both a continuous risk score and assigns patients to ‘low’, ‘intermediate’
or ‘high’ relapse risk. For the purposes of the OPTIMA trial we have combined the OPTIMA prelim cases
classified by Oncotype DX as ‘low‘ (54% of cases) and ‘intermediate’ risk (28% of cases) into a single
category of ‘low’ risk of relapse/low probability of chemotherapy benefit (called low score for convenience).
For other tests, patients were categorised on the basis of pre-established cut-off points or, in the cases of
tests providing subtype information (e.g. BluePrint), on the basis of subtype (luminal A vs. all others).
Comparison of risk categorisation and subtype prediction between tests
Of the five tests that categorise risk, Oncotype DX, Prosigna and IHC4 predicted similar rates of ‘low-risk’
cases, while MammaPrint identified fewer biologically low-risk cases in the OPTIMA prelim population (see
Table 26). It should, however, be recognised that with the small sample size available (302 patients) we are
not able to state clearly that, for example, Oncotype DX identifies more ‘low-risk’ patients than ‘Prosigna’,
or vice versa. However, at a simple level the proportion of patients who, on the basis of these five tests,
might safely avoid chemotherapy, is comparable and can be used to inform cost-effectiveness analyses
(see Discussion of the health economic methodology and results). Differences in proportions of cases
identified between tests will impact on the cost-effectiveness of different tests in the context of the main
OPTIMA trial.
Three tests (BluePrint, Prosigna and MammaTyper) provide information on molecularly defined intrinsic
subtypes. BluePrint and Prosigna provide this information alongside molecular profiling for residual risk,
while MammaTyper is specifically focused on providing subtype information including a stratification
of ‘luminal B’ cases into low and high risk.
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As with risk scores, we show a broad similarity in the proportion of OPTIMA prelim cases, all of which are
centrally confirmed as ER-positive and HER-negative, assigned by each test to luminal A or to luminal B/
HER2 enriched/basal-like. BluePrint assigned 61%, MammaTyper assigned 62% and Prosigna assigned
60% of cases to the luminal A category and 39%, 38% and 40%, respectively, to non-luminal A subtypes.
Although interesting, given that the study was recruiting only patients with luminal breast cancer, the
identification of small numbers of ‘HER2-enriched’ or ‘basal-like’ ER-positive/HER2-negative cancers,
particularly with complex multiparameter tests like Prosigna, is unsurprising and has been frequently
reported in other studies (e.g. Parker et al.28).
What is also clear from these data is that different tests commonly disagree about individual tumours. Only
93 (31%) of patients were classified as low/intermediate risk by all five tests (IHC4, IHC4 AQUA, Oncotype
DX, MammaPrint and Prosigna) and only 26 (8%) patients were classified as high risk by all five tests. Over
60% of patients were classified as high risk by at least one test and low risk by at least one test. A similar
finding has been reported in a comparison between PAM50 and Oncotype DX.55 Similar, but perhaps more
surprising, disagreement between the three tests that predict subtype was observed; only 59% of cases
were consistently classed as either luminal A or ‘non-luminal A’ by all three subtyping tests. Kappa values
give a measure of this disagreement where test thresholds are similar; for example, in the comparisons
between Oncotype DX and IHC4 risk categorisation, and in the subtype predictions made by BluePrint and
Prosigna, the kappa values were 0.53 and 0.55, respectively, indicating modest agreement.
The discrepancies between the tests are likely to reflect the differences in both the specific genes and the
number of genes assessed by the individual tests. Test training may also contribute to discrepancies,
although most of the tests were developed in ER-positive patient populations treated with endocrine
therapy but not chemotherapy. This aspect of the OPTIMA prelim study will be of interest as we seek to
understand the factors that underlie the different risk and subtype classifications.
It is not possible for us to draw any conclusions about the relative clinical performance of the tests in the
absence of outcome data, and, in any case, the sample size is too small to allow an adequately powered
comparison to be made. Our conclusion from this analysis is that these tests, each of which is
independently validated as a tool to assess residual risk of relapse (although as yet there is no formal
publication of validation studies for IHC4 AQUA and MammaTyper), are all modestly accurate meaning
that differences between risk categorisation highlight the potential for improvements in assessment of
residual risk without, at this stage, providing a means of discriminating between tests currently available.
Summary
In one of the few detailed comparisons of risk signatures at a patient level we have demonstrated that
marked differences between diagnostic tests exist at an individual patient level. This is as predicted from
the relatively modest performance of all current residual risk tests. Other studies performed in the field,
although with fewer comparisons, suggest that all existing tests are broadly similar in the overall ‘quantity’
of risk information they provide to patients.43,55,56 The analysis from the OPTIMA prelim study, although we
lack clinical outcome, is consistent with this conclusion. Therefore, although interesting and informative,
this test-to-test comparison is unable to direct choice of tests for the OPTIMA main trial beyond triaging
towards those tests most likely to be cost-effective in the economic analyses described in Discussion of the
health economic methodology and results. Some tests, clearly, may be less ideal as candidates for the main
OPTIMA trial for technical reasons, but others cannot be easily discarded at this stage, and indeed may
be selected solely on the basis of potential cost-effectiveness between these biologically similar
test approaches.
What this test-to-test comparison does reveal, illustrated by those cases where discrepancies between tests
exist, is that collectively there is significant room for improvement of the predictive impact of tests of
residual risks, which at present remains unrealised.
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Discussion of the health economic methodology and results
The economic analysis excluded IHC4 because of lack of cost information and because of concern about
its analytical validity. Although MammaTyper has demonstrated analytical validity, there are no published
clinical validation data and no cost information available. There are no published data on either the
analytical or the clinical validity of IHC4 AQUA.
The results of the economic analysis require careful interpretation. The differences in the expected value
between the alternative tests are relatively small, and the uncertainty in the evidence for all tests is
substantial. Even the test with the best current clinical evidence base, Oncotype DX, is less (rather than
more) likely to be a good use of limited NHS resources when considered in comparison with alternative
tests, according to NICE’s standard value criteria.148,196
MammaPrint is expected to be dominated by, that is produce fewer health benefits and cost more than, other
options in all of the scenarios, and the probability of MammaPrint being cost-effective never exceeds single
figures. On this basis, it seems reasonable to exclude MammaPrint from consideration for current adoption, as
such a low proportion of simulations indicate that choosing MammaPrint would be a suboptional decision.
One can speculate why this is the case, but it may be that because this is a dichotomous test, developed
across the whole spectrum of breast cancer subtypes, it may not have been optimised for the patient cohort of
those with a luminal breast cancer, which is the target population for the OPTIMA study. Despite its apparent
low expected cost-effectiveness, MammaPrint is associated with considerable uncertainty and this manifests as
research value in the value-of-information analysis.
The other strong conclusion is that test-directed chemotherapy appears to be cost-effective, regardless of
the choice of tests. This supports the further development of an evidence base sufficient for robust
adoptions decision-making.
An additional question is whether or not there is value in further research on some of these tests.
The estimates of the value of further research for Oncotype, MammaPrint and Prosigna tests are sufficient
to justify UK NHS investment in studies capable of reducing the test-specific uncertainty. The range of
analyses presented here show that there is substantial uncertainty about the performance of each of the
tests and there is also substantial uncertainty about the appropriate characterisation of the long-term
outcome, as demonstrated by the variation in the results of the analyses across the different scenarios.
Addressing the latter source of uncertainty within the trial may require a trial design with long-term
detailed follow-up. It may be efficient to reduce the uncertainty on these factors through analysis of
existing cancer registry data, in addition to within a clinical trial, as information on cancer recurrence and
post-recurrence treatments starts to be captured in national data sets.
It is important to note that differing conclusions are drawn regarding the optimal use of Prosigna (ROR_PT
or Subtype) depending on which sensitivity analysis is correct. This kind of model-dependent structural
uncertainty is difficult to characterise in the value-of-information analysis. Given the lack of consensus
between models it is difficult to recommend an optimal use of Prosigna based on purely economic
grounds. Ideally, different ROR_PT cut-off points should be explored in further prospective research. If a
single cut-off point needs to be chosen, as appears to be the case in light of the manufacturer’s marketing
strategy, then it may be reasonable to base its choice using clinical or mechanistic justification.
The final notable observation from these results is that the value of undertaking further research around
Oncotype DX, when the comparator is ‘chemotherapy for all’, is considerably lower than for the
comparator technologies in all scenarios. This difference is likely to be driven by the higher uncertainties
around the longer-term clinical outcomes, which is amplified in the model by discordance with Oncotype
DX. The price differential will also be contributing, with Oncotype DX being more expensive per test than
Prosigna. Again, further sensitivity analysis is required to fully understand what is driving the value of
information and a more granular EVPPI analysis will enhance understanding.
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The economic analysis conducted at the end of the OPTIMA prelim has presented a number of challenges.
The use of value-of-information analysis to inform a design decision between a feasibility study and a fully
powered RCT is a new application for this method, much advocated by methodologists in the UK and
worldwide.146 The need for influential assumptions within the model prior to the availability of evidence
from a definitive trial necessitates extensive scenario analysis to test these assumptions. This has resulted in
the need for three different model specifications and multiple scenarios, making the results complex to
understand. The recommendation of Prosigna as most valuable for further research has withstood testing
of the main assumptions, suggesting that it is a robust recommendation.
A particular additional challenge in the use of value-of-information analysis within a short analysis period is
the computational expense. Each EVPPI calculation in this analysis, which uses 5000 Monte Carlo
simulations in both the inner and outer loops, required in excess of 7 months of processing time using a fast
processor. The OPTIMA prelim analysis was therefore only possible using a high-performance computing
facility (White Rose Grid: www.whiterose.ac.uk/projectswhite-rose-grid/) to implement analyses in parallel.
A desirable further sensitivity analysis is exploration of the influence of Adjuvant! Online as a forecasting
tool in the main economic analysis. It is possible that the reliance on this tool has biased the results in favour
of tests for which the risk score correlates most highly with it. This is exemplified in Figures 18 and 19,
which show that Prosigna ROR_PT is more highly correlated with Adjuvant! Online predictions than is
Oncotype DX. The lack of CIs around Adjuvant! Online estimates also means that uncertainty will be
underestimated in the model. The validation model is protected from this bias and further work exploring
alternative tests using this model would be warranted. It is disappointing that validated alternatives to
Adjuvant! Online reporting RFS are not available.
Overall conclusions
OPTIMA prelim has succeeded in all of its aims. The study was designed to establish whether or not a
large-scale RCT of test-directed chemotherapy in patients with early breast cancer who are at significant
future recurrence risk by virtue of axillary lymph-node involvement is feasible in the UK. The underlying
hypothesis is that multiparameter assays are predictive of chemotherapy efficacy, which is a recommendation
for future research in the NICE DG10 guidelines.117
Prespecified targets were built into the protocol and the study was opened in a broadly representative set
of UK centres. All targets were met, indicating feasibility of a study designed to demonstrate non-inferiority
of chemotherapy allocation based on the outcome of a multiparameter assay performed on individual
patients’ tumour samples.
Recruitment posed significant challenges. PPI in the study design and in the early phases of recruitment,
and an integrated QRS provided valuable insights into barriers to recruitment, and resulted in changes to
the PIS and to advice given to participating centres. These insights will be important for the main study.
Oncotype DX was used as the primary discriminator for chemotherapy decisions in the OPTIMA prelim.
Additional multiparameter assays were performed on participant tumour samples and health-economic
modelling was performed using the data. A substantial degree of discordance was demonstrated in the
risk assignments/biological subtype of individual tumours although the overall amount of information
provided by each assay in the overall population appears to be similar. Effectiveness studies are required to
demonstrate whether or not the differences between assays are clinically significant. The health economics
analysis suggests that, of the assays that were evaluated, there is substantial value in further research
involving all tests, although Prosigna can currently be considered the highest priority from the perspective
of the UK NHS. The level of uncertainty in health economics analyses undertaken, however, is substantial.
A prospective study is therefore required to validate both the clinical and economic hypotheses that
underlay the OPTIMA prelim.
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Recommendations for further research
OPTIMA prelim has succeeded in its aims of demonstrating the feasibility, within the UK, of a large-scale
clinical trial to establish a method of selecting patients with moderate- or high-risk hormone-sensitive
primary breast cancer who are likely to benefit or not benefit from post-operative chemotherapy and to
establish the cost-effectiveness of alternative test-guided treatment strategies. Existing data that support
the use of multiparameter assays as an aid to making chemotherapy decisions are based on retrospective
analysis of historical data. Very few data are available on the clinical validity of multiparameter assays
in patients with lymph node involvement, which is the population in whom the cost-effectiveness of
test-guided treatment decisions is likely to be greatest. The NICE DG10 guidance,117 which applies only to
women with lymph node-negative breast cancer, recommends that further research on the ability of
multiparameter assays to predict chemotherapy benefit be performed. A prospective clinical trial designed
to answer these questions would be of benefit to the NHS and should be undertaken. It should be noted
that, from the perspective of the NHS, the value of information for further research into Prosigna is
higher than for the other two assays that were evaluated in the base-case analysis. The discrepancies
demonstrated between the tests that were evaluated in this study at an individual patient/sample level
show that there is substantial scope for refinement of exiting multiparameter assays.
Implications for practice
OPTIMA prelim was not designed and is not expected to generate any information that will result in a
change in clinical practice. The finding of significant disagreement between multiparameter assays at an
individual patient level should give clinicians currently using these technologies in their clinical practice
pause for thought. As there is no established ‘best test’, not only are there limitations to the evidence base
supporting multiparameter assay use but there are also limitations to the technology that is currently
available. Nevertheless, the data generated by this study do not in any way undermine existing data
supporting multiparameter assays use to guide chemotherapy decisions.
DISCUSSION
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Appendix 1 Methods used for multiparameter
assay cost-effectiveness literature review
A literature review was conducted to identify economic evaluations of multiparameter genomic testswithin the relevant population. The search was conducted in Ovid MEDLINE(R) In-Process and Other
Non-Indexed Citations and Ovid MEDLINE(R), from 1946 to April 2014, using a predefined search filter
together with relevant key words related to breast cancer and the different tests [Intercollegiate, S.G.N.,
2012197 (InterTASC Information Specialists’ Sub-Group search filters resource – economic evaluations)].
References of identified studies were searched for additional relevant literature. A total of 33 potentially
relevant studies were identified in Ovid, of which 29 were discarded for not being full economic
evaluations owning to use of an inappropriate population. Full economic evaluations are studies in which
a comparison of two or more treatments or care alternatives is undertaken in which both costs and
outcomes of the alternatives are examined. This includes cost–benefit analyses, cost–utility analysis and
cost-effectiveness analyses. A total of seven studies,74,111–116 published between 2005 and 2013, were
identified in the review: four directly from Ovid, and three via additional hand-searching. No head-to-head
comparisons of the alternative genomic tests were identified.
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Appendix 2 Patient information sheet and
consent form
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Appendix 3 Consolidated criteria for reporting
qualitative research guidelines
The reporting of the qualitative methods was checked against the COREQ (a 32-item checklist forinterviews and focus groups). The checklist is shown below; the final column details where evidence
can be found that the relevant criterion is satisfied (or information provided justify why the criterion is not
satisfied). (Table source: http://intqhc.oxfordjournals.org/content/19/6/349.long141)
Number Item Guide questions/description
Cross-reference where included in
report/reason for non-inclusion
Domain 1: research team and reflexivity
Personal characteristics
1. Interviewer/
facilitator
Which author/s conducted the interview
or focus group?
Included in Chapter 2, Qualitative recruitment
study methods
2. Credentials What were the researcher’s credentials?
e.g. PhD, MD
Included in QRS researcher biographies
(see Appendix 11)
3. Occupation What was their occupation at the time
of the study?
Included in QRS researcher biographies
(see Appendix 11)
4. Gender Was the researcher male or female? Included in QRS researcher biographies
(see Appendix 11)
5. Experience
and training
What experience or training did the
researcher have?
Included in QRS researcher biographies
(see Appendix 11)
Relationship with participants
6. Relationship
established
Was a relationship established prior to
study commencement?
Included in Appendix 12
7. Participant
knowledge of
the interviewer
What did the participants know about
the researcher? e.g. personal goals,
reasons for doing the research
Included in Appendix 12
8. Interviewer
characteristics
What characteristics were reported about
the interviewer/facilitator? e.g. bias,
assumptions, reasons and interests in the
research topic
Included in Appendix 12
Domain 2: study design
Theoretical framework
9. Methodological
orientation
and theory
What methodological orientation was
stated to underpin the study?
e.g. grounded theory, discourse analysis,
ethnography, phenomenology,
content analysis
Included in Chapter 2, Qualitative recruitment
study methods
Participant selection
10. Sampling How were participants selected?
e.g. purposive, convenience,
consecutive, snowball
Included in Chapter 2, Qualitative recruitment
study methods
11. Method
of approach
How were participants approached?
e.g. face to face, telephone, mail, e-mail
Included in Chapter 2, Qualitative research
guidelines methods
12. Sample size How many participants were in
the study?
Included in Chapter 2, Qualitative recruitment
study methods and Chapter 4, qualitative
recruitment study results
13. Non-participation How many people refused to participate
or dropped out? Reasons?
Included in Chapter 2, Qualitative recruitment
study methods
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Number Item Guide questions/description
Cross-reference where included in
report/reason for non-inclusion
Setting
14. Setting of data
collection
Where was the data collected?
e.g. home, clinic, workplace
Included in Chapter 2, Qualitative recruitment
study methods
15. Presence of
non-participants
Was anyone else present besides the
participants and researchers?
No other individuals were present in interviews
16. Description
of sample
What are the important characteristics of
the sample? e.g. demographic data, date
Included in Chapter 2, Qualitative recruitment
study methods
Data collection
17. Interview guide Were questions, prompts, guides
provided by the authors? Was it
pilot tested?
Included in QRS methods and the topic guide
included in Appendix 4
18. Repeat
interviews
Were repeat interviews carried out?
If yes, how many?
Repeat interviews were not carried out in this
study, and have therefore not been reported
19. Audio/
visual recording
Did the research use audio or visual
recording to collect the data?
Included in Chapter 2, Qualitative recruitment
study methods
20. Field notes Were field notes made during and/or
after the interview or focus group?
Included in Chapter 2, Qualitative recruitment
study methods
21. Duration What was the duration of the interviews
or focus group?
Included in Chapter 2, Qualitative recruitment
study methods
22. Data saturation Was data saturation discussed? Included in Chapter 2, Qualitative recruitment
study methods
23. Transcripts
returned
Were transcripts returned to participants
for comment and/or correction?
Transcripts were not returned to participants in
this study
Domain 3: analysis and findings
Data analysis
24. Number of
data coders
How many data coders coded the data? Included in Chapter 2, Qualitative recruitment
study methods
25. Description of
the coding tree
Did authors provide a description of the
coding tree?
Included in Chapter 2, Qualitative recruitment
study methods (analysis)
26. Derivation
of themes
Were themes identified in advance or
derived from the data?
Included in Chapter 2, Qualitative recruitment
study methods (analysis)
27. Software What software, if applicable, was used to
manage the data?
Included in Chapter 2, Qualitative recruitment
study methods (analysis)
28. Participant
checking
Did participants provide feedback on
the findings?
Included in QRS findings (i.e. description of
feedback meetings with research participants)
Reporting
29. Quotations
presented
Were participant quotations presented to
illustrate the themes/findings? Was each
quotation identified? e.g. participant
number
Yes – demonstrated throughout QRS findings
30. Data and
findings
consistent
Was there consistency between the data
presented and the findings?
Yes – demonstrated throughout QRS Findings
31. Clarity of
major themes
Were major themes clearly presented in
the findings?
Yes – demonstrated throughout QRS findings.
Themes rather than descriptive detail have
been included, with some explanation of
‘one-off’ cases where relevant
32. Clarity of
minor themes
Is there a description of diverse cases or
discussion of minor themes?
Yes – demonstrated throughout QRS findings.
Themes rather than descriptive detail have
been included, with some explanation of
‘one-off’ cases where relevant
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Appendix 4 Qualitative research study interview
schedule (final version used)
Version 2.0, 1 June 2013
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Appendix 5 Qualitative research study interview
schedules (original version)
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Appendix 6 Additional details of the
multiparameter tests
Oncotype DX
Provides risk classification based on risk of distant recurrence at 10 years:
l < 10% risk – low, RS < 18
l 10–20% risk – intermediate, RS 18–31
l > 20% risk – high, RS > 31.
The test was developed in a node-negative population of both pre- and post-menopausal women treated
with tamoxifen for 5 years.
IHC4 conventional staining
Provides risk classification based on risk of distant recurrence at 10 years. The risk groups were chosen for
consistency with other tests. The IHC4 values that define the cut-off points were derived from an
unpublished analysis of the data presented in Cuzick et al.56 (I Sestak, J Cuzick, Queen Mary University of
London, 12 May 2014, personal communication).
l < 10% risk – low
l 10–20% risk – low/intermediate
l > 20% risk – high.
The test was developed in a population of post-menopausal women treated with tamoxifen or AI for 5 years.
MammaPrint
Provides a high- or low-risk classification based on risk of distant recurrence at 5 years.
The test was developed in a population of both pre- and post-menopausal women with either ER-positive
or ER-negative disease who did not receive any systemic adjuvant therapy.
BluePrint
Provides subtyping classification of either luminal, basal or HER2 type. Luminal tumours may be divided
into luminal A and luminal B according to MammaPrint risk classification (low vs. high).
Prosigna
The ROR_PT or Prosigna score is provided on a scale of 0 to 100, which is correlated with the probability
of distant recurrence at 10 years for post-menopausal women with hormone receptor-positive, early-stage
breast cancer. The score is calculated using coefficients from a Cox model that includes the Pearson
correlation to a 46-gene subset of the 50 genes used to calculate each intrinsic subtype, a proliferation
score and tumour size. Predefined risk categories based on cut-off points for ROR determined in a clinical
validation study are provided in Table 39. The test was developed in a population of post-menopausal
women treated with tamoxifen or AI for 5 years.
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NanoString provide the following information for each sample, where ROR is the risk of recurrence,
P indicates proliferation weighting, T incorporates tumour size and N represents the nodal status:
l ROR_PT: cleared algorithmic result of Prosigna available through appropriate use of tumour size
l ROR_P: approximated by setting tumour size to ≤ 2 cm for all samples
l ROR_PTN: defined risk categories using nodal status information to define cut-off points – cleared
result of Prosigna available through appropriate use of tumour size and nodal status (low,
intermediate, high)
l ROR_PN: defined risk categories using nodal status information to define cut-off points
l ROR_P: defined risk categories using node-negative cut-off points
l ROR_PT: defined risk categories using node-negative cut-off points
l intrinsic subtypes: luminal A, luminal B, HER2 enriched, basal-like.
MammaTyper
Provides subtyping classification (luminal A, luminal B, HER2-positive, triple-negative breast cancer).
In addition, luminal B tumours are further classified into:
l low-risk luminal B tumours if Ki67 < 36
l high-risk luminal B tumours if Ki67 ≥ 36.
References
Cuzick J, Dowsett M, Pineda S, Wale C, Salter J, Quinn E, et al. Prognostic value of a combined
estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2
immunohistochemical score and comparison with the Genomic Health recurrence score in early breast
cancer. J Clin Oncol 2011;29:4273–8.56
TABLE 39 Prosigna ROR score cut-off points
Risk category Criteria Node negative
One positive
node
Two positive
nodes
Three positive
nodes
Four or more
positive nodes
Low < 10% risk
of DR
0–40 0–35 0–25 NA NA
Intermediate 10–20% risk
of DR
41– 60 36–55 26–45 0–25 NA
High > 20% risk
of DR
61–100 56–100 46–100 26–100 0–100
DR, distant recurrence; NA, not applicable.
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Appendix 7 Health utility literature review
Aim
An extensive literature review was carried out to identify the relevant health-utility values for the OPTIMA
study. This search was aimed to update the search performed for Health-state utility values in breast
cancer by Peasgood et al. in 2010172 as the information provided in this paper was used primarily as a
source of information for health states. The main focus was to update health utility information for breast
cancer patients in the following stages:
l disease free (no chemotherapy) (DFnC)
l disease free (after chemotherapy) (DFC)
l local recurrence (LR)
l distant recurrence (DR).
Methodology
To achieve the aim, the following sources were used.
The Cochrane Library databases (Wiley)
Date range searched: 1992 to July 2013.
Date of search: July 2013.
EconLit (EBSCOhost)
Date range searched: 1886 to July 2013.
Date of search: July 2013.
Cost-Effectiveness Analysis Registry (Tufts)
Date range searched: 2009 to present.
Date of search: July 2013.
EMBASE (Ovid)
Date range searched: 1947 to 10 July 2013.
Date of search: July 2013.
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Google Scholar
Date range searched: 2009 to present (July 2013).
Date of search: July 2013.
MEDLINE (Ovid)
Date range searched: 1946 to July 2013.
Date of search: July 2013.
MEDLINE In Process & Other Non-Indexed Citations (Ovid)
Date range searched: inception to 19 July 2013.
Date of search: July 2013.
Web of Science (Science Citation Index Expanded, Conference
Proceedings Citation Index)
Date range searched: inception to July 2013.
Date of search: July 2013.
The search strategy main concepts were breast cancer and health utilities. A series of search filters were
constructed for each of the electronic databases used in the search. (Full details on this search can be
found in Search strategy.) An initial search was run in December 2012, and later updated in July 2013.
After removing the duplicates, a first selection was made based on published title. Articles not making any
reference to health utility and breast cancer were eliminated. A second sift based on the published abstract
and a set of predefined of inclusion and exclusion criteria was performed. Table 40 shows the inclusion
and exclusion criteria followed.
TABLE 40 Inclusion and exclusion criteria for health utility literature review
Inclusion criteria Exclusion criteria
Studies whose main objective was to estimate the quality of
life of breast cancer patients either by direct estimation or via
a systematic review of the literature
Studies where estimating the quality of life of breast
cancer patients was not their primary objective
Studies focused on stages not related to those of interest:
DFnC, DFC, LR, DR
Studies referring to concomitant conditions or treatments
(except chemotherapy) that might affect the estimation of
the quality of life of the studied population
DFC, disease free (after chemotherapy); DFnC, disease free (no chemotherapy); DR distant recurrence; LR, local recurrence.
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After the second sift, a more detailed third selection was made by reviewing both the published abstract
and the full text. Only those articles following both the inclusion and the exclusion criteria were selected.
Articles in which the estimation of the quality of life was based on clinical trials, systematic reviews or via
recollection of patient information through questioners were considered. These were subject to a more
thorough review. Only those articles with information that most closely resembled the disease stages of
interest were selected and the parameters retrieved.
Results
Figure 20 shows the flow diagram of the article retrieval and selection process. The full search results can
be found in Results tables.
The search and selection process identified 10 relevant articles.172,174,198–205 Table 41 shows the author, year,
title, country, quality of life or QALY estimation method and published journal. Relevant data were
extracted from each of the relevant articles. Based on the information retrieved, two articles were selected
as a potential source of health utility data.172,174 Table 42 describes the outcome and the reasons for the
selection status.
The two selected articles were chosen because of the type of information provided.172,174 Campbell et al.174
was selected as the primary source of information as its data came from clinical trials performed in the UK
and it was published more recently than Peasgood et al.172 The values reported are shown as decrements
of a baseline HRQoL quality of life based estimates on the EQ-5D outcome measure (Table 43). A detailed
description of each of the 10 selected articles can be found in Tables 47–55.
Identified through the databases used
(n = 1751)
Duplicates removed
(n = 681)
Removed based on published title
(n = 1020)
Removed based on exclusion criteria
(n = 27)
Removed based on inclusion criteria
(n = 13)
After removing duplicates
(n = 1070)
After first screening based on 
published title
(n = 50)
After second selection
(n = 23)
After third selection
(n = 10)
FIGURE 20 Flow diagram of the search and selection process.
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TABLE 42 Data extraction, selected and not selected articles
Author Status Comment
Peasgood
et al., 2010172
Selected Contains information related to the disease free, local recurrence and distant
recurrence event
Campbell
et al., 2011174
Selected Contains information related to the disease free, local recurrence and distant
recurrence event
Shabaruddin
et al., 2013198
Not selected Utility estimates mostly based on adverse events or concomitant events related
to breast cancer
Moro-Valdezate
et al., 2013199
Not selected Utility estimates based on different aspects of live after breast cancer
Shih et al.,
2012200
Not selected Contains information about local recurrence, distant recurrence. However, it is
based on an Asian population. Some parameters might be of use if other
sources of information are not available
Matalqah et al.,
2011201
Not selected Information not detailed in terms of disease free, local recurrence or distant
recurrence
Farkkila et al.,
2011202
Not selected Some of the descried health states might be useful if no other sources of
information are available such as after remission, metastatic disease and
terminal care
Delgado-Sanz
et al., 2011203
Not selected Not enough information to populate the intended health states
Anhoury et al.,
2011204
Not selected Only one utility parameter was reported: disease-free patients
Prescott et al.,
2007205
Not selected Only radiotherapy vs. no radiotherapy QALY parameters were estimated
TABLE 43 Health utility parameters extracted from Campbell et al.,174 2011
Parameters HRQoL decrement (SE)a
Disease free (no chemotherapy) –0.003 (0.03)
Disease free (on chemotherapy) –0.099 (0.033)
Local recurrence –0.108 (0.04)
Distant recurrence –0.303 (0.16)
a Decrements from age- and sex-matched controls (Kind et al.206)
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Search strategy
Health state utilities for breast cancer: update on previous search done at
the School of Health and Related Research in 2009
The Cochrane Library: Cochrane Central Register of Controlled Trials,
Database of Abstracts of Reviews of Effects and NHS Economic
Evaluation Database
Search strategy
#1 MeSH descriptor: [Breast Neoplasms] explode all trees
#2 MeSH descriptor: [Neoplasms] explode all trees
#3 MeSH descriptor: [Carcinoma] explode all trees
#4 MeSH descriptor: [Adenocarcinoma] explode all trees
#5 MeSH descriptor: [Breast] explode all trees
#6 #2 or #3 or #4
#7 #5 and #6
#8 (carcinoma near/3 breast*):ti,ab,kw
#9 (neoplas* near/3 breast*):ti,ab,kw
#10 (adenocarcinoma near/3 breast*):ti,ab,kw
#11 (cancer* near/3 breast*):ti,ab,kw
#12 (tumour* near/3 breast*):ti,ab,kw
#13 (tumor* near/3 breast*):ti,ab,kw
#14 (malignan* near/3 breast*):ti,ab,kw
#15 #8 or #9 or #10 or #11 or #12 or #13 or #14
#16 #1 or #7 or #15
#17 (HALex):ti,ab,kw
#18 (euroqol or “euro qol*” or eq5d or “eq 5d*”):ti,ab,kw
#19 qaly*:ti,ab,kw
#20 “quality adjusted life year*”:ti,ab,kw
#21 hye*:ti,ab,kw
#22 “health* year* equivalent*”:ti,ab,kw
#23 “health utilit*”:ti,ab,kw
#24 “hui”:ti,ab,kw
#25 “quality of well being”:ti,ab,kw
#26 “quality of wellbeing”:ti,ab,kw
#27 “qwb”:ti,ab,kw
#28 (qald* or qale* or qtimes*):ti,ab,kw
#29 (“quality adjusted life day*” or “quality adjusted life expectanc*” or “quality adjusted survival*”):ti,
ab,kw
#30 MeSH descriptor: [Quality-Adjusted Life Years] explode all trees
#31 “standard gamble*”:ti,ab,kw
#32 “time trade off”:ti,ab,kw
#33 “time tradeoff”:ti,ab,kw
#34 “tto”:ti,ab,kw
#35 “visual analog* scale*”:ti,ab,kw
#36 “discrete choice experiment*”:ti,ab,kw
#37 (sf6 or “sf 6” or “short form 6” or “shortform 6” or “sf six” or “sfsix” or “short form six”):ti,ab,kw
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#38 (sf12 or “sf 12” or “short form 12” or “shortform 12” or “sf twelve” or sftwelve or “short form
twelve”):ti,ab,kw
#39 (sf6d or “sf 6d” or “short form 6d” or “shortform 6d” or “sf 6 d”):ti,ab,kw
#40 “health state* utilit*”:ti,ab,kw
#41 “health state* value*”:ti,ab,kw
#42 “health state* preference*”:ti,ab,kw
#43 #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29 or #30
or #31 or #32 or #33 or #34 or #35 or #36 or #37 or #38 or #39 or #40 or #41 or #42
#44 #16 and #43 from 2009 to 2012 (Word variations have been searched)
Cost-Effectiveness Analysis Registry
Only simple search allowed: used Breast Cancer – c. 50 hits since 2009, test showed hits already found via
other searches.
EconLit: via EBSCOhost
Search strategy
S1 AB ( cancer* or neoplasm* or carcinoma* or adenocarcinoma* or malignan* or tumour* or tumor*) OR TI
( cancer* or neoplasm* or carcinoma* or adenocarcinoma* or malignan* or tumour* or tumor* )
S2 AB ( breast or breasts ) OR TI ( breast or breasts )
S3 TI (HALex or euroqol or “euro qol” or eq5d or “eq 5d”) OR AB ( HALex or euroqol or “euro qol” or eq5d or
“eq 5d”)
S4 TI (qaly* or “quality adjusted life year*”) OR AB ( qaly* or “quality adjusted life year*”)
S5 TI ( hye* or “health* year* equivalent*”) OR AB ( hye* or “health* year* equivalent*”)
S6 TI (health utilit* or hui) OR AB (health utilit* or hui)
S7 TI ( “quality of well being” or “quality of wellbeing” or qwb ) OR AB ( “quality of well being” or “quality
of wellbeing” or qwb )
S8 AB ( “Standard gamble*” or “time trade off” or “time tradeoff” or tto or “visual analog* scale*” or
“discrete choice experiment*”) OR TI ( “Standard gamble*” or “time trade off” or “time tradeoff” or tto or
“visual analog* scale*” or “discrete choice experiment*”)
S9 AB ( sf6 or “sf 6” or “short form 6” or “shortform 6” or “sf six” or sfsix or “short form six” or “shortform
six”) OR TI ( sf6 or “sf 6” or “short form 6” or “shortform 6” or “sf six” or sfsix or “short form six” or
“shortform six”)
S10 AB ( sf12 or “sf 12” or “short form 12” or “shortform 12” or “sf twelve” or sftwelve or “short form
twelve” or “shortform twelve”) OR TI ( sf12 or “sf 12” or “short form 12” or “shortform 12” or “sf twelve” or
sftwelve or “short form twelve” or “shortform twelve”)
S11 AB ( sf6d or “sf 6d” or “short form 6d” or “shortform 6d” or “sf 6 d”) OR TI ( sf6d or “sf 6d” or “short
form 6d” or “shortform 6d” or “sf 6 d”)
S12 AB “health state*” OR TI “health state*"
S13 AB ( “health state* utilit*” or “health state* value*” or “health state* preference*”) OR TI ( “health
state* utilit*” or “health state* value*” or “health state* preference*”)
S14 S8 OR S9 OR S10 OR S11 OR S12 OR S13
S15 S3 OR S4 OR S5
S16 S6 OR S7
S17 S14 OR S15 OR S16
S18 S1 AND S2 AND S17
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EMBASE Classic and EMBASE
Date range searched: 1947 to 10 December 2012.
Search strategy
1. exp breast tumor/ (332,292)
2. exp neoplasm/ (3,374,500)
3. exp breast/ (92,709)
4. 2 and 3 (57,167)
5. 1 or 4 (344,576)
6. (carcinoma adj3 breast$).tw. (34,630)
7. (neoplas$ adj3 breast$).tw. (2667)
8. (adenocarcinoma adj3 breast$).tw. (2312)
9. (cancer$ adj3 breast$).tw. (220,550)
10. (tumour$ adj3 breast$).tw. (5856)
11. (tumor$ adj3 breast$).tw. (23,736)
12. (malignan$ adj3 breast$).tw. (7722)
13. or/5-12 (372,624)
14. HALex.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device
manufacturer, drug manufacturer, device trade name, word] (27)
15. (euroqol or euro qol or eq5d or eq 5d).tw. (5077)
16. qaly$.tw. (6910)
17. quality adjusted life year$.tw. (6789)
18. hye$.tw. (1031)
19. health$ year$ equivalent$.tw. (41)
20. health utilit$.tw. (1315)
21. hui.tw. (799)
22. quality of well being.tw. (344)
23. quality of wellbeing.tw. (18)
24. qwb.tw. (174)
25. (qald$ or qale$ or qtimes$).tw. (140)
26. (quality adjusted life day$ or quality adjusted life expectanc$ or quality adjusted survival$).tw. (937)
27. exp quality adjusted life year/ or short form 12/ (10,976)
28. standard gamble$.tw. (726)
29. time trade off.tw. (863)
30. time tradeoff.tw. (213)
31. tto.tw. (765)
32. visual analog$ scale$.tw. (32,527)
33. discrete choice experiment$.tw. (443)
34. (sf6 or sf 6 or short form 6 or shortform 6 or sf six or sfsix or short form six).tw. (1457)
35. (sf12 or sf 12 or short form 12 or shortform 12 or sf twelve or sftwelve or short form twelve).mp.
[mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer,
drug manufacturer, device trade name, keyword] (3523)
36. (sf6d or sf 6d or short form 6d or shortform 6d or sf 6 d).tw. (528)
37. health state$ utilit$.tw. (391)
38. health state$ value$.tw. (144)
39. health state$ preference$.tw. (95)
40. or/14-39 (57,626)
41. letter*.pt,ti. (845,685)
42. editorial*.pt,ti. (445,924)
DOI: 10.3310/hta20100 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 10
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Stein et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
159
43. comment*.pt,ti. (92,999)
44. or/41-43 (1,358,961)
45. 40 and 13 (1249)
46. 45 not 44 (1213)
47. (2009* or 2010* or 2011* or 2012*).em. (4,696,303)
48. 46 and 47 (675)
Google Scholar (advanced screen)
At least one of the following: HUI OR TTO OR SG OR EQ-5D OR SF-6D OR SF-12 OR VAS OR QWB OR
HALex OR Euroqol
Exact phrases “breast cancer” AND “health state utilities”
Limits Material since 2009 and in subject areas: Medicine, Pharmacology, and Veterinary Science OR Social
Sciences, Arts, and Humanities
Note: special interface used: http://scholar.google.co.uk/advanced_scholar_search?hl=en&as_sdt=0,5
Ovid MEDLINE(R)
Date range searched: 1946 to week 3, November 2012.
Search strategy
1. exp breast neoplasms/ (202,474)
2. exp neoplasms/ (2,414,772)
3. exp carcinoma/ (457,980)
4. exp adenocarcinoma/ (265,518)
5. exp breast/ (30,049)
6. or/2-4 (2,414,772)
7. 5 and 6 (16472)
8. (carcinoma adj3 breast$).tw. (25,132)
9. (neoplas$ adj3 breast$).tw. (2066)
10. (adenocarcinoma adj3 breast$).tw. (1673)
11. (cancer$ adj3 breast$).tw. (158,629)
12. (tumour$ adj3 breast$).tw. (3909)
13. (tumor$ adj3 breast$).tw. (17,709)
14. (malignan$ adj3 breast$).tw. (5633)
15. or/8-14 (184,068)
16. 1 or 7 or 15 (238,389)
17. HALex.mp. [mp=title, abstract, original title, name of substance word, subject heading word, protocol
supplementary concept, rare disease supplementary concept, unique identifier] (14)
18. (euroqol or euro qol or eq5d or eq 5d).tw. (2952)
19. qaly$.tw. (4186)
20. quality adjusted life year$.tw. (4825)
21. hye$.tw. (587)
22. health$ year$ equivalent$.tw. (36)
23. health utilit$.tw. (873)
24. hui.tw. (556)
25. quality of well being.tw. (307)
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26. quality of wellbeing.tw. (5)
27. qwb.tw. (154)
28. (qald$ or qale$ or qtimes$).tw. (91)
29. (quality adjusted life day$ or quality adjusted life expectanc$ or quality adjusted survival$).tw. (707)
30. quality-adjusted life years/ (6160)
31. standard gamble$.tw. (595)
32. time trade off.tw. (640)
33. 34 tto.tw. (490)
34. visual analog$ scale$.tw. (22,860)
35. discrete choice experiment$.tw. (284)
36. (sf6 or sf 6 or short form 6 or shortform 6 or sf six or sfsix or short form six).tw. (924)
37. time tradeoff.tw. (192)
38. (sf12 or sf 12 or short form 12 or shortform 12 or sf twelve or sftwelve or short form twelve).mp.
[mp=title, abstract, original title, name of substance word, subject heading word, protocol supplementary
concept, rare disease supplementary concept, unique identifier] (2085)
39. (sf6d or sf 6d or short form 6d or shortform 6d or sf 6 d).tw. (318)
40. health state$ utilit$.tw. (215)
41. health state$ value$.tw. (105)
42. health state$ preference$.tw. (72)
43. or/17-42 (38,587)
44. letter.pt. (766,872)
45. editorial.pt. (310,993)
46. comment.pt. (493,546)
47. or/44-46 (1,166,749)
48. 43 not 47 (37,884)
49. 16 and 48 (660)
50. (200903* or 200904* or 200905* or 200906* or 200907*or 200908* or 200909* or 200910* or
200911* or 200912* or 2010* or 2011* or 2012*).ed. (2,851,442)
51. 49 and 50 (230)
Ovid MEDLINE(R) In-Process and Other Non-Indexed Citations
Date searched: 6 December 2012.
Same as OVID MEDLINE. Eleven results.
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Web of Science
Search strategy
# 1 1737 Topic=(HALex or euroqol or “euro qol” or eq5d or “eq 5d”) OR Title=(HALex or euroqol or “euro
qol” or eq5d or “eq 5d”)
Databases= SCI-EXPANDED, SSCI, CPCI-S Timespan= 1 January 2009 – 18 December 2012
Lemmatization=Off
# 2 2304 Topic=(qaly* or “quality adjusted life year*”) OR Title=(qaly* or “quality adjusted life year*”)
Databases= SCI-EXPANDED, SSCI, CPCI-S Timespan= 1 January 2009 – 18 December 2012
Lemmatization=Off
# 3 893 Topic=(hye* or “health* year* equivalent*”) OR Title=(hye* or “health* year* equivalent*”)
Databases= SCI-EXPANDED, SSCI, CPCI-S Timespan= 1 January 2009 – 18 December 2012
Lemmatization=Off
# 4 5853 Topic=(health utilit* or hui) OR Title=(health utilit* or hui)
Databases= SCI-EXPANDED, SSCI, CPCI-S Timespan= 1 January 2009 – 18 December 2012
Lemmatization=Off
# 5 57 Topic=(“quality of well being” or “quality of wellbeing” or qwb) OR Title=(“quality of well being”
or “quality of wellbeing” or qwb)
Databases= SCI-EXPANDED, SSCI, CPCI-S Timespan= 1 January 2009 – 18 December 2012
Lemmatization=Off
# 6 8435 Topic=(“Standard gamble*” or “time trade off” or “time tradeoff” or tto or “visual analog*
scale*” or “discrete choice experiment*”) OR Title=(“Standard gamble*” or “time trade off” or “time
tradeoff” or tto or “visual analog* scale*” or “discrete choice experiment*”)
Databases= SCI-EXPANDED, SSCI, CPCI-S Timespan= 1 January 2009 – 18 December 2012
Lemmatization=Off
# 7 1388 Topic=((sf6 or “sf 6” or “short form 6” or “shortform 6” or “sf six” or sfsix or “short form six” or
“shortform six”)) OR Title=((sf6 or “sf 6” or “short form 6” or “shortform 6” or “sf six” or sfsix or “short form
six” or “shortform six”))
Databases= SCI-EXPANDED, SSCI, CPCI-S Timespan= 1 January 2009 – 18 December 2012
Lemmatization=Off
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# 8 1009?Topic=((sf12 or “sf 12” or “short form 12” or “shortform 12” or “sf twelve” or sftwelve or “short
form twelve” or “shortform twelve”)) OR Title=((sf12 or “sf 12” or “short form 12” or “shortform 12” or “sf
twelve” or sftwelve or “short form twelve” or “shortform twelve”))
Databases= SCI-EXPANDED, SSCI, CPCI-S Timespan= 1 January 2009 – 18 December 2012
Lemmatization=Off
# 9 235 Topic=((sf6d or “sf 6d” or “short form 6d” or “shortform 6d” or “sf 6 d”)) OR Title=((sf6d or “sf
6d” or “short form 6d” or “shortform 6d” or “sf 6 d”))
Databases= SCI-EXPANDED, SSCI, CPCI-S Timespan= 1 January 2009 – 18 December 2012
Lemmatization=Off
# 10 1238 Topic=(“health state*”) OR Title=(“health state*”)
Databases= SCI-EXPANDED, SSCI, CPCI-S Timespan= 1 January 2009 – 18 December 2012
Lemmatization=Off
# 11 19,991 #10 OR #9 OR #8 OR #7 OR #6 OR #5 OR #4 OR #3 OR #2 OR #1
Databases= SCI-EXPANDED, SSCI, CPCI-S Timespan= 1 January 2009 – 18 December 2012
Lemmatization=Off
# 12 40,529 TI=((cancer* or neoplasm* or carcinoma* or adenocarcinoma* or malignan* or tumour* or
tumor* or oncol*) AND (breast or breasts or mammary))
Databases= SCI-EXPANDED, SSCI, CPCI-S Timespan= 1 January 2009 – 18 December 2012
Lemmatization=Off
# 13 206 #12 AND #11
Databases= SCI-EXPANDED, SSCI, CPCI-S Timespan= 1 January 2009 – 18 December 2012
Lemmatization=Off
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Results tables
TABLE 44 Results from first search (date: 19 December 2012)
Database and dates covered Date searched
Concept search
strategy Hits Notes
The Cochrane Library: CENTRAL (Wiley) 12 December 2012 Breast cancer+
health utilities
41 Three databases searched
at once on the same
interface (Wiley): but
results are exported from
each individual database
The Cochrane Library: DARE (Wiley) 12 December 2012 Breast cancer+
health utilities
1
The Cochrane Library: NHS Economic
Evaluations Database (Wiley)
12 December 2012 Breast cancer+
health utilities
59
Cost-Effectiveness Analysis Registry 19 December 2012 Breast cancer 0
EconLit (EBSCOhost) 18 December 2012 13
EMBASE Classic+ EMBASE: searched
from 1947 to 10 December 2012
12 December 2012 Breast cancer+
health utilities
Since 2009
675
Google Scholar 19 December 2012 153
Ovid MEDLINE(R): searched from 1946
to week 3 November 2012
11 December 2012 Breast cancer+
health utilities
Since April 2009
230
Ovid MEDLINE(R) In-Process and Other
Non-Indexed Citations: searched
6 December 2012
11 December 2012 Same as above 11
Web of Science 18 December 2012 206
CENTRAL, Cochrane Central Register of Controlled Trials; DARE, Database of Abstracts of Reviews of Effects.
Total hits= 1389.
Deduplicated EndNote (Thomson Reuters, CA, USA) library contains: 901 hits.
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TABLE 45 Results from update search (date: 23 July 2013)
Database and dates covered Date searched
Concept search
strategy Hits Notes
The Cochrane Library: CENTRAL (Wiley) 23 July 2013 Breast cancer+
health utilities
6 Limit of 2012 to 2013
applied
The Cochrane Library: DARE (Wiley) 23 July 2013 Breast cancer+
health utilities
0
The Cochrane Library: NHS Economic
Evaluations Database (Wiley)
23 July 2013 Breast cancer+
health utilities
14
Cost-Effectiveness Analysis Registry 23 July 2013 Breast cancer 0 All from 2012 already
in library
EconLit – EBSCOhost 23 July 2013 Breast cancer+
health utilities
15 No date limit applied as
EBSCOhost interface
working only intermittingly
EMBASE Classic+ EMBASE searched
from 1947 to 19 July 2013
22 July 2013 Breast cancer+
health utilities
since 2009
143 Limit 2012 to 2013 applied
Google Scholar 23 December 2012 Breast cancer+
health utilities
2012–2013
25 About 100 results. Chose
those where “health state
utilities” and “Breast
cancer” were prominent
Ovid MEDLINE(R): searched from 1946
to week 2 July 2013
22 July 2013 Breast cancer+
health utilities
since April 2009
39
Ovid MEDLINE(R) In-Process and Other
Non-Indexed Citations. Date searched
19 July 2013
22 July 2013 Same as above 39
Web of Science 23 July 2013 78 Limit 2012 to 2013 applied
RePEc 23 July 2013 Breast cancer 3 Imported via Google
Scholar
CENTRAL, Cochrane Central Register of Controlled Trials; DARE, Database of Abstracts of Reviews of Effects;
RePEc, Research Papers in Economics.
Total hits= 362.
Deduplicated EndNote library contains: 169 hits.
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Detailed descriptions of the relevant articles
TABLE 46 Detailed description of Campbell et al., 2011174
Authors (year) Title Country Population
Campbell et al.,
2011174
The cost-effectiveness of adjuvant
chemotherapy for early breast cancer:
a comparison of no chemotherapy
and first, second, and third generation
regimens for patients with differing
prognoses
UK Women diagnosed with early breast
cancer. Women were divided into
those under and those over 50 years
of age
QALY estimation
method
Women entering the model were assumed to have HRQoL on average equivalent to women
in age-matched UK general population. During chemotherapy, the decrements in HRQoL
(using the EQ-5D) were estimated for each regimen based on trial data: ABC, NEAT and TACT.
Some estimations were made based on a literature review
Relevant QALY
measures Value Source
Baseline HRQoL based
on EQ-5D
Age and sex adjusted. UK population norms (Department of Health, 1998)
Decrements in HRQoL from underlying levels (early breast cancer)
Patients not receiving
chemotherapy
–0.003 ABC trial
Patients receiving CMF –0.057 NEAT, TACT
Patients receiving
E-CMF/FEC60
–0.067 TACT
Patients receiving
FEC-D
–0.099 ABC trial, NEAT, TACT
Decrements in HRQoL from underlying levels (metastatic breast cancer)
With CMF year 1 –0.057 ABC trial
With E-CMF/FEC60
year 1
–0.038 ABC trial
With FEC-D year 1 –0.035 NEAT, TACT
With local recurrence –0.108 (SE 0.04) TACT trial
With metastatic
recurrence
–0.303 (SE 0.16) (Hayman et al. 1997;207 Sorensen
et al. 2004;208 Stalmeier 2002;209
Suh et al. 2005210)
With contralateral/
second primary
breast tumour
–0.108 (SE 0.04) (Chie et al. 2000;211 Cykert et al.
2004;212 Grann et al. 1999;213
Stalmeier 2002209)
HRQoL final
3 months of life
0.159 (SE 0.04) (Sorensen et al. 2004;208 Stalmeier
2002;209 Suh et al. 2005210)
Status Selected
ABC, Adjuvant Breast Cancer; FEC-D, fluorouracil, epirubicin, cyclophosphamide and docetaxel; HRQoL, health-related
quality of life; NEAT, National Epirubicin Adjuvant Trial; TACT, Taxotere as Adjuvant Chemotherapy Trial.
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TABLE 47 Detailed description of Shabaruddin et al., 2013198
Authors (year) Title Country Population
Shabaruddin et al.
2013198
A systematic review of utility values
for chemotherapy-related adverse
events
Not country-specific Articles that assess chemotherapy
treatments that value utility of
chemotherapy-related AEs.
No discrimination on the type of
cancer being treated
QALY estimation
method
The review aim was to identify published articles that have reported utility values for chemotherapy
based on different instruments such as standard gamble, visual analogue scale and time trade-off
Relevant QALY
measures Value Source/comments
Nausea and/or
vomiting
32 values measuring different degrees of nausea and/or
vomiting. Expressed in utility decrements or means in
comparison with a base state
Several. Details can be found in
the online appendix 3 of the
published paper198
Neuropathy 21 values measuring different degrees/types of neuropathy.
Expressed in utility decrements or means in comparison with
a base state
Neutropenia 12 values measuring different degrees/types of neutropenia.
Expressed in utility decrements or means in comparison with
a base state
Anaemia 34 values measuring different degrees of anaemia. Expressed
in utility decrements or means in comparison with a
base state
Alopecia Seven values measuring different degrees/types of alopecia.
Expressed in utility decrements or means in comparison with
a base state
Skin reaction Five values measuring different degrees of skin reactions.
Expressed in utility decrements or means in comparison with
a base state
Hand–foot
syndrome
Five values measuring different degrees of hand–foot
syndrome. Expressed in utility decrements or means in
comparison with a base state
Fatigue Eight values measuring different degrees of fatigue.
Expressed in utility decrements or means in comparison with
a base state
Diarrhoea 12 values measuring different degrees of diarrhoea.
Expressed in utility decrements or means in comparison with
a base state
Stomatitis 10 values measuring different degrees of stomatitis.
Expressed in utility decrements or means in comparison with
a base state
Secondary cancers Two utility measures of secondary malignant neoplasms.
Expressed in means in comparison with a base state
Pyrexia Three values measuring different degrees of pyrexia.
Expressed in utility decrements or means in comparison with
a base state
continued
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TABLE 47 Detailed description of Shabaruddin et al., 2013198 (continued )
Authors (year) Title Country Population
Relevant QALY
measures Value Source/comments
Cardiovascular
disease
Three values measuring different degrees of cardiovascular
disease. Expressed in utility decrements or means in
comparison with a base state
Ototoxicity Two values measuring different degrees of ototoxicity
disease. Expressed in utility decrements or means in
comparison with a base state
Flu-like syndrome Three values measuring different degrees of
flu-like syndrome. Expressed in terms decrements or means
in comparison with a base state
Oedema Two values measuring different degrees of oedema.
Expressed in decrements or means in comparison with a
base state
Infection-related
events
Five utility measures of infection-related events: pneumonia,
infection without hospitalisation and sepsis. Expressed in
terms of means in comparison with a base state
Myalgia pain Two values measuring different degrees of myalgia pain.
Expressed in means in comparison with a base state
Common adverse
events specific to
chemotherapy drug
Six utility measures of common AEs: toxicity from paclitaxel,
docetaxel, and vinorelbine. Expressed in means utility values
Adverse events
leading to
hospital stay
Six utility measures of AEs leading to hospitalisation: 1-day
inpatient or outpatient stay; hospitalisation from 2 to 5 days.
Expressed in utility decrements in comparison with a
base state
Non-specific event
relating to AEs
37 utility measures of non-specific AE related to AEs: low,
moderate, high or extremely high AE, low, moderate or high
treatment efficacy and poor or positive well-being. Expressed in
terms of means utility values
Status Not selected. Potentially useful for some toxicity adverse events
AE, adverse event.
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TABLE 48 Detailed description of Moro-Valdezate et al. 2013199
Authors (year) Title Country Population
Moro-Valdezate et al.,
2013199
Evolution of health-related quality
of life in breast cancer patients
during the first year of follow-up
Spain Total of 364 women after surgery
followed for 1 year. Patients on Stage IV
were excluded. Participants‘ age ranged
from < 50 years to > 70 years, with a
mean age of 59 years (most frequent
60–69 years age group). Most of
respondents had breast-conserving
surgery 61%, radiotherapy 74% and
adjuvant chemotherapy 97%
QALY estimation method Observational, multicentre and prospective study of a cohort of breast cancer patients,
assessing HRQoL at 1, 6 and 12 months after surgery using three questionnaires:
EuroQol-5D-3L, EORTC QLQ-C30 and EORTC QLQ-BR23
Relevant QALY measures Value Source/comments
EQ-5D-3L
VAS 1 month: 70; 6 months: 70; 1 year: 80 321 respondents
Score 1 month: 0.81; 6 months: 0.83; 1 year: 0.83 336 respondents
EORTC QLQ-C30
Global health status 1 month: 66.67; 6 months: 83.33; 1 year: 100
Specific utilities values were also estimated
such as physical, role, emotional, cognitive,
social functioning, fatigue, pain, nausea/
vomiting, dyspnoea, insomnia, appetite loss,
constipation, diarrhoea and financial
difficulties. Values can be found in the
published article197
335 respondents
EORTC QLQ-C30
Body image 1 month: 83.33; 6 months: 91.67;
1 year: 100
316 respondents
Sexual functioning 1 month: 100; 6 months: 86.67;
1 year: 86.67
268 respondents
Sexual enjoyment 1 month: 66.67; 6 months: 66.67;
1 year: 66.67
116 respondents
Future perspective 1 month: 33.33; 6 months: 66.67;
1 year: 66.67
334 respondents
Systematic therapy
side effects
1 month: 19.05; 6 months: 14.29;
1 year: 9.52
263 respondents
Breast symptoms 1 month: 25.00; 6 months: 16.67;
1 year: 16.67
326 respondents
Arms symptoms 1 month: 22.22; 6 months: 11.11;
1 year: 11.11
330 respondents
Upset by hair loss 1 month: 33.33; 6 months: 33.33;
1 year: 0.00
77 respondents
Status Not selected. Potentially useful for patients in the disease-free stage
EORTC, European Organization for Research and Treatment of Cancer; EQ-5D-3L, European Quality of Life–5 Dimensions-3
Levels; QLQ-BR23, Quality of Life Questionnaire for Breast Cancer Patients; QLQ-C30, Quality of Life Questionnaire for
Cancer Patients for use in International Clinical Trials; VAS, visual analogue scale.
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TABLE 49 Detailed description of Shih et al., 2012200
Authors (year) Title Country Population
Shih et al., 2012200 Health state utility
assessment for
breast cancer
Singapore Men or women over the age of
21 years with at least 2 years’
experience in the oncology
department
QALY estimation
method
Health states utilities were obtained from using the VAS and SG methods
Relevant QALY
measures
Value
VAS score,
RAWa
VAS score
adjusteda
SG score,
RAWa
SG score,
adjustedb Source/comments
No recurrence with no
side effect
0.870 0.860 0.678 0.673 Medical personal survey in an
oncology department hospital
in Singapore
No recurrence with
hip fracture
0.514 0.482 0.504 0.353
No recurrence with
wrist fracture
0.508 0.475 0.533 0.386
No recurrence with
spine fracture
0.508 0.372 0.458 0.383
No recurrence with
vaginal bleeding
0.725 0.704 0.554 0.473
No recurrence with
deep-vein thrombosis
0.582 0.554 0.515 0.357
No recurrence with
pulmonary embolism
0.368 0.329 0.463 0.395
No recurrence with cataract 0.547 0.519 0.519 0.355
No recurrence with ischaemic
cerebrovascular events
0.299 0.256 0.408 0.289
No recurrence with
common side effects
musculoskeletal disorder
0.653 0.629 0.510 0.371
No recurrence with common
side effects hot flushes
0.749 0.730 0.588 0.520
No recurrence with
endometrial cancer
0.506 0.472 0.501 0.365
New contralateral breast
cancer
0.500 0.468 0.443 0.284
Locoregional recurrence with
no side effects
0.525 0.491 0.473 0.376
Locoregional recurrence with
side effects: general
0.506 0.473 0.438 0.336
Distant recurrence with no
side effects
0.438 0.400 0.470 0.371
Distant recurrence with
side effects: chemotherapy
0.404 0.365 0.458 0.356
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TABLE 49 Detailed description of Shih et al., 2012200 (continued )
Relevant QALY
measures
Value
VAS score,
RAWa
VAS score
adjusteda
SG score,
RAWa
SG score,
adjustedb Source/comments
Distant recurrence with
side effects: endocrine
therapy
0.410 0.370 0.445 0.299
Worse health 0.033 –0.032 0.364 –0.160
Current health 0.944 0.941 0.916 0.973
Status Probable. Possible problems as values are based on Asian populations
SG, standard gamble; VAS, visual analogue scale.
a Mean values. Median values can be found in the main text of the article.
b Median values.
TABLE 50 Detailed description of Matalqah et al., 2011201
Authors (year) Title Country Population
Matalqah et al.,
2011201
Health-related quality of life using EQ-5D
among breast cancer survivors in
comparison with age-matched peers
from the general population in the state
of Penang, Malaysia
Malaysia Women age 20 years or older with
confirmed diagnosis of breast cancer
compared with a similar group of
women without
QALY estimation
method
The EQ-5D instrument in two languages, the English version for Malaysia and the Malay version,
was used in face-to-face interviews for valuating and describing the HRQoL
Relevant QALY
measures
Value
Source/commentsBreast cancer survivors
General
population
General EQ–5D 0.71± 0.25 0.87± 0.16
< 50 years of age 0.79± 0.22 0.91± 0.13
> 50 years of age 0.67± 0.26 0.83± 0.17
General EQ VAS 72.7± 16.9 74.6± 13.2
< 50 years of age 75.0 75.3
> 50 years of age 71.1 74.0
Status Not selected. Not enough data to populate the model. The values might be used for the
disease-free stage
EQ VAS, EuroQol Group instrument visual analogue scale; HRQol, health-related quality of life.
DOI: 10.3310/hta20100 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 10
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Stein et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
171
TABLE 51 Detailed description of Farkkila et al., 2011202
Authors (year) Title Country Population
Farkkila et al., 2011202 Health state
utilities in
breast cancer
Finland Patients diagnosed with breast cancer between the
ages of 31 and 90 years in a hospital in Helsinki, Finland
QALY
estimation method
A total of 778 BC patients assessed their HRQoL with different quality of life questionnaires.
Patients were divided based on disease state
Relevant QALY
measures
Value
Source/commentsGeneric 15D EQ-5D
Baseline before
treatment
0.896± 0.083 0.818± 0.228
First year remission after
diagnosis or recurrence
0.901± 0.80 0.860± 0.178
Second year or following
years after remission
0.884± 0.103 0.843± 0.189
Metastatic disease 0.825± 0.113 0.746± 0.251
Terminal care 0.756± 0.110 0.514± 0.300
Status Probable. Some health stages might be useful, in particular those after remission, metastatic
disease and terminal care
15D, 15-dimensional health-related quality of life measure.
TABLE 52 Detailed description of Delgado-Sanz et al., 2011203
Authors (year) Title Country Population
Delgado-Sanz et al.,
2011203
Heath-related quality of life in Spanish
breast cancer patients: a systematic
review
Spain Systematic review on existing
literature related to health-related
quality of life in Spanish population
QALY estimation
method
Authors consulted MEDLINE, PubMed, EMBASE, PsycINFO, Dialnet, and other Spanish and Latin
American databases: ‘Índice Bibliográfico Español en ciencias de la Salud’ and ‘Literatura
Latinoamericana y del Caribe en ciencias de la Salud’. Two researchers participated in the selection
and extraction of the relevant information. Detailed analysis was performed only on those articles
reporting Spanish studies
Relevant QALY
measures Value Source/comments
None provided
Status Not selected. A brief description of the main findings of the selected papers is provided. The authors
did not extract utility values from the retrieved articles. It is based only on Spanish population
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TABLE 53 Detailed description of Anhoury et al., 2011204
Authors (year) Title Country Population
Anhoury et al.,
2011204
Health-related quality of life among
women with a history of breast cancer
in Europe
UK, Germany,
France, Italy
and Spain
Authors used data from the 2010 EU
(UK, Germany, France, Italy and
Spain) National Health and Wellness
Survey (NHWS). Data on 579 women
reported history of breast cancer.
Most were cancer free (76.9%)
QALY estimation
method
The history of women with and without breast cancer was compared and adjusted using
demographic characteristics to estimate their utility values
Relevant QALY
measures
Value
Source/observationsBreast cancer positive (BC+)
Breast cancer
negative (BC–)
Health states
utilities
0.69 0.71 Subsequent analyses of just the
BC+ group revealed that the primary
predictors of health state utilities
included age (b= 0.002), employment
(b= 0.43), exercise behaviour
(b= 0.04), alcohol use (b= 0.04),
comorbidity burden (b= –0.01), years
diagnosed (b= 0.002), and current
cancer stage (b’s= –0.01 to –0.08)
(all p values < .05)
Status Not selected. Only one utility parameter reported. This might be useful if no other information on
disease-free patients is found
Note: ‘b’ is the correlation coefficient.
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TABLE 55 Detailed description of Prescott et al., 2007205
Authors (year) Title Country Population
Prescott et al.,
2007205
A randomised controlled trial of
postoperative radiotherapy following
breast-conserving surgery in a
minimum-risk older population.
The PRIME trial
UK Patients ≥ 65 years of age, provided
that their cancer was considered to
be at low risk of local recurrence,
were suitable for breast-conserving
surgery, were receiving endocrine
therapy and were able and willing
to give informed consent
QALY estimation
method
The objective of the PRIME trial was to determine whether or not adjuvant breast irradiation
significantly changes the QoL of older women with breast cancer treated with breast-conserving
surgery and adjuvant endocrine therapy. The QLC-C30 and QLQ-BR23 were used to complement the
EORTC QLQ-C30 scale QoL measures
Relevant QALY
measures
Value
Source/commentsRadiotherapy No radiotherapy
EQ-5D
Baseline 0.77 (0.73 to 0.80) 0.74 (0.70 to 0.77)
3.5 months 0.78 (0.74 to 0.81) 0.76 (0.73 to 0.79)
9 months 0.76 (0.71 to 0.81) 0.72 (0.68 to 0.76)
15 months 0.74 (0.70 to 0.78) 0.73 (0.69 to 0.77)
Unadjusted QALYs 0.95 (0.90 to 0.99) 0.92 (0.88 to 0.95)
EORTC, European Organization for Research and Treatment of Cancer; QLQ-BR23, Quality of Life Questionnaire for Breast
Cancer Patients; QLQ-C30, Quality of Life Questionnaire for Cancer Patients for Use in International Clinical Trials;
QoL, quality of life.
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Appendix 8 Detailed findings from qualitative
recruitment study phase 1: understanding recruitment
issues in the OPTIMA prelim study
This appendix presents the detailed findings about recruitment issues in OPTIMA prelim, which wereundertaken as part of phase 1 of the integrated QRS. They form the basis on which QRS interventions
to improve recruitment were developed and implemented in close collaboration with the CfI and TMG.
These data were obtained, and the interventions implemented, during recruitment.
Qualitative recruitment study data set
Fourteen semistructured interviews were conducted with participants across six sites, including eight
oncologists (three of whom were also members of the TMG); four research nurses; one surgeon; and a
non-recruiting member of the TMG. Interviews were conducted at ‘mid-range’ centres by chance rather
than by design. One of the centres included in the QRS had failed to recruit any patients; the remaining
centres’ recruitment rates ranged from 0.32 to 1.85 patients per month compared with an overall range of
0 to 2.20 in the study. At least one site from each of the OPTIMA prelim geographical clusters participated
in interviews. Eight structured telephone interviews with research nurses were conducted to get a broad
overview of the patient pathway for each site. A total of 36 audio-recordings were obtained from
29 patient consultations. First and second oncology consultations were recorded for 7 of the 29 patients.
First oncology consultations were available for 21 patients and the second oncology consultation available
for one patient. Twelve different recruiters led the consultations (10 consultant oncologists and two
oncology registrars) and audio-recordings were obtained from all geographical clusters.
Presentation of data
Quotations from semistructured interviews and audio-recorded consultations have been selected on the
basis of how clearly and succinctly they illustrate the key themes to emerge from the research. Quotations
from divergent cases presented if these existed. Some themes have been supported through data from
interviews and audio-recorded consultations. The following identifiers have been used for quotations:
‘Int’= interviewer (LR or JD); ‘Onc’= oncologist; ‘RN’= research nurse; ‘Pat’= patient; ‘Relative’= patient’s
relative; ‘Friend’= patient’s friend.
Phase 1: understanding recruitment issues
The recruitment issues identified through the QRS were in three overarching themes:
l eligibility processes and patient pathways
l missed opportunities for discussing the trial
l opportunities for improving communication and information provision.
Structured and semistructured interviews were the principal data collection methods informing recruitment
difficulties that manifested outside of recruitment consultations. Recruitment challenges that occurred
within recruitment consultations not only arose through listening to audio-recordings, but were also hinted
at in interviews with recruiters and screening log analysis. Each of the above categories of ‘recruitment
difficulties’ will be discussed in turn, with ‘potential action points’ indicated for the QRS intervention
presented at the end of the section for phase 1 in the main body of the report.
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Eligibility processes and patient pathways
Eligibility processes and patient pathways were felt to be difficult by recruiters. These included clinicians’ and
triallists’ decision-making about patients’ eligibility and the series of OPTIMA prelim-related events patients
experienced in the lead up to entering (or declining) the trial. These processes had potential to hinder
recruitment, and so provided an initial focus for phase 1. Obtaining an overview of these processes from the
OPTIMA prelim staff also provided a useful framework for placing specific barriers to recruitment into context.
At the commencement of the trial, screening logs recorded patients from only the point of registration and
randomisation; this made elucidating the full patient pathway challenging. The details of eligibility processes
and patient pathways described below are based on interview data, but quotations are not included as the
information presented consists of factual details of processes (rather than views or opinions). Much of the
information was based on LR’s field notes made during structured interviews with research nurses.
Eligibility assessment processes
The first stage of assessing patient eligibility occurred during the MDT meetings. This was the first point at
which patients’ post-surgical pathology results were discussed by the clinical team. Research nurses and
oncologists working on the study were principally responsible for flagging potentially eligible patients, but
the final decision to pursue the trial was based on team consensus. Research nurses reassessed identified
patients’ eligibility by reviewing patient notes and double-checking pathology results following the MDT
meeting; if still eligible, the patient would be approached about OPTIMA prelim. Any drop-outs owing to
ineligibility after this point were a result of ineligibility on central screening or the emergence of new
knowledge about medical history or health status.
Patient pathway: events occurring from the patient’s perspective
The pathway for patients potentially eligible for OPTIMA prelim was simple and consistent across centres,
with good continuity of care owing to the support given by research nurses. The pathway broadly
consisted of an initial surgical consultation followed by two consultations with oncologists on separate
days (Figure 21).
The OPTIMA prelim study became potentially relevant to a patient’s pathway after surgical removal of the
tumour. The first point of clinical contact after surgery was with the surgeons, sometimes accompanied by
breast care nurses. The main purpose of this consultation was to review the results of the surgery. The
study and potential further treatments were sometimes briefly mentioned to inform the patient of what to
expect at their next consultation. However, the first consultation with the oncologist was usually the first
point at which OPTIMA prelim was introduced and explained in depth. Information sheets were distributed
at this first oncology consultation, and patients were introduced to research nurses as their primary point
of contact for study-related matters. Patients generally gave their decisions regarding trial participation in a
second oncology consultation, organised approximately 1 week after the first. Regardless of the patient’s
decision about the trial, the next steps in the patient’s treatment pathway were discussed and set into
motion in this second oncology consultation.
Research nurse involvement
Research nurse services were generally well integrated into patient pathways. Aside from being the first
point of contact for patient queries, research nurses supported patients through offering face-to-face
consultations immediately after the first oncology consultation (where feasible), or giving patients the
option of a follow-up telephone conversation. In some cases, research nurses telephoned patients within a
few days of the first oncology consultation as a matter of routine.
Declining the OPTIMA study via telephone
Patients’ initial decisions relating to trial participation were generally discussed face to face in the second
oncology consultation. This system allowed oncologists the opportunity to explore patients’ views and
reasoning. In contrast, patients’ decisions were initially expressed over the telephone (to research nurses) at
two of the QRS centres. If patients declined OPTIMA prelim, the second oncology consultation focused on
organising the next steps in the treatment plan, with no further discussion of the trial. This removed
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potential for oncologists to answer questions or clear misunderstandings about the trial and reduced the
possibility for in-depth discussion.
Summary of eligibility processes and patient pathways
Eligibility processes appeared straightforward, but systems were not always in place to map eligibility from
the first point at which patients were considered for the study. This probably led to potentially eligible
patients not being offered the opportunity to consider OPTIMA prelim. Patient pathways were clear, simple
and appeared successfully integrated into research nurses’ services, but discussion of the patients’ decision
regarding OPTIMA prelim participation via telephone (at some centres) meant that some patients may not
have discussed their thoughts on participation with an oncologist. Consequently, patients’ reasons for
declining the trial could not always be assessed through audio-recordings of consultations.
Missed opportunities for discussing OPTIMA prelim with patients
Interviews and early TMG meetings showed recurring concern among staff that fewer than anticipated
patients were being approached about the study. Regular telephone conversations with research nurses
frequently suggested that no eligible patients had been identified. Six interview informants from five
different centres talked about the limited flow of eligible patients they had encountered at the time of
interview. This was the most frequently reported issue raised by informants when asked about their views
on the main barriers to recruitment:
I don’t know why we’re not actually identifying (any); it’s not that we’re deciding that we’re . . . no,
it’s not that we’re approaching patients and they’re saying ‘No’.
RN1
With the starting pool of potential eligible patients unknown, little could be deduced with regard to the
numbers of patients deemed ineligible or the associated underlying reasons for ineligibility. This led to
TMG members producing broad, non-specific explanations of why the numbers of patients approached for
the OPTIMA prelim were lower than expected when the study was conceived:
[Dr A] will probably tell you but at the meeting yesterday [they] said how surprised [they were] about how
small the pool of eligible patients is. It’s much smaller than (they) thought it would be [. . .]; that’s like a
change of tune, really, from before we started recruiting (they) were very positive about how big the pool
was [. . .]. So I think (their) experiences in trying to identify eligible patients have shown that perhaps the
expectation of how many eligible patients there would be, were a bit, perhaps slightly over-enthusiastic.
TMG member
Further evidence supporting the theory that the full pool of eligible patients was not being considered for
the study came in the form of recruitment figures and acceptance rates. Actual recruitment figures trailed
behind target figures throughout the recruitment period, while ‘acceptance’ rates consistently exceeded
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FIGURE 21 The OPTIMA prelim patient pathway: from surgery to decision to accept/decline the trial.
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targets. Interviews with recruiters gave insight into potential attitudinal factors that may have played a role
in restricting the pool of eligible patients. These explanations were viewed as potential contributors rather
than absolute reasons; in reality, the factors described below may have acted in conjunction with a
genuine over-estimation in the prevalence of the target population.
Discomfort surrounding eligibility criteria
Discomfort surrounding various aspects of the eligibility criteria appeared to be widespread, reported by staff
members from every centre participating in interviews. Research staff varied in their readiness to accept
increasing risk (in terms of disease status). Increasing lymph node involvement, tumour size and grade
caused discomfort surrounding the upper thresholds of the eligibility criteria stated in the protocol.
Research nurses and oncologists from four different centres commented that they felt that the upper limit
of permitted lymph node involvement in the eligibility criteria was particularly high (nine nodes). This was
especially pertinent given that oncologists discussed how their clinical training had always connected any
lymph node involvement with chemotherapy:
The only . . . yeah, the only thing that surprised me with the criteria is the lymph node status: one,
because it’s almost ingrained in our practice and certainly as oncology trainees as we go through
doing the exams and so on, that lymph node positivity is a risk factor for a recurrence, and that those
patients who are highest risk benefit from chemotherapy most . . .
Onc7
Two research nurses shared this discomfort about the upper permitted levels of lymph node involvement.
While one dismissed her views as unimportant, the second felt that her feelings on this matter were shared
by her clinical team; this led on to her suggestion that patients at the upper limits of inclusion criteria may
not have been considered for the trial at her centre:
INT: Yeah, so you were mentioning about you feel eight nodes should get chemo, yet the eligibility
criteria says [up to] nine nodes. Have you had any patients with that level of nodal . . .
RN2: No, we haven’t, no. I think they wouldn’t have been offered the trial myself.
Discomfort surrounding high levels of lymph node involvement could be alleviated if recruiters had
sufficient confidence in the Oncotype DX test’s accuracy in determining appropriate chemotherapy
provision, as explained by one recruiting oncologist. This oncologist was deemed a standalone case, being
the only recruiter outside the TMG to express confidence in the Oncotype DX test (which in this case,
alleviated concerns about ‘higher-risk’ patients):
But I have to say I’m fairly confident if they had the testing they’d probably end up having the chemo
anyway because they’d probably come out at high risk, so I’m not worried that we’d under treat people.
Onc4
Recruiters’ confidence in the Oncotype DX test was only one facet of a complex decision-making process
for offering the trial to patients. The views of the wider clinical team (i.e. within MDT meetings) appeared
to be just as important as recruiters’ attitudes. For example, one of the oncologists (Onc7) spoke of the
lymph node criteria being problematic for surgical colleagues, although these attitudes had started to
change with increasing confidence in the Oncotype DX test:
Actually you can [i.e. are permitted to] put into OPTIMA patients with really quite high-risk disease,
like nine positive nodes, and initially my surgical colleagues would only allow us to offer OPTIMA to
patients with low-/intermediate-risk disease, which severely restricted the pool. But in the last couple
of weeks I’ve noticed they’re becoming much more relaxed about it and they’re saying things like
‘Oh, well if this patient needs chemo, the testing will be able to pick them out’.
Onc7
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A number of participants – research nurses and oncologists – talked about a combination of lymph node
involvement and other proxies for risk (e.g. tumour size, grade), as factors that collectively influenced views
on whether the OPTIMA prelim was an appropriate option for patients:
Well . . . I think the smaller tumours and with maybe just one or two positive nodes I feel fine about
that [comfortable with entering into OPTIMA], but maybe the larger ones like that last lady I discussed,
I’m not sure about what I’ve heard about it at all.
RN4
Ultimately, a range of clinical characteristics contributed to clinicians’ ‘gut feelings’ about the likely benefit
of chemotherapy. The oncologist below gave an example of a specific patient being excluded because of
the MDT’s assessment of multiple factors that labelled the patient as ‘high risk’. As expressed below,
overcoming clinical intuition could be problematic:
There was a girl, last week, who I think was premenopausal but who had eight positive nodes, so I
think we [inaudible] felt if she [laughs] . . . although she was eligible for the trial, we would probably
be uncomfortable if she had received hormones. Whether or not that’s based on our preconceptions
and not on what the tumour biology might tell us, is another matter.
Onc5
The reliance on ‘gut feelings’ conflicted with one of the OPTIMA prelim study’s major aims: to investigate
whether or not the Oncotype DX test was a more sophisticated approach to assessing potential to benefit
from chemotherapy – one that went above and beyond the crude indicators informing clinicians’ instincts.
Where OPTIMA becomes very interesting, it is, OPTIMA is supposed to tell you in a way better than
your own gut feelings.
Onc6
Finally, although not widely reported across the sample, staff members from one particular centre talked
about applying their own eligibility filters to determine systematically who should be considered for
OPTIMA prelim. This extra filter was an online predictor tool that estimated the benefits of chemotherapy
provision, and patients scoring above a certain estimated level of benefit were automatically deemed
inappropriate for the study:
So I’m a little bit uncomfortable with entering patients into the OPTIMA trial where I think I would
have liked to have seen an upper limit of benefit, which means that if the patient benefit from
chemotherapy using accepted criteria would save more than 8% in 10 years, then they shouldn’t be
considered for the OPTIMA trial.
Surgeon
It should be noted that this centre was deemed a stand-alone case within the QRS, but it is possible that
similar practices were occurring in centres that were not participating in the QRS.
Concern about patients’ ability to handle information
Some clinical informants gave general or specific examples of refraining from offering the trial to patients
on the basis of their clinical judgement. Three individuals from two different centres suspected cases or
had experienced cases where patients were anticipated to have likely difficulties understanding the trial,
and so were not approached:
I suspect more may have been eligible but there’s been reasons for not going ahead and discussing it
with them. In fact there’s one that I haven’t put in my sheet and it’s initially because they felt that this
lady couldn’t take that information. That she wasn’t . . . it was a step too far for her, it wasn’t even
discussed with her.
RN4
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These judgments about patients’ abilities to interpret information – whether or not intentional – had the
potential to influence recruiters’ efforts in explaining the trial. In these cases, they avoided providing clear,
full explanations of the trial:
So we . . . we might . . . if we thought they weren’t really suitable, we might say ‘Well, we do have a
trial that would help us choose whether to have chemotherapy or not and would you like us to
explain that to you?’ in a kind of very general way, and kind of probably hoping the patient will say
‘No, I don’t want anything like . . . oh no I don’t want that.’
RN2
Some recruiters alluded to abandoning efforts if they sensed that the patient did not have the capacity to
absorb information about the trial, be this because of underlying health issues or the way the patient was
feeling at the time. This was often a conscious choice on the recruiters’ part:
I’m thinking of one situation where somebody I didn’t think had the mental capacity to get her head
around the trial. So we just decided what to do (outside of that). And that will happen occasionally
when you see people and you think this is going to be too much to cope with [. . .]. You just don’t
want to burden them with extra information.
Onc4
Failure to approach patients owing to a clinician’s discretion would not breach the study protocol as
the eligibility criteria clearly stated that the ‘Patient must be fit to receive chemotherapy and other
trial-specified treatments with no concomitant medical, psychiatric or social problems that might interfere
with informed consent, treatment compliance or follow up.’
However, the issue arises about whether or not judgments not to inform patients about the opportunity to
take part in the OPTIMA prelim study were always appropriate or well founded. Such judgments, if applied
differently across different centres, could have had implications for the numbers of patients being invited
to join the study.
Priority of OPTIMA prelim at multidisciplinary team meetings and among surgeons
Although research nurses were well versed in the inclusion and exclusion criteria, some felt that they did
not always have the necessary expertise or voice to flag a patient as an OPTIMA prelim candidate at an
MDT meeting:
RN4: I tend to just whisper across the table, ‘the OPTIMA trial,’ and [clinician x] or [clinician y] will
maybe say ‘No’, or ‘We can think about it’, but I think I might need to have a word with them as well
and say . . . I think we ought to, possibly tomorrow, we have an MDT, maybe have a word with them
before we start and say ‘Look can we really look at the OPTIMA trial if the patients are eligible,’ . . .
INT: Rather than . . . I see . . . so has OPTIMA ever been discussed in the MDT then?
RN4: Not in any great depth, no I don’t think. It’s because it’s about four surgeons and they’re all
trying to get their patients discussed and what we’re going to do and everything else. It’s quite manic.
Some research nurses also expressed this view in QRS feedback meetings.
Summary of missed opportunities for discussing OPTIMA prelim
with patients
To summarise, findings from QRS interviews and informal discussion/observation in meetings suggested
that there had been missed opportunities to approach eligible patients about the OPTIMA prelim study.
This was a key finding from the QRS and suggested that there would be opportunities to increase levels of
recruitment. These findings were supported through the observation that while numbers of eligible
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participants were falling short of targets, the study seemed very acceptable to patients who were informed
about it, as the percentage of eligible patients agreeing to randomisation consistently exceeded targets.
Opportunities for improving communication and information provision
Recruitment consultations varied in length and structure across and between centres, with some formats
more conducive to explaining OPTIMA prelim than others. Difficulties emerged in relation to how trial
processes and concepts such as ‘uncertainty’ were explained to patients. Staff attitudes also played a
role in influencing the direction consultations took, particularly when it came to exploring patients’ views
and perspectives on study participation. Each of these areas will be briefly summarised in turn, with
supporting data from consultation recordings, interviews and screening logs (where relevant).
Explaining randomised controlled trial processes: treatment allocation
and blinding
A fundamental challenge to recruitment identified by interview informants was the difficulty perceived in
explaining study design. Five interview informants commented on OPTIMA prelim’s particular complexity
relative to other trials they had worked on:
I think it’s probably a bit more difficult for patients to understand and I think from my experience of
patients that we have seen and discussed with, I think that it takes them a while to work out how the
trial is designed [. . .].
RN3
Having an arm that split into two further arms, combining random and test-directed treatment allocations,
and the partially blinded design were all thought of as potentially confusing to patients. Some interview
informants had directly experienced patients dismissing the trial on this basis:
This particular lady just didn’t go into any detail at all she said, I just didn’t know what it was talking
about, and I said, and I tried to explain bits of it too her, but no, she said, I just, I don’t, I just want to,
I don’t understand it, she just said locked her mind off completely to it.
RN4
In the light of the above, analysis of audio-recorded consultations focused on recruiters’ explanations of
trial processes and scrutinised information exchange that led up to evidence of patient misconceptions or
confusion. Particular practices were identified as being potentially detrimental to patient understanding.
This included absent or incomplete explanations of RCT processes, and scope for greater clarity in the
communication of what ‘uncertainty’ related to and meant.
Most evidence of patient misunderstandings tended to occur in relation to the OPTIMA prelim design.
While individual patient knowledge and experiences undoubtedly played a role in comprehension, there
was an opportunity for some recruiters to focus on, or refine, explanations of trial processes and
terminology. This was particularly relevant for explanations of randomisation and descriptions of what each
of the study arms entailed.
Recruiters sometimes provided incomplete descriptions of what randomisation entailed and why it was
carried out. In a number of cases, the term ‘random’ was not explained at all:
Then it’s decided at random whether you go down the Oncotype testing path or whether you just get
the standard treatment.
Onc14 (consultation)
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Where randomisation was explained, recruiters usually conveyed the idea that there would be two groups
of patients of equal size, but did not explain the removal of patient or clinician choice in allocation. This
was sometimes in contrast to recruiters’ interview accounts of how they would explain randomisation, as
seen below:
Yeah. I usually say that there are two arms of the trial, and half the people go into one and half into
the other, and we don’t choose. And we don’t know which one you’ve been put in; that’s done on a
special basis.
Onc4 (interview)
It’s a randomised trial so half the people get the standard treatment; so if you go into the study, you
may just get chemotherapy irrespective of what the test shows because that’s our standard. That
would be considered the control arm of the study [. . .]. The other arm, which is the experimental arm,
will have a decision based on the result of that test.
Onc4 (consultation)
Incomplete explanations of randomisation are likely to have contributed to common misconceptions,
including patients’ assumptions that they were ‘choosing’ to receive the Oncotype DX test or that their
treatment allocation would be based on the clinician’s view of what is ‘best’ for them (see extracts 1–3,
below). These understandings were all reasonable interpretations of the limited information provided
by recruiters.
Extract 1
We might as well let them do the test, mightn’t we?
Pat (consultation)
Extract 2
Pat: So – the tumours that were taken out get tested . . .
Relative: Well it’s if they do it, yes.
Pat: If they do it, yes.
Relative: If you say you want it done.
Consultation
Extract 3
But you still get the best treatment for you even though you go into this computer?
Pat (consultation)
Explanations of the trial arms also revealed examples of ‘loaded’ terminology, including use of the words
‘standard’ and ‘experimental’ to describe the arms. Use of these words does not enable the arms to be
considered as equivalent, leading to implications for how acceptable randomisation would be.
The concept of blinding was often omitted or not fully explained by recruiters in the first oncology
consultation. Where blinding was covered, patients’ reactions were usually a good indication of how well
they had understood the trial design. While some understood, others asked for clarification of misconceived
ideas, or expressed confusion.
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Extract 4
Onc15: But I don’t get the actual result; I get told whether you’re going to have chemo or not. When
you’re tested, if it comes back as a low score, then you get no chemotherapy. If it comes back as
anything, intermediate or higher-risk score, you get chemo.
Pat: Either you make the decision, or you let someone else make it for you?
Consultation
Extract 5
Onc6: One thing, however, is that the study is what is called ‘partially blind’, which means that if you
end up having chemotherapy, neither I nor you will know whether or not you actually had the
Oncotype test.
Pat: Each lady has the Oncotype test?
Consultation
Recruiters’ descriptions of what happens in each study arm were also sometimes confusing. Explanations
did not always specify that endocrine therapy would be provided in all treatment arms, possibly
encouraging patients’ assumptions that this was a trial of ‘treatment’ versus ‘no treatment’, or
‘chemotherapy’ versus some other unknown treatment.
Extract 6
Onc4: It’s a randomised trial so half the people get the standard treatment . . . so if you go into the
study, you may just get chemotherapy irrespective of what the test shows because that’s our standard,
that would be considered the control arm of the study. Make sense so far?
Pat: Mhm.
Friend: Yeah.
Onc4: The other arm which is the experimental arm will have a decision based on the result of that
test [. . .] if you’re high risk you get the chemo, if you’re low risk they think actually the chemo’s not
going to be much benefit, you don’t get the chemotherapy.
[Later in consultation]
Friend: So how, if [patient] didn’t have the chemo . . . and she had this new trial, how is that taken,
how is that given?
Consultation
Tailoring consultations to the OPTIMA prelim study
Recruiters varied in the extent to which they presented OPTIMA prelim as the primary focus of the
discussion. This was reflected most clearly by the point at which the study was introduced in the
consultation, and the way in which non-study-related information was framed. Details of surgery outcomes,
pathology results and non-chemotherapy treatment recommendations were generally covered prior to
introducing OPTIMA prelim, and this ‘lead up’ time ranged from approximately 2 to 25 minutes. Some
consultations were particularly long (up to 52 minutes), covering non-trial-related information in some detail
prior to introducing the study.
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In some ways, it could be considered that many consultations were not ‘recruitment consultations’.
Although there was the opportunity to present the OPTIMA prelim study, this opportunity was not always
fully utilised. In some cases, OPTIMA prelim was presented as a ‘next step’ in a series of ‘information
blocks’, rather than the heart of the consultation.
Uncertainty: chemotherapy provision and accuracy of the Oncotype DX test
The issue of uncertainty was an important theme to arise from audio-recorded consultations, particularly in
relation to the discussions about chemotherapy benefits and the accuracy of the test. These areas of
uncertainty were the essence of OPTIMA prelim’s aims and thus fundamental points to communicate.
Apart from issues of trial design, most examples of patient confusion or misconception arose from
incomplete understandings of uncertainty in relation to chemotherapy and/or the Oncotype DX test.
Chemotherapy as an uncertainty
There were occasional examples where patients still believed that they would definitely benefit from and/or
receive chemotherapy, even after the trial had been explained. This prompted us to scrutinise how
chemotherapy was first introduced into recruitment consultations by the oncologist. Broadly speaking,
descriptions fell into two categories: ‘chemotherapy as a beneficial treatment’, and ‘chemotherapy as
an uncertainty’.
In some consultations, chemotherapy was initially presented as a treatment that would offer some benefit,
with varying descriptions of what this benefit was and how it was expressed (i.e. in quantitative or
qualitative terms). This would later be countered as recruiters explained that chemotherapy might not be
beneficial at all, leading on to descriptions of the trial. These consultations tended to be longer than
others, and there were increased opportunities for patients to become confused about the role of
chemotherapy. As a consequence, it became more difficult to explain the rationale behind the trial.
Patients who were introduced to chemotherapy as a certainty were more likely to show signs of confusion
about chemotherapy provision later in the consultation:
Extract 7
Onc1: Back to drugs. The other thing that we have to consider, and it’s I would say a case of icing on
the cake, but nevertheless, we should talk about it, is the benefits of a course of chemotherapy [. . .].
Pat: Would you recommend it then?
Onc1: I think with what you have there is probably enough benefit for it to be worthwhile. It should
be considered quite seriously. [Introduces OPTIMA and the Oncotype DX test.]
Pat: You’ve completely confused me now. OK, so I accept that I’ve got to have the chemotherapy and
tablets . . .
Consultation
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Extract 8
Onc1: And, a lot of – you know – we would normally give chemotherapy, um, for, a tumour such
as this.
Pat: Yes.
Onc 1: Because again it reduces the risk of it coming back.
Pat: Right.
[Later]
Pat: I want to get everything finished with.
RN: You just want to get on with it.
Pat: [Yeah, yeah].
RN: [And just] have the chemo.
Pat: Yeah. Bad enough I got to have both.
Consultation
Within consultations that presented chemotherapy as a certainty, there were some examples where the
language carried subtle suggestions that chemotherapy was the optimal (e.g. ‘icing on the cake’) or
‘responsible’ choice:
Onc9: I usually say this sort of treatment that we offer, like chemotherapy is a bit like having fire
insurance on your house. You probably don’t need it because you’re going to be OK without it. But
you’d feel a bit silly if your house catches fire and you haven’t got it.
Onc6: Currently there is no straightforward method of identifying better who is likely to benefit and
not benefit, so we play safe.
Interview
In contrast, some recruiters framed chemotherapy as an uncertainty from the outset, alluding to this being
a ‘difficult decision’, or a ‘question mark’. This approach to introducing chemotherapy seemed mostly to
lead to clearer patient understanding of OPTIMA prelim and the role of chemotherapy.
Extract 9
We would certainly recommend [endocrine therapy]. The one that can sometimes be a little bit more
difficult is the chemotherapy treatment, and the reason for that is when you start to think about side
effects and down sides of the treatment, it is more complicated. Um, there are more potential side
effects, so you have to be really sure that that treatment is of benefit.
Onc10 (consultation)
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Extract 10
Onc6: That leaves the question of whether we should also give you a course of chemotherapy or not,
which is a slightly more tricky question [explains probability of benefits]. What we’d love to do is be
able to pick which those five are, and not treat everyone else.
Pat: But you can’t do that . . .
Consultation
Extract 11
Onc11: The thing that’s a little harder to decide is whether you need chemotherapy or not.
Pat: It’s the big one, yeah.
Onc11: It’s a harder decision for two reasons. One is, that its, lots of patients like yourself would be fine
even if they didn’t have it, and, uh, also it has obviously more side effects [explains probability of benefit].
That means, though, that 90 of them or more who have had chemotherapy, have had no benefit.
Pat: It’s just whether I’m one of those ones.
Consultation
Uncertainties surrounding the Oncotype DX test
Uncertainty surrounding the use of the Oncotype DX test in treatment decision-making was a difficult
concept to communicate according to recruiters’ interview accounts (i.e. oncologists and research nurses).
Recruiters’ reported experiences and screening log date showed that patients sometimes declined the trial
with the intention of paying for the Oncotype DX test privately to guarantee receipt of the test (8% of
reasons for declining the trial). In contrast, others did not trust the test’s ability to accurately inform
appropriate chemotherapy provision. One recruiter described difficulties in giving a balanced explanation
of the benefits and potential risks of the test. Over-selling the benefits could prompt patients to pay for
the test privately, whereas an overly cautious approach ran the risk of obscuring any incentives for
participating in OPTIMA prelim. These considerations raised the dilemma of how best to reassure patients
while conveying the inherent risk of participating a study where treatment allocation may be determined
by a test that requires further research.
The trouble is if in our initial interview we sort of really down play the test as not being useful, then
nobody would want to go in the trial in the first place. And if we play it too much they think ‘well it’s
such a great test, I don’t want to risk not having it in the trial’ and go and find out the information.
So again, it’s that fine balance.
Onc4 (interview)
The TMG meetings revealed that a particular point of concern was a line in the PIS that highlighted the
uncertainty surrounding the test’s accuracy. Based on TMG members’ experiences (not audio-recorded),
patients had reportedly refused the trial once they had read this:
The test might not work so well for patients with larger tumours or involved lymph glands. We do not
believe this to be the case. However, if it was, then in the future we might realise that we should have
given you chemotherapy.
It was noted that this issue reportedly materialised after (rather than within) the first oncology consultation
(i.e. once the patients had read the information sheets). This prompted us to consider how the Oncotype
DX test was described in consultations, with a focus on how uncertainty was communicated and
responded to.
APPENDIX 8
NIHR Journals Library www.journalslibrary.nihr.ac.uk
188
Uncertainty was most commonly conveyed through the idea of having insufficient evidence and/or
information about using the test in node-positive women, or the desire to ‘learn more’ about use of the
test in this group of women; however, some recruiters were less specific, making indirect references to
uncertainty (n= 5):
Extract 12
There is a new very sophisticated test that has been developed, that is only available in one laboratory
in America, and is now used as a routine for patients who have lymph node negative cancers where
there is no involvement of the lymph nodes. [1-second pause] And it’s now being looked at in women
who have a lymph node involved.
Onc17 (consultation)
Extract 13
It’s a test that is reasonably well established, but the exact . . . where exactly we should be using it is
still kind of being looked at.
Onc1
Some patients questioned the purpose of the trial in response to indirect or non-specific communication
of uncertainty:
Extract 14
Onc10: Now. This is something that’s already used in the US for people without a lymph node. So
they do this already [. . .]. So the next stage of that is to look to people who have one lymph node
that’s moved slightly away. And, as I say, it helps with the ‘not sure whether or not we should give
chemotherapy’. [Later explains trials design].
Pat: Why don’t – if that’s the case – why don’t they just save the money on chemotherapy for those
people who don’t need it? Why not just do the test on everybody?
RN18: The test is to see if it’s accurate.
Pat: Oh I see – you’re not sure how accurate the test is?
Consultation
Recruiters also varied in the extent to which they coupled uncertainty with reassurance. It was common for
recruiters to talk about the routine use of the Oncotype DX test in America, and less frequently, the
existence of retrospective data to support its use in patients with lymph node involvement. Some recruiters
went one step further by expressing their personal views on the test’s accuracy. All recruiters who did this
expressed confidence in the Oncotype DX test coupled with a specific statement about uncertainty
(e.g. insufficient evidence, not enough information):
Extract 15
Obviously, we wouldn’t do this if it put some patients at extra risk. We’re confident that this test
predicts which patients need chemotherapy better than the old-fashioned way we did it with just the
size of the tumour and the nodes. This test is, actually, now available on the NHS for a different group
of patients [. . .]. What we’re trying to find out is to prove that it’s a good test to do for patients
who’ve got involved lymph nodes. So we already know this is a good test, basically, it’s just a question
of trying to expand its use in patients who’ve got involved lymph nodes.
Onc12 (consultation)
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Patient preferences
Screening logs and interview informants’ accounts suggested that patients’ preference either for or against
chemotherapy was the most common reason for declining the trial (50% of reasons for decline in final
screening logs: 33% for and 17% against):
We have a very good functioning wider unit [. . .]. There’s nothing that’s blocking us from doing it
other than patient preference.
Onc3 (interview)
A common thread that ran throughout informants’ portrayal of patient preferences was the implication
that the outcome of recruitment consultations was fixed, and independent of events and discussions
occurring within the consultations. Breast cancer patients in particular were thought likely to have set
preferences given the influence of the media, peers and the well-publicised nature of the disease. As such,
some recruiters completely disassociated themselves from patients’ preferences, evoking a sense
of powerlessness:
The people who say ‘well my friend down the road had breast cancer and she had chemotherapy and
so therefore that’s what I’m going to have or I don’t want to have it’ – those people are more difficult
I think because then they’ve already made their decision I guess.
Onc2 (interview)
The idea that surgeons/breast care nurses may create or reinforce expectations for a particular treatment
regimen was considered as a possibility by most interview informants, but generally dismissed as not being
an issue at their particular centre; their own clinical teams were presented as cohesive in their support of
the OPTIMA prelim trial. Despite this, a number of audio-recordings showed examples where patients had
come to the recruitment consultation with clear expectations for or against chemotherapy, based on advice
received in previous consultations with surgeons (i.e. prior to the first consultation with the oncologist)
Extract 16
Relative: ‘Cos – I know, before today, my wife had decided that she wasn’t going to go on the trial.
Onc8: OK.
Pat: Um, purely because when I spoke to [Mr X], my husband asked him what would he actually do.
And he said if it was his sister, he would highly advise the chemo.
Consultation
Extract 17
Relative: Because at first, initially, she was given the impression that it would just be take the lump
out, be given radiotherapy, end of.
Pat: Tablets, yes.
Relative: So you’re saying that’s not the case?
Consultation
Do patients really have fixed views?
Patient preferences were difficult to assess based on the limited number of audio consultations, especially
given that most of these captured the first oncology consultation rather than the consultations where
patient decisions were expressed. Patients tended to take a passive role in consultations, quietly absorbing
the information provided by the oncologist. There was usually space provided for patients to comment.
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These spaces were usually filled with indications of assent (e.g. elongating words such as ‘ahhh’, or ‘I see’,
definitively stating ‘right’), or patients inviting the oncologist to continue speaking (e.g. ‘right’, ‘uh hum’,
stated with a rising intonation). There was little evidence of patients voicing strong preferences for a
particular treatment at this stage of the pathway, although evidence of concerns or preconceived ideas
sometimes appeared, as shown in the previous section. Nonetheless, recordings of first oncology
consultations did not provide any evidence to support the assertion that patients had ‘fixed views’
(although equally, it cannot be said that these fixed views were not internalised).
Exploring patients’ decision and preferences
The small numbers of recordings of second oncology consultations gave the opportunity to analyse how
patient decisions and preferences were handled. Generally, these revealed recruiters’ reluctance to explore
patients’ reasons for declining the trial. This seemed to be related to recruiter discomfort with discussing
such views, or the belief that exploring decisions had no practical value. Recruiters’ discomfort stemmed
from concerns about the potential for coercion, or that raising these issues would jeopardise their
relationships with patients. When asked how they reacted when patients declined the trial, all interview
informants expressed acceptance and a shift in direction within the consultation:
Onc6: Well I think it’s quite important not to . . . it has the potential to kind of damage the
relationship with the patient because the patient then feels . . . there’s risk that they might feel they’re
letting you down.
RN2: We don’t do a hard sell you know, we don’t really force them. We don’t want to coerce
anybody into it, so we respect their wish and go with that.
Interview
Recruiters who saw no value in exploring patients’ decisions were also more likely to dissociate the
outcome of recruitment consultations from their own actions, instead focusing on factors that were not
amenable to change (e.g. patient personality). If patients’ decisions were to be explored, this was merely
seen as a tick-box exercise for trial-reporting purposes:
Onc8: I go back to it, perhaps at the end of it and say would you mind just answering a couple of
questions about your reasons why because it’s really helpful to the trial, trying to work out why it’s
acceptable or not.
INT: Would you feel comfortable once a patient had said no, personally would you feel comfortable
exploring that?
Onc8: No. Well I don’t know. I mean . . . I think I wouldn’t . . . I wouldn’t explore it there and then
basically because there’s not . . . there isn’t the time and is not . . . but I have no problem to go back
afterwards and discuss that with them.
INT: Have you . . . have you done that or . . .?
Onc8: No I haven’t done it because I’ve not . . . I’ve not seen the [. . .] If it was part of the study I
would be willing to do it, but I think I would . . . I just . . . I feel that I accept their decision basically.
INT: Yeah. Yeah no I can . . . can understand. I can understand that. And you feel it is kind of partly
due to logistics of not really having time to go in and . . .?
Onc8: Well it also the . . . what would I learn from exploring it?
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[Later]
Onc8: I suspect that there will be certain characteristics about the patient that if you have the right
questionnaire to give them before they come to see me, if they have certain traits the chance of
accepting a trial will be kind of less than 5%.
Interview
Recordings of patients declining the trial were available for seven consultations. Even in this small sample,
there was evidence of patients declining the trial based on concerns that could potentially have been
alleviated. This included concern about the safety of treatment delays resulting from participation in
OPTIMA prelim and a worry about hair loss. Recruiters appeared to accept patient decisions without any
attempt to rectify these misconceptions or offer potential solutions to concerns. Only one recruiter actively
explored patients’ decisions by reviewing details of the trial that were misconceived and discussing new
information to alleviate concerns. These measures could only be taken if relevant and appropriate, but this
could not be determined if there was a reluctance to initially explore patients’ decisions. Aside from missed
opportunities to address misconceptions and fully inform patients, recruiters’ reluctance to explore
patients’ reasons for declining the study impeded the potential to learn about the acceptability of OPTIMA
prelim to patients. According to screening logs, no reason was given in 24% of cases where patients
declined the trial.
Delay
Patients’ concern about the delay attributed to the Oncotype DX test was a dominant theme to emerge
from audio-recorded consultations. Almost every consultation analysed supported this, with most patients
asking about how long the testing process would take.
Extract 18
I’m just thinking every minute counts, but, yeah.
Pat (consultation)
Two staff interview informants gave specific examples of patients declining the trial owing to the delay this
imposed on initiating treatment; likewise, screening logs suggested that this was the principal reason for
declining the trial in 4% of cases. While some recruiters reassured patients that the delays associated with
OPTIMA prelim were safe, this was not consistently done across consultations. This therefore also
represented a missed opportunity to reassure patients.
Summary of opportunities for improving communication and
information provision
Analysis of audio-recorded consultations revealed opportunities to clarify and refine recruiters’ explanations
of trial specific processes to patients, reconsider use of terminology and frame explanations of treatment
options around the OPTIMA prelim trial design. Both interview data and audio-recorded consultations
revealed recruiters’ discomfort and reluctance to explore patients’ decisions to decline the trial. These
attitudes stemmed from concerns of being seen to coerce and the belief that patients’ views are fixed at
the outset of consultations. We found no evidence of clear ‘fixed’ patient preferences in the consultations
we listened to, but there were examples of patient expectations for chemotherapy/no chemotherapy,
which had stemmed from previous interactions with clinicians (e.g. surgeons) prior to the first
oncology consultation.
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Appendix 9 The OPTIMA prelim guidance
for recruiters
personalised treatment
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Appendix 10 Limitations of the qualitative
research study methods
In addition to the limitations presented in Chapter 6, the discussion below relates to the specificlimitations of the QRS methodology.
Data saturation was achieved within the interview study, as sampling was under the control of the QRS
researcher. Such claims cannot be made for collection of audio-recorded consultations. It should be kept in
mind that listening to audio-recorded consultations primarily served a practical purpose, and to this end,
successfully identified challenges that recruiters were able to engage with in feedback meetings. However,
the study would have benefited from a larger sample of audio-recordings, from a wider range of centres.
Despite encouragement from the QRS team and TMG, recording of consultations did not occur as a matter
of routine and the full range of interactions with patients was not captured. This is particularly true for
second oncology consultations (where patients sometimes gave their decisions about participation).
Incomplete recordings of each patient’s ‘journey’ made it difficult to track events, and made deciphering
patients’ reasons for declining the trial problematic. In addition, limited numbers of audio-recordings
for each individual recruiter restricted opportunities to assess the impact of QRS interventions through
‘before-and-after’ comparisons. Reluctance to routinely record consultations may have been an indirect
consequence of recruiters perceiving the QRS as an ‘optional’ additional task. Future studies of this nature
will need to frame the QRS as an integrated component of the trial.
The practices reported in interviews might have been influenced by recollection bias and/or the temptation
to offer socially desirable answers. This is particularly true given the potentially sensitive nature of subjects
discussed in consultations and the possibility of clinicians perceiving that their actions were under scrutiny.
Similar sources of bias may also have influenced behaviours in consultations that were audio-recorded. In
some cases, interviews focused on recruiters’ perceptions of why patients declined participation in OPTIMA
prelim. Recruiters’ responses will have been based on their subjective interpretation of events, which may
not have reflected reality. This consideration is also applicable to the data reported in screening logs,
where recruiters were required to state the reason(s) why patients declined the OPTIMA prelim.
Interviewing patients directly could have provided source triangulation (or contradictions), but the OPTIMA
prelim QRS prioritised addressing the challenges already identified through recruiter interviews and
audio-recorded consultations. There was an intention to interview patients if necessary, but given the
exploratory nature of the QRS, the nature and extent of challenges identified early on could not be
anticipated when the QRS was designed. Consideration should be given to interviewing patients if the
OPTIMA main study proceeds.
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Appendix 11 Qualitative research study profiles
The authors LR, SP and JLD are non-clinical (female) researchers employed by the University of Bristol(both currently and at the time of conducting data collection). LR and SP work within a team that
specialises in identifying and addressing recruitment issues in challenging RCTs, which is led by JLD. At
the time of interviews, LR (the main researcher undertaking data collection) had 1 year of post-doctoral
experience, with over 4 years of training in the use of qualitative methodology. JLD, who conducted one
interview, is a professor of social medicine with over 20 years of experience in the application of qualitative
(among other) research methods.
LR approached this project as a naive researcher, with little knowledge of the field or literature. JLD and SP
had prior experience of working on identifying recruitment challenges across a number of other RCTs, and
thus had extensive knowledge of the field through their awareness of the literature and personal research.
This prior knowledge may have influenced SP’s and JLD’s interpretation of data, although their contributions
were largely based on LR’s initial interpretation and analytical thoughts, rather than raw data. SP’s prior
knowledge may have influenced her double coding (conducted on 10% of transcripts), but analytical
thoughts were largely similar to those expressed by LR (who was more likely to have a more purely inductive
approach to analysis). Any differences in views were discussed and resolved in double-coding exercises.
We have no reason to believe that any of the researchers’ personal experiences or life histories would have
influenced their approaches to data collection and analysis in a noteworthy way.
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Appendix 12 Qualitative research study prior
relationship/contact with research participants
The authors LR and JLD had no prior contact or relationships with the majority of research participantsprior to initiation of the OPTIMA prelim. There was one exception, where JLD had met one of the
research participants during an academic meeting, which in turn prompted JLD’s collaboration in OPTIMA
prelim. LR met a number of the research participants in advance of interviews at the launch meeting for
OPTIMA prelim, but these encounters were limited to introductions.
Research participants all received study information sheets in advance of data collection processes, which
explained why the research was being undertaken. Information sheets contained no personal details about
the researchers or their personal aspirations. As such, interview participants will not have been informed
of any personal information about the researchers prior to being interviewed, although they will have
known the identity of the researchers (through e-mail correspondence), and thus had opportunity to read
about researchers’ research interests in advance (e.g. via the internet). Although this was not explicit in
interviews, there is a possibility that participants’ prior knowledge of researchers’ interests influenced their
accounts and responses.
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